"organism"	"reference accession"	"reference database name"	"nucleotide position"	"original mutation description"	"nucleotide mutation"	"amino acid mutation"	"amino acid mutation alias"	"gene name"	"gene symbol"	"protein name"	"protein symbol"	"measured variant functional effect"	"inferred variant functional effect"	"viral life cycle functional effect"	"variant functional effect description"	"CVX code"	"DrugBank Accession Number"	"Antibody Registry ID"	"author"	"publication year"	"URL"	"DOI"	"PMID"	"peer review status"	"curator"	"mutation functional annotation resource"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"viral load"	""	""	"This mutant causes a 0.41x fold change in the infectious virus production rate."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutant has a 0.66x fold change in EC50 value with Remdesivir."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutant has an inhibition rate of virus production by Remdesivir of 0.80."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutant has a 0.27x fold change in EC50 value with Remdesivir."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutant has an inhibition rate of virus production by Remdesivir of 0.78."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"1703"	"F480L"	"NC_045512.2:g.1438T>C"	"YP_009724389.1:p.Phe480Leu"	"YP_009724389.1:Phe300Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"viral load"	""	""	"This mutant causes a 0.48x fold change in the infectious virus production rate."	""	""	""	"Torii"	"2022"	"https://doi.org/10.1101/2022.02.22.481436"	"doi:10.1101/2022.02.22.481436"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,22992,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,S477N,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,22992,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,S477N,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,22992,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,S477N,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,22992,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,S477N,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,21846,22317,22319,22320,23012,23399,23401,23402,23403,23664"	"L5F,T95I,D253G,D253G,D253G,E484K,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,22992,23012,23664"	"L5F,S477N,E484K,A701V"	"NC_045512.2:g.13C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 114 test-positive were Iota. Two dose vaccine efficacy against Iota was 95.7 (81.7-99.0%), one dose VE was 88.8 (0.7-98.7)%."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21575,25186"	"L5F,Q1208H"	"NC_045512.2:g.13C>T,NC_045512.2:g.3624G>T"	"YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Gln1208His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Four of the convalescent sera tested showed 4-fold or greater improvement in neutralization efficiency."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21587"	"P9S"	"NC_045512.2:g.25C>T"	"YP_009724390.1:p.Pro9Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2L28, S2M28, S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21597"	"S12F"	"NC_045512.2:g.35C>T"	"YP_009724390.1:p.Ser12Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"A variant in low % circulation, predicted to have a similar effect to the experimentally verified S12P, which introduces a new signal peptide, altering cleavage to occur between residues C15 and V16, thereby eliminating the C15-C136 disulfide bond – similarly to escape mutants at positions C15 and C136. This in turn decreases to varying degrees N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600"	"S13I"	"NC_045512.2:g.38G>T"	"YP_009724390.1:p.Ser13Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"The S13I mutation dampened binding of 5 mAbs and abrogated binding of 5 additional mAbs out of 11 neutralizing mAbs evaluated. Predicted to shift the signal peptide cleavage site from S13-Q14 to C15-V16, which can affect NTD conformation.  PG: in saying S12F does not shift the signal peptide nor affect mAb binding, this manuscript appears to contradict the  text of McCallum et al.'s earlier 2021 manuscript stating that S12F *does* affected some mAb binding via putative signal peptide shift."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018"	"S13I,W152C"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Antibody neutralization assays showed 6.7-fold resistance against 7/8 convalescent plasma."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold)."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.03.19.436183"	"doi:10.1101/2021.03.19.436183"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR=1.28; 95% CI:1.00-1.64). The reproductive number was estimated to be modestly higher than other lineages spreading in California during the second half of 2020."	""	""	""	"Peng"	"2021"	"https://doi.org/10.1093/cid/ciab283"	"doi:10.1093/cid/ciab283"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917"	"S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 2.7x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 2.3x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21600,22018,22915,22916,22917,23399,23401,23402,23403,25135"	"S13I,W152C,L452R,L452R,L452R,D614G,D614G,D614G,D614G,K1191N"	"NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3573G>T"	"YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys1191Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for CAL.20C (B.1.429),  and a slight decrease in CD8+ percentage (p=0.0201) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21604,21604"	"Q14H,Q14H"	"NC_045512.2:g.42G>C,NC_045512.2:g.42G>T"	"YP_009724390.1:p.Gln14His,YP_009724390.1:p.Gln14His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21605"	"C15R"	"NC_045512.2:g.43T>C"	"YP_009724390.1:p.Cys15Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28 Eliminates the C15-C136 disulfide bond."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21606"	"C15F"	"NC_045512.2:g.44G>T"	"YP_009724390.1:p.Cys15Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28 Eliminates the C15-C136 disulfide bond."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614"	"L18F"	"NC_045512.2:g.52C>T"	"YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614"	"L18F"	"NC_045512.2:g.52C>T"	"YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614"	"L18F"	"NC_045512.2:g.52C>T"	"YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614"	"L18F"	"NC_045512.2:g.52C>T"	"YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614"	"L18F"	"NC_045512.2:g.52C>T"	"YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2."	""	""	""	"Riou"	"2021"	"https://doi.org/10.1126/scitranslmed.abj6824"	"doi:10.1126/scitranslmed.abj6824"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132"	"L18F,T20N,P26S,D138Y,R190S"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.03.01.433466"	"doi:10.1101/2021.03.01.433466"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.03.01.433466"	"doi:10.1101/2021.03.01.433466"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.03.01.433466"	"doi:10.1101/2021.03.01.433466"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.03.01.433466"	"doi:10.1101/2021.03.01.433466"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue)."	""	""	""	"Malta Romano"	"2021"	"https://doi.org/10.1590/S1678-9946202163036"	"doi:10.1590/S1678-9946202163036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Gamma (P.1) variant is 0.6x fold the wildtype."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 3.0x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 349 test-positive were Gamma. Two dose vaccine efficacy against Gamma was 95.5 (90.9-97.8%), one dose VE was 74.2 (43.8-88.1%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Three healthcare workers (29-50yo) had confirmed P.1 [Gamma] re-infection in the Amazonas region of Brazil 3-9 months after initial  infection from viruses with distinct lineage from P.1, but mild symptoms upon re-infection and evidence for infectiousness during re-infection."	""	""	""	"Naveca"	"2021"	"https://doi.org/10.21203/rs.3.rs-318392/v1"	"doi:10.21203/rs.3.rs-318392/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer."	""	""	""	"Montagutelli"	"2021"	"https://doi.org/10.1101/2021.03.18.436013"	"doi:10.1101/2021.03.18.436013"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P=0.0039 for mild resistance."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples, P=0.0020."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used)."	""	""	""	"Gallagher"	"2021"	"https://doi.org/10.1101/2021.05.03.442455"	"doi:10.1101/2021.05.03.442455"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed."	""	""	""	"Andrade"	"2021"	"https://doi.org/10.1101/2021.04.14.439719"	"doi:10.1101/2021.04.14.439719"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed."	""	""	""	"Andrade"	"2021"	"https://doi.org/10.1101/2021.04.14.439719"	"doi:10.1101/2021.04.14.439719"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%; 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period."	""	""	""	"Hitchlings"	"2021"	"https://doi.org/10.1101/2021.04.07.21255081"	"doi:10.1101/2021.04.07.21255081"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ or CD8+ cell count effect for P.1 by Activation Induced Marker (AIM) assay (cellular immunity measurement). No signficant change in IF-gamma or IL-5 spot  forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested."	""	""	""	"Mendes-Correa"	"2021"	"https://doi.org/10.1101/2021.05.11.21256908"	"doi:10.1101/2021.05.11.21256908"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ or CD8+ cell count effect for P.1 by Activation Induced Marker (AIM) assay (cellular immunity measurement). No signficant change in IF-gamma or IL-5 spot  forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections)."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ or CD8+ cell count effect for P.1 by Activation Induced Marker (AIM) assay (cellular immunity measurement). No signficant change in IF-gamma or IL-5 spot  forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against P.1 at various time points using pseudovirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 85%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 256 for B.1.1.7 virus. Compare to somewhat stronger neutralization titer for wild type (456.1) in the same sera."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 2896 for P.1 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"PBMCs of 11 mild COVID-19 patients collected 38-80 days after symptom onset were stimulated with the 15-mer peptide pools (w/ 10 residue overlaps) from the wholle viral proteome,  showing no significant CD4+ cell count effect for P.1,  and a slight increase in CD8+ percentage (p=0.0195) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  [in the text, this increase is not noted as signficant, even though p=0.05 is used elsewhere in the text as a signficance threshold]"	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 2896 for P.1 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,22812,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525,24642,25088"	"L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,T1027I,V1176F"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"P.1 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted,  with Lilly mAb combination LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of P.1.  There was also escape from neutralization of P.1 by REGN10933 (one of 2 in Regeneron's mAb cocktail)  and a modest reduction in neutralization of P.1 by AstraZeneca's AZD8895 (while AZD1061 and AZD7442 showed  equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized P.1 with all reaching a plateau at 100% neutralization; interestingly, ADG30  showed a slight increase of neutralization of P.1. S309 Vir was largely unaffected, although for several viruses, including P.1, the antibody failed to completely  neutralize, conceivably reflecting incomplete glycosylation at N343, since the sugar interaction is key to binding of this antibody."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21621,21638,21974,22132,23012,23060,23061,23062,23063,23399,23401,23402,23403,23521,23522,23524,23525"	"L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions"	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21801,22206,22334,22600,22600,22810,22811,22812,22813,22813,22879,22881,22882,22882,22986,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,D80A,D215G,W258R,R346S,R346S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,A475V,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.772T>C,NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1424C>T,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Trp258Arg,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ala475Val,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]"	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801"	"L18F,D80A"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region."	""	""	""	"Cai"	"2021"	"https://doi.org/10.1101/2021.04.13.439709"	"doi:10.1101/2021.04.13.439709"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors"	""	""	""	"Cele"	"2021"	"https://doi.org/10.1038/s41586-021-03471-w"	"doi:10.1038/s41586-021-03471-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In human sera 8 weeks post-vaccination with INO-4800, a ~7-fold reduction in B.1.351 neutralization was observed."	""	""	""	"Andrade"	"2021"	"https://doi.org/10.1101/2021.04.14.439719"	"doi:10.1101/2021.04.14.439719"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with  INO-4800 (DNA plasmid pGX9501 encoding full length Spike)."	""	""	""	"Riddell"	"2021"	"https://doi.org/10.1101/2021.04.17.440246"	"doi:10.1101/2021.04.17.440246"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with  INO-4800 (DNA plasmid pGX9501 encoding full length Spike)."	""	""	""	"Riddell"	"2021"	"https://doi.org/10.1101/2021.04.17.440246"	"doi:10.1101/2021.04.17.440246"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pzifer vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351,  as compared with unvaccinated individuals (odds ratio of 8:1), but were all infected before 14 days post second vaccination."	""	""	""	"Kustin"	"2021"	"https://doi.org/10.1101/2021.04.06.21254882"	"doi:10.1101/2021.04.06.21254882"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers."	""	""	""	"Wu"	"2021"	"https://doi.org/10.1101/2021.04.13.439482"	"doi:10.1101/2021.04.13.439482"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers."	""	""	""	"Wu"	"2021"	"https://doi.org/10.1101/2021.04.13.439482"	"doi:10.1101/2021.04.13.439482"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23593,23593,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers."	""	""	""	"Wu"	"2021"	"https://doi.org/10.1101/2021.04.13.439482"	"doi:10.1101/2021.04.13.439482"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351."	""	""	""	"Skelly"	"2021"	"https://doi.org/10.21203/rs.3.rs-226857/v1"	"doi:10.21203/rs.3.rs-226857/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"DARPin SR22 molecule had a 1.57x fold change in IC50 in B.1.351 Beta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"B.1.351 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted, with LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of B.1.351. There was also escape from neutralization of B.1.351 by REGN10933 and a modest reduction in neutralization of B.1.351 by AZD8895  (while AZD1061 and AZD7442 showed equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized B.1.351."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR16m had a 0.054x fold change in IC50 in B.1.351 Beta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 8 for B.1.351 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Sera from individuals who have been infected with Delta does not have strong neutralising activity against Beta."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Beta neutralizing antibodies is 0.803x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3)."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Pseudotype lentivirus for the full B.1.351 Spike variant list shows increase affinity for ACE2 as measured by IC50. This is in contrast to B.1.1.7 which showed no major change, indicating that the shared N501Y mutation is the driver of affinity change, attentuated in the B.1.1.7 mutatioon set, but maintained in the B.1.351 lineage."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 6.3x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Beta Variant B.1.351 RBD significantly better than w.t. SARS-CoV-2 RBD. Determined using Surrogate Viral Neutralization Tests."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR22 had a 0.07x fold change in IC50 in B.1.351 Beta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."	""	""	""	"Madhi"	"2021"	"https://doi.org/10.1056/NEJMoa2102214"	"doi:10.1056/NEJMoa2102214"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against Beta."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351."	""	""	""	"Skelly"	"2021"	"https://doi.org/10.21203/rs.3.rs-226857/v1"	"doi:10.21203/rs.3.rs-226857/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"The neutralizing activity of 16/20 convalescent sera was significantly lower against this pseudotyped virus model of B.1.351, with similar results for the live virus."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Beta neutralizing antibodies is 0.899x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants."	""	""	""	"Shinde"	"2021"	"https://doi.org/10.1056/NEJMoa2103055"	"doi:10.1056/NEJMoa2103055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type)."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants."	""	""	""	"Shinde"	"2021"	"https://doi.org/10.1056/NEJMoa2103055"	"doi:10.1056/NEJMoa2103055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera; 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera; 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."	""	""	""	"Madhi"	"2021"	"https://doi.org/10.1056/NEJMoa2102214"	"doi:10.1056/NEJMoa2102214"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.351-v1 reduced 6.9x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera; 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.351-v1 reduced 6.9x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"B.1.351 pseudotyped virus model ablates neutralization by RBD-directed mAbs CB6, 4-20, 2-4, 2-43, 910-30, 2-302-15, LY-Cov555, C121. B.1.351 pseudotyped virus model severely impairs neutralization by RBD-directed mAb 1-20. B.1.351 pseudotyped virus model impairs neutralization by RBD-directed mAb REGN10933. B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 4-19. B.1.351 pseudotyped virus model severely impairs neutralization by N-terminal-domain-directed mAb 2-17. B.1.351 pseudotyped virus model impairs neutralization by N-terminal-domain-directed mAb 5-7. PG: Live virus data for the same mAbs is similar, but 1-20 becomes severally impaired, REGN10933 activity is ablated, and Brii-196 becomes impaired."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type)."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"3.2x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type)."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]"	""	""	""	"Voysey"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants."	""	""	""	"Shinde"	"2021"	"https://doi.org/10.1056/NEJMoa2103055"	"doi:10.1056/NEJMoa2103055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants."	""	""	""	"Shinde"	"2021"	"https://doi.org/10.1056/NEJMoa2103055"	"doi:10.1056/NEJMoa2103055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"tissue specific neutralization"	""	""	"The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization)."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"A 1.8-fold drop in FRNT50 for B.1.351 was observed in 44 sera collected between 1 and 301 post-infection."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"DARPin SR16m molecule had a 0.036x fold change in IC50 in B.1.351 Beta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664,21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V,T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T,NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"DARPin SR16m molecule had a 99.7x fold change in IC50 in B.1.617.2 Delta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664,21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V,T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T,NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"DARPin SR16m molecule had a 6.7x fold change in IC50 in B.1.617.2 Delta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"L18F,D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with all key mutations from B.1.351 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing modest decrease in infection rate amongst the cells, suggesting some synergy between the mutations to decrease cell entry fitness (i.e. cell entry is liklely not the driver of this lineage's dominance)."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22206,23060,23061,23062,23063,22810,22811,22812,22813,22813,23012,23399,23401,23402,23403"	"L18F,D80A,D215G,N501Y,N501Y,N501Y,N501Y,K417N,K417N,K417N,K417N,K417N,E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"The most significant loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against authentic B.1.351 lineage virus (9.2-fold). Neutralization against 10 convalescent plasma was poorer (18.7x)."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.03.19.436183"	"doi:10.1101/2021.03.19.436183"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks."	""	""	""	"Meister"	"2021"	"https://doi.org/10.1093/infdis/jiab260"	"doi:10.1093/infdis/jiab260"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to D614G, this mutation set (B.1.351+) demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"L18F,D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to D614G, this mutation set (B.1.351+) demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI = 2.9 - 11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95%CI = 5.01-11.83; p <0.0001) comparing with November-December. This maybe due to a combination of changes in pathogenicity and virulence profiles, and health system overload. [exact mutations used to define P.1 lineage not disclosed in this publication]"	""	""	""	"Ribas Freitas"	"2021"	"https://doi.org/10.1101/2021.04.13.21255281"	"doi:10.1101/2021.04.13.21255281"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]"	""	""	""	"Santos de Oliviera"	"2021"	"https://doi.org/10.1101/2021.03.24.21254046"	"doi:10.1101/2021.03.24.21254046"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI = 2.9 - 11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95%CI = 5.01-11.83; p <0.0001) comparing with November-December. This maybe due to a combination of changes in pathogenicity and virulence profiles, and health system overload. [exact mutations used to define P.1 lineage not disclosed in this publication]"	""	""	""	"Ribas Freitas"	"2021"	"https://doi.org/10.1101/2021.04.13.21255281"	"doi:10.1101/2021.04.13.21255281"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI = 2.9 - 11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95%CI = 5.01-11.83; p <0.0001) comparing with November-December. This maybe due to a combination of changes in pathogenicity and virulence profiles, and health system overload. [exact mutations used to define P.1 lineage not disclosed in this publication]"	""	""	""	"Ribas Freitas"	"2021"	"https://doi.org/10.1101/2021.04.13.21255281"	"doi:10.1101/2021.04.13.21255281"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21614,22915,22916,22917,23060,23061,23062,23063,23521,23522,23524,23525"	"L18F,L452R,L452R,L452R,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.52C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel  with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased  to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced  by BNT162b2 (Pfizer) vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the  wild-type and B.1.1.7 strains."	""	""	""	"Mallm"	"2021"	"https://doi.org/10.1101/2021.04.27.21254849"	"doi:10.1101/2021.04.27.21254849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22224,22227,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,A222V,A222V,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.665C>T,NC_045512.2:g.665C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Relative to B.1, Delta (B.1.617.2) shows mean 2.1x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273)."	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22224,22227,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,A222V,A222V,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.665C>T,NC_045512.2:g.665C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Relative to B.1, Delta (B.1.617.2) shows 3.64x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]"	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,22915,22916,22917,23012,23399,23401,23402,23403"	"T19R,T95I,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Using ACE2-GFP+Spike-RFP fluorescence assay, this lineage defining mutation combination from B.1.617.3 increased syncytium formation ~2.3x."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,22915,22916,22917,23012,23399,23401,23402,23403"	"T19R,T95I,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this lineage defining mutation combination from B.1.617.3 conferred a ~11.8x drop in neutralization (NT50) [suggesting role for T19R and T95I in half the sera]."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,22915,22916,22917,23012,23399,23401,23402,23403"	"T19R,T95I,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this lineage defining mutation combination from B.1.617.3 conferred a ~4.5x infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21846,23399,23401,23402,23403"	"T19R,T95I,D614G,D614G,D614G,D614G"	"NC_045512.2:g.56C>G,NC_045512.2:g.284C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 did not confer an infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22028,22915,22916,22917,23604,23399,23401,23402,23403,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,E156del,L452R,L452R,L452R,P681R,D614G,D614G,D614G,D614G,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.467_472del,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.2042C>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4.5x cleavage of S2 relative to WA1 (D614G) wildtype by Delta (B.1.617.2) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~3.5x for closely related Kappa B.1.617.1 also with P681R at the cleavage site)."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. [Mutation list in publication appears to contain a typo with R158del instead of R158G]"	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 4.0x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Modelling the Delta variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increased 11x relative to wild type (15.3 vs 1.4). [del ~157 truncated due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a coinfection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.08.12.456173v3"	"doi:10.1101/2021.08.12.456173v3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 2.6x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR16m had a 0.020x fold change in IC50 in B.1.617.2 Delta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR22 had a 0.10x fold change in IC50 in B.1.617.2 Delta"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22915,22916,22917,22992,22995,23399,23401,23402,23403,24410"	"T19R,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"In primary human airway epithelial cultures, S1 to full length Spike ratio (measuring Spike furin cleavage  processivity) increase 1.9x relative to wild type (2.7 vs 1.4).  This is the Delta variant with the P681R furin cleavage site mutation absent. [del ~157 truncated due to ambiguity]"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.08.12.456173v3"	"doi:10.1101/2021.08.12.456173v3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Plasma neutralizing activity was also assessed against SARS-CoV-2 Delta, Omicron BA.1, BA.2 and BA.4/5 variants using viruses pseudotyped with appropriate  variant spikeproteins. Delta breakthrough infection resulted in 15-fold increased neutralizing titers."	""	""	""	"Wang"	"2022"	"https://doi.org/10.1101/2022.08.11.503601"	"doi:10.1101/2022.08.11.503601"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Plasma neutralizing activity in 49 participants was measured using HIV-1 pseudotyped with the 100 WT SARS-CoV-2 spike protein. Delta breakthrough infection  resulted in 11-fold increased geometric mean half-maximal neutralizing titer (NT50)."	""	""	""	"Wang"	"2022"	"https://doi.org/10.1101/2022.08.11.503601"	"doi:10.1101/2022.08.11.503601"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Delta neutralizing antibodies is 0.872x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Delta Variant B.1.617.2 RBD or w.t. SARS-CoV-2 RBD with nearly equal potency determined using Surrogate Viral Neutralization Tests."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 507 pM for binding to the Delta  B.1.617.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Delta neutralizing antibodies is 0.952x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"The incidence rate of Covid-19 during the Delta-dominant period (Jul-Aug 2021) was lower for late vaccinated (49.0/1000 person-years) [formerly placebo]  versus early vaccinated (77.1/1000 person-years) participants in the Moderna mRNA-1273 Phase 3 trials, representing a 36.4% VE reduction (95% CI 17.1%-51.5%). There were fewer severe Covid-19 cases in the late group (6; 6.2/1000 person-years) than early (13; 3.3/1000 person-years), representing a 46.0%  reduction (95% CI −52.4%-83.2%). Three Covid-19 related hospitalizations occurred with two resulting deaths in the early group."	""	""	""	"Baden"	"2021"	"https://doi.org/10.1101/2021.09.17.21263624"	"doi:10.1101/2021.09.17.21263624"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%."	""	""	""	"Nanduri"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e3"	"doi:10.15585/mmwr.mm7034e3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.92x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Delta Molnupiravir (MK-4482) had ~4x fold drop."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.  Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose. The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.08.11.21261885"	"doi:10.1101/2021.08.11.21261885"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Of 218 individuals with B.1.617.2 infection in Singapore, 84 had received a mRNA vaccine of which 71 were fully vaccinated,  130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of  severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001)."	""	""	""	"Chia"	"2021"	"https://doi.org/10.1101/2021.07.28.21261295"	"doi:10.1101/2021.07.28.21261295"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%."	""	""	""	"Nanduri"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e3"	"doi:10.15585/mmwr.mm7034e3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.  Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose. The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.08.11.21261885"	"doi:10.1101/2021.08.11.21261885"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%."	""	""	""	"Nanduri"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e3"	"doi:10.15585/mmwr.mm7034e3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%."	""	""	""	"Nanduri"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e3"	"doi:10.15585/mmwr.mm7034e3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.  Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose. The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.08.11.21261885"	"doi:10.1101/2021.08.11.21261885"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Of 218 individuals with B.1.617.2 infection in Singapore, 84 had received a mRNA vaccine of which 71 were fully vaccinated,  130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of  severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001)."	""	""	""	"Chia"	"2021"	"https://doi.org/10.1101/2021.07.28.21261295"	"doi:10.1101/2021.07.28.21261295"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%."	""	""	""	"Nanduri"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e3"	"doi:10.15585/mmwr.mm7034e3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated; 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI = 26%–84%) compared with 91% (95% CI = 81%–96%) during the  months preceding Delta predominance. This trend should be interpreted with caution because VE might also be declining as time since vaccination increases and because of  poor precision in estimates due to limited number of weeks of observation and few infections among participants. As with all observational VE  studies, unmeasured and residual confounding might be present."	""	""	""	"Fowlkes"	"2021"	"https://doi.org/10.15585/mmwr.mm7034e4"	"doi:10.15585/mmwr.mm7034e4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination  with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62).  [variant list included is ancestral Delta, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%; 95% confidence interval [CI], 25.2 to 35.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death."	""	""	""	""	"2021"	"https://doi.org/10.1503/cmaj.211248"	"doi:10.1503/cmaj.211248"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the UK, of 43338 COVID-19-positive patients, 8682 had the Delta variant (median age 31 years [IQR 17–43]) and 196 were admitted to hospital within 14  days after the specimen was taken (adjusted hazard ratio [HR] 2.26 [95% CI 1.32–3.89] relative to Alpha cases). Being admitted to hospital or attending emergency care within 14 days for Delta cases had an adjusted HR 1.45 [95% CI 1.08–1.95] relative to Alpha. Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients were similar: 1.94 [95% CI 0.47–8.05] for hospitalization and 1.58 [0.69–3.61]) for hospital admission or  emergency care attendance."	""	""	""	"Twohig"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death."	""	""	""	""	"2021"	"https://doi.org/10.1503/cmaj.211248"	"doi:10.1503/cmaj.211248"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	""	""	""	""	""	""	"https://www.moh.gov.sg/news-highlights/details/3-new-cases-of-locally-transmitted-covid-19-infection-28apr2021-update"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In the UK, of 43338 COVID-19-positive patients, 8682 had the Delta variant (median age 31 years [IQR 17–43]) and 196 were admitted to hospital within 14  days after the specimen was taken (adjusted hazard ratio [HR] 2.26 [95% CI 1.32–3.89] relative to Alpha cases). Being admitted to hospital or attending emergency care within 14 days for Delta cases had an adjusted HR 1.45 [95% CI 1.08–1.95] relative to Alpha. Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients were similar: 1.94 [95% CI 0.47–8.05] for hospitalization and 1.58 [0.69–3.61]) for hospital admission or  emergency care attendance."	""	""	""	"Twohig"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death."	""	""	""	""	"2021"	"https://doi.org/10.1503/cmaj.211248"	"doi:10.1503/cmaj.211248"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Vaccination of health care workers in Delhi was started in early 2021, with the ChdOx-1 (Astra Zeneca) vaccine. Surveillance has suggested B.1.1.7 dominance in the Delhi area during early 2021, with growth of B.1.617 since March 2021. During the wave of infections during March and April an outbreak of SARS-CoV-2 was confirmed in 33 vaccinated staff  members at a single tertiary centre (age 27-77 years). Sequencing revealed that 16/33 were B.1.617.2, with a range of other B lineage viruses including B.1.1.7 for the rest except one A lineage case.  Importantly no severe cases were documented in this event."	""	""	""	"Ferreira"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	""	""	""	""	""	""	"https://www.moh.gov.sg/news-highlights/details/3-new-cases-of-locally-transmitted-covid-19-infection-28apr2021-update"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Case 62541 cluster in Singapore included a fully vaccinated nurse 2 months post-vaccine [likely Pfizer based on dates and supply],  and a doctor of unknown vaccine status. This cluster was caused by a B.1.617.2 virus [via crossreference to"	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In Denmark, for the period Jan 1 to Jun 27, 2021, Delta variant was associated with increased an risk ratio of 2.83 [95% CI 2.02–3.98] for hospitalization."	""	""	""	"Bager"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.2 aka Delta) showed a 2.34x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred and represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.64x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.89x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 47D10. Delta (B.1.617.2) has an IC50 fold change of 46.5x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Delta (B.1.617.2) variant is 0.6x fold the wildtype."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Delta (B.1.617.2) has an IC50 fold change of 0.57x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Delta (B.1.617.2) has an IC50 fold change of 0.87x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,22028,22028,22034,22915,22916,22917,22992,22995,23399,23401,23402,23403,23604,24410,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"T19R,E156del,R158G,R158G,L452R,L452R,L452R,T478K,T478K,D614G,D614G,D614G,D614G,P681R,D950N,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.56C>G,NC_045512.2:g.467_472del,NC_045512.2:g.467_472del,NC_045512.2:g.472A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.2848G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp950Asn,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Delta (B.1.617.2) has an IC50 fold change of 0.15x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21618,23399,23401,23402,23403"	"T19R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.56C>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21627"	"T22I"	"NC_045512.2:g.65C>T"	"YP_009724390.1:p.Thr22Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain, frequently observed in various human infection lineages, reduces the  tropism of SARS-CoV-2 in F81 (cat kidney, Felis catus) and BHK-21 (golden hamster kidney, Mesocricetus auratus) cell line cultures using a pseudotyped VSV assay."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21648"	"T29I"	"NC_045512.2:g.86C>T"	"YP_009724390.1:p.Thr29Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain significantly reduced the tropism of SARS-CoV-2 to MfuKi (eastern bent-wing bat kidney cell, Miniopterus fuliginosus) cell cultures using a pseudotyped VSV assay."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21717,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23012,23399,23401,23402,23403,23593,23593,24224"	"Q52R,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,E484K,D614G,D614G,D614G,D614G,Q677H,Q677H,F888L"	"NC_045512.2:g.155A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2662T>C"	"YP_009724390.1:p.Gln52Arg,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Phe888Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21717,23012,23593,23593,24224"	"Q52R,E484K,Q677H,Q677H,F888L"	"NC_045512.2:g.155A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C,NC_045512.2:g.2662T>C"	"YP_009724390.1:p.Gln52Arg,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Phe888Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021)."	""	""	""	"Albertsen"	"2021"	"https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21752,21752"	"W64R,W64R"	"NC_045512.2:g.190T>A,NC_045512.2:g.190T>C"	"YP_009724390.1:p.Trp64Arg,YP_009724390.1:p.Trp64Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection, but also in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal immunity escape variant."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21759"	"H66R"	"NC_045512.2:g.197A>G"	"YP_009724390.1:p.His66Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears  convergent, especially on a D614 wildtype background."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This deletion outside the receptor binding domain in pseudotyped VSV promoted the capacity of pseudotyped VSV to transduce black flying fox (Pteropus alecto) kidney PabKi.1 cells (17.8%) to a level twice that of human epithelial-like Huh-7 cells (9.8%)"	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI)."	""	""	""	"Rees-Spear"	"2021"	"https://doi.org/10.1101/2021.01.15.426849"	"doi:10.1101/2021.01.15.426849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralization activity of almost all convalescent sera tested decreased ~2x."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7."	""	""	""	"Kemp"	"2020"	"https://doi.org/10.1101/2020.12.14.422555"	"doi:10.1101/2020.12.14.422555"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"No notable change in neutralization efficiency, despite N439K by itself showing a ~2x decrease on average in 16 health workers' convalescent sera."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,21987,21990,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23039,23040,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,Y145del,Y145del,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q493R,Q493R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]"	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,21987,21990,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23039,23040,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,Y145del,Y145del,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q493R,Q493R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50=72)."	""	""	""	"Wang"	"2022"	"https://doi.org/10.1101/2022.08.11.503601"	"doi:10.1101/2022.08.11.503601"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently."	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G"	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection."	""	""	""	"Shete"	"2022"	"https://doi.org/10.1101/2022.05.12.491584"	"doi:10.1101/2022.05.12.491584"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection."	""	""	""	"Shete"	"2022"	"https://doi.org/10.1101/2022.05.12.491584"	"doi:10.1101/2022.05.12.491584"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23048,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604,24130"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,G496S,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H,N856K"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1486G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2568C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection."	""	""	""	"Shete"	"2022"	"https://doi.org/10.1101/2022.05.12.491584"	"doi:10.1101/2022.05.12.491584"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently."	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22679,22686,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,S373P,S375F,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G"	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21987,21990,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21987,21990,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,21987,21990,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample. Contrast this with 1.3-fold reduction for just the pseudovirus combination of ""key"" B.1.1.7 mutation N501Y."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild to modest decrease in infection rate amongst the cells, suggesting a net mild  negative effect on human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing moderate decrease in infection rate amongst the cells, significantly lower than the  deletion or Y453F alone, or their combination, suggesting a synergistic effect on  poorer human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, much closer to D614G activity level than Y453F alone, suggesting compensatory effects between the  deletion and the mutation in human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920,23399,23401,23402,23403,25249,25249,25249"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F,D614G,D614G,D614G,D614G,M1229I,M1229I,M1229I"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3687G>C,NC_045512.2:g.3687G>A,NC_045512.2:g.3687G>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose)  and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920,25249,25249,25249"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F,M1229I,M1229I,M1229I"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T,NC_045512.2:g.3687G>C,NC_045512.2:g.3687G>A,NC_045512.2:g.3687G>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells, markedly higher infectivity than  either mutation alone, suggesting a synergistic net neutral effect on human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920,25249,25249,25249"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F,M1229I,M1229I,M1229I"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T,NC_045512.2:g.3687G>C,NC_045512.2:g.3687G>A,NC_045512.2:g.3687G>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Lentiviral pseudotyped with the key mutations from Mink Cluster 5 was neutralized more easily than D614G in 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,22920,25249,25249,25249"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y453F,M1229I,M1229I,M1229I"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1358A>T,NC_045512.2:g.3687G>C,NC_045512.2:g.3687G>A,NC_045512.2:g.3687G>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr453Phe,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with all key mutations from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major (~50%) decrease in infection rate amongst the cells, suggesting that this  anthropozoonotic event is driven by other factors at the expense of human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23012,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,E484K,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.7+E484K reduced 2.8x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. Compare with 1.2x reduction for B.1.1.7 without E484K."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23012,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,E484K,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23012,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,E484K,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23012,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,E484K,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data"	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02). Mean age was 36 yo."	""	""	""	"van Loon"	"2021"	"https://doi.org/10.1101/2021.04.15.21255389"	"doi:10.1101/2021.04.15.21255389"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02). Mean age was 36 yo."	""	""	""	"van Loon"	"2021"	"https://doi.org/10.1101/2021.04.15.21255389"	"doi:10.1101/2021.04.15.21255389"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p=0.029), in London between March 13th 2020 and February 17th 2021 (400 B.1.1.7 cases out of 1470 total sequenced)."	""	""	""	"Snell"	"2021"	"https://doi.org/10.1101/2021.03.16.21253377"	"doi:10.1101/2021.03.16.21253377"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1136/bmj.n1088"	"doi:10.1136/bmj.n1088"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"clinical indicators"	""	""	"After adjusting for the age factor, in a prospective Chinese cohort study B.1.1.7 variant infection (compared to B.1.140) was the risk factor for  C-reactive protein (P = 0.045, Odds ratio [OR] 2.791, CI [1.025, 0.8610]),  Serum amyloid A (0.011, 5.031, [1.459, 17.354]), Creatine Kinase (0.034, 4.34, [0.05, 0.91]),  CD4+ T lymphocyte (0.029, 3.31, [1.13, 9.71]), and Ground Glass Opacity (0.005, 5.418, [1.656, 17.729])"	""	""	""	"Song"	"2021"	"https://doi.org/10.1101/2021.05.04.21256655"	"doi:10.1101/2021.05.04.21256655"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"SARS-CoV-2 infection was confirmed in three HCWs working a single shift; all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE)."	""	""	""	"Loconsole"	"2021"	"https://doi.org/10.1016/j.cmi.2021.05.007"	"doi:10.1016/j.cmi.2021.05.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1136/bmj.n1088"	"doi:10.1136/bmj.n1088"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1136/bmj.n1088"	"doi:10.1136/bmj.n1088"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"SARS-CoV-2 infection was confirmed in three HCWs working a single shift; all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE)."	""	""	""	"Loconsole"	"2021"	"https://doi.org/10.1016/j.cmi.2021.05.007"	"doi:10.1016/j.cmi.2021.05.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"SARS-CoV-2 infection was confirmed in three HCWs working a single shift; all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE)."	""	""	""	"Loconsole"	"2021"	"https://doi.org/10.1016/j.cmi.2021.05.007"	"doi:10.1016/j.cmi.2021.05.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1136/bmj.n1088"	"doi:10.1136/bmj.n1088"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion)."	""	""	""	"Marquez"	"2021"	"https://doi.org/10.1017/ice.2021.195"	"doi:10.1017/ice.2021.195"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Second infection in December 2020 with B.1.1.7 after April 2020 initial infection with B.2 in a 78-year-old man with a history of Type 2 diabetes mellitus,  diabetic nephropathy on hemodialysis, chronic obstructive pulmonary disease (COPD), mixed central  and obstructive sleep apnea, ischemic heart disease, with no history of immunosuppression."	""	""	""	"Harrington"	"2021"	"https://doi.org/10.1093/cid/ciab014"	"doi:10.1093/cid/ciab014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM for binding to the Alpha  B1.1.7. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Lessens the potency of mAbs	COVA2-17 (~5x, similar to N501Y alone), COVA1-12 (~11x) and COVA1-21 (>100x), which do not compete allosterically."	""	""	""	"Rees-Spear"	"2021"	"https://doi.org/10.1101/2021.01.15.426849"	"doi:10.1101/2021.01.15.426849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 1.7x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"B.1.1.7 pseudotyped virus model impairs binding by RBD-directed mAb 910-30. B.1.1.7 pseudotyped virus model abolishes N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8. B.1.1.7 pseudotyped virus model impairs binding by N-terminal-domain-directed mAbs 2-17, 4-19, 5-7."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020. Possible reinfections were  identified in 249 (0.7% [95% CI 0.6-0.8]) of 36509 app users who reported a positive swab test before Oct 1, 2020,  but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants."	""	""	""	"Graham"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"~20x resistence to mAb CQ038 by B.1.1.7 pseudotyped virus"	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Alpha Variant B.1.1.7 RBD significantly better than GenScript IgG FL18-740 w.t. ACE-2 mAB. Determined using Surrogate Viral Neutralization Tests."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.1.7. We observed a dramatic increase (relative to D614G) in binding of soluble  ACE2 to B.1.1.7, and to a lesser extent to B.1.351, which both carry the N501Y mutation (see Fig 3)."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion)."	""	""	""	"Marquez"	"2021"	"https://doi.org/10.1017/ice.2021.195"	"doi:10.1017/ice.2021.195"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]"	""	""	""	"Puranik"	"2021"	"https://doi.org/10.1101/2021.08.06.21261707"	"doi:10.1101/2021.08.06.21261707"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%; 95% confidence interval [CI], 45.5 to 51.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7);  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2; 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined"	""	""	""	"Haas"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 (n=15) and day 14 (n-14) post-2nd dose) against a B.1.1.7 variant (USA/CA_CDC_5574/2020  [USA/CA-SEARCH-5574/2020?]) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease."	""	""	""	"Emary"	"2021"	"https://doi.org/10.2139/ssrn.3779160"	"doi:10.2139/ssrn.3779160"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots."	""	""	""	"Woldemeskel"	"2021"	"https://doi.org/10.1172/JCI149335"	"doi:10.1172/JCI149335"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus."	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1093/jtm/taab051"	"doi:10.1093/jtm/taab051"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for B.1.1.7,  and a slight increase in CD8+ percentage (p=0.0314) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed."	""	""	""	"Tarke"	"2021"	"https://doi.org/10.1101/2021.02.27.433180"	"doi:10.1101/2021.02.27.433180"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against symptomatic infection caused by Alpha, vaccine effectiveness with partial vaccination (≥14 days after dose 1) was higher for mRNA-1273 (83%) than BNT162b2 (66%) and ChAdOx1 (64%), and full vaccination (≥7 days after dose 2) increased vaccine effectiveness for BNT162b2 (89%) and mRNA-1273 (92%)."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%; 95% confidence interval [CI], 45.5 to 51.7); the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1056/NEJMoa2108891"	"doi:10.1056/NEJMoa2108891"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant."	""	""	""	"Hall"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]"	""	""	""	"Amit"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"aerosolization"	""	""	"Alpha variant cases in a large campus study showed fine-aerosol shedding amongst unmasked participants remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptom. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding."	""	""	""	"Adenaiye"	"2021"	"https://doi.org/10.1093/cid/ciab797"	"doi:10.1093/cid/ciab797"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~2.5x cleavage of S2 relative to WA1 (D614G) wildtype by Alpha variant variant as measured by mass spectrometry of Vero-TMPRSS culture."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"First documented cases of domestic cat and dog infections with the B.1.1.7 strain."	""	""	""	"Hamer"	"2021"	"https://doi.org/10.1111/tbed.14122"	"doi:10.1111/tbed.14122"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the 47D10. Alpha (B.1.1.7) has an IC50 fold change of 0.40x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks."	""	""	""	"Meister"	"2021"	"https://doi.org/10.1093/infdis/jiab260"	"doi:10.1093/infdis/jiab260"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively."	""	""	""	"Schuit"	"2021"	"https://doi.org/10.1093/infdis/jiab171"	"doi:10.1093/infdis/jiab171"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively."	""	""	""	"Schuit"	"2021"	"https://doi.org/10.1093/infdis/jiab171"	"doi:10.1093/infdis/jiab171"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.44x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"CryoEM analysis of B.1.1.7 demonstrates an increased propensity for 'up', receptor accessible conformation of the Spike protein trimer."	""	""	""	"Cai"	"2021"	"https://doi.org/10.1101/2021.04.13.439709"	"doi:10.1101/2021.04.13.439709"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China). Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The sera of 16 individuals with time course collection was evaulated against VSV pseudotypes: neutralized D614G at week 2,  whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were  similarly neutralized at week 4 (1 week after booster dose)."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant."	""	""	""	"Lopez Bernal"	"2021"	"https://doi.org/10.1136/bmj.n1088"	"doi:10.1136/bmj.n1088"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used)."	""	""	""	"Gallagher"	"2021"	"https://doi.org/10.1101/2021.05.03.442455"	"doi:10.1101/2021.05.03.442455"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"We observed a sharp decline in cases when ∼50% of the elderly population was 2 weeks beyond their first  vaccination dose and at a time point during which the B.1.1.7 variant gained transmission dominance.  In support of this finding, it was suggested that, after the first vaccination dose, more than 70% of  patients develop neutralization antibodies,15 and the vaccine efficiency can reach 85%."	""	""	""	"Munitz"	"2021"	"https://doi.org/10.1016/j.xcrm.2021.100264"	"doi:10.1016/j.xcrm.2021.100264"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used)."	""	""	""	"Gallagher"	"2021"	"https://doi.org/10.1101/2021.05.03.442455"	"doi:10.1101/2021.05.03.442455"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Live virus was tested ex vivo in reconstituted brochial epithelium, and out competed wild type."	""	""	""	"Touret"	"2021"	"https://doi.org/10.1101/2021.03.22.436427"	"doi:10.1101/2021.03.22.436427"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.39x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n=15), 2.1-fold (28 days post 2nd dose AstraZeneca, n=10),  and 3.3-fold (7-17 days post 2nd dose Pfizer-BioNTech, n=25). [D1119H was included in the original paper, assumed typographical error and changed to D1118H]"	""	""	""	"Supasa"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.033"	"doi:10.1016/j.cell.2021.02.033"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 1 (B.1.1.7) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"SARS-CoV-2 infection was confirmed in three HCWs working a single shift; all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE)."	""	""	""	"Loconsole"	"2021"	"https://doi.org/10.1016/j.cmi.2021.05.007"	"doi:10.1016/j.cmi.2021.05.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly  transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency."	""	""	""	"Graham"	"2021"	"https://doi.org/10.1016/j.immuni.2021.03.023"	"doi:10.1016/j.immuni.2021.03.023"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Modelling the Alpha variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increase 3.9x relative to wild type (5.4 vs 1.4). This is less efficient than Delta (11x vs wildtype using a P681R mutation instead). [del ~144 changed due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a co-infection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.08.12.456173v3"	"doi:10.1101/2021.08.12.456173v3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"tissue specific neutralization"	""	""	"The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose)  and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA. Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is  equivalent at the protein level to the more commonly annotated Y144del."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Alpha (B.1.1.7) variant is 1.0x fold the wildtype in 42 COVI."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Alpha Molnupiravir (MK-4482) had ~2.75x fold drop."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"NVX-CoV2373 [Novavax] vaccine in phase 3 trial was 89.7% (95% CI, 80.2-94.6) effective in preventing COVID-19, with no hospitalizations or  deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of  96.4% (73.8-99.5) and 86.3% (71.3-93.5) against the prototype strain and B.1.1.7 variant, respectively."	""	""	""	"Heath"	"2021"	"https://doi.org/10.1101/2021.05.13.21256639"	"doi:10.1101/2021.05.13.21256639"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Alpha (B.1.1.7) has an IC50 fold change of 1.19x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	""	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,23709,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,T716I,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.1.7 lineage effectiveness was observed as 29.5% (95% CI [22.9,35.5]) against infection, and 54.1% against severe/critical/fatal disease  (95% CI [26.1-71.9]). Two weeks or more after 2nd dose, effectiveness climbed to 89.5% [85.9,92.3] against infection, and 100% against  severe/critical/fatal disease (95% CI [81.7,100])."	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,24506"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,S982A"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2944T>G"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Lilly's LY-CoV16 showed marked reduction in neutralization of B.1.1.7."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23604,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,P681H,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Sera neutralized the B1.1.7 isolate with a lower potency (2-fold; 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency had undetectable heterotypic potency (2/25)."	""	""	""	"Skelly"	"2021"	"https://doi.org/10.21203/rs.3.rs-226857/v1"	"doi:10.21203/rs.3.rs-226857/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23399,23401,23402,23403,23709,23604,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,D614G,D614G,D614G,D614G,T716I,P681H,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2147C>T,NC_045512.2:g.2042C>A,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"tissue specific replication effects"	""	""	"In this report, by using a lower infectious dose, we demonstrate that B.1.1.7  (cultured sample Hong Kong/HKPU-00015/2021) exhibits higher infectivity and/or  replication efficiency in the nasal epithelium. (Hamster model of infection)"	""	""	""	"Mok"	"2021"	"https://doi.org/10.1101/2021.04.19.440414"	"doi:10.1101/2021.04.19.440414"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older."	""	""	""	"Nyberg"	"2021"	"https://doi.org/10.48550/arXiv.2104.05560"	"doi:10.48550/arXiv.2104.05560"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 (""UK variant"").  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H."	""	""	""	"Ratcliff"	"2021"	"https://doi.org/10.1101/2021.02.24.21251989"	"doi:10.1101/2021.02.24.21251989"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1038/s41586-021-03426-1"	"doi:10.1038/s41586-021-03426-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7."	""	""	""	"Graham"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively."	""	""	""	"Roquebert"	"2021"	"https://doi.org/10.1101/2021.03.19.21253971"	"doi:10.1101/2021.03.19.21253971"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7."	""	""	""	"Graham"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66)."	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66)."	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38])."	""	""	""	"Frampton"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 (""UK variant"").  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H."	""	""	""	"Ratcliff"	"2021"	"https://doi.org/10.1101/2021.02.24.21251989"	"doi:10.1101/2021.02.24.21251989"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <=55yo,  but not in the 14 sera from those >55yo. A ~20% change is not considered immunologically significant historically in influenza antibody studies."	""	""	""	"Muik"	"2021"	"https://doi.org/10.1126/science.abg6105"	"doi:10.1126/science.abg6105"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <=55yo,  but not in the 14 sera from those >55yo. A ~20% change is not considered immunologically significant historically in influenza antibody studies."	""	""	""	"Muik"	"2021"	"https://doi.org/10.1126/science.abg6105"	"doi:10.1126/science.abg6105"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The mortality hazard ratio associated with infection with [B.1.1.7] compared with infection with previously circulating variants was  1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community (54906 matched pairs of  participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021). In this comparatively low risk  group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases."	""	""	""	"Challen"	"2021"	"https://doi.org/10.1136/bmj.n579"	"doi:10.1136/bmj.n579"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 ""wild type"" SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples."	""	""	""	"Couzens"	"2021"	"https://doi.org/10.1101/2021.04.02.21254832"	"doi:10.1101/2021.04.02.21254832"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 (""UK variant"").  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H."	""	""	""	"Ratcliff"	"2021"	"https://doi.org/10.1101/2021.02.24.21251989"	"doi:10.1101/2021.02.24.21251989"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1038/s41586-021-03426-1"	"doi:10.1038/s41586-021-03426-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older."	""	""	""	"Nyberg"	"2021"	"https://doi.org/10.48550/arXiv.2104.05560"	"doi:10.48550/arXiv.2104.05560"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older."	""	""	""	"Nyberg"	"2021"	"https://doi.org/10.48550/arXiv.2104.05560"	"doi:10.48550/arXiv.2104.05560"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7. After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.). Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second  Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older."	""	""	""	"Nyberg"	"2021"	"https://doi.org/10.48550/arXiv.2104.05560"	"doi:10.48550/arXiv.2104.05560"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1038/s41586-021-03426-1"	"doi:10.1038/s41586-021-03426-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 (""UK variant"").  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H."	""	""	""	"Ratcliff"	"2021"	"https://doi.org/10.1101/2021.02.24.21251989"	"doi:10.1101/2021.02.24.21251989"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 ""wild type"" SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples."	""	""	""	"Couzens"	"2021"	"https://doi.org/10.1101/2021.04.02.21254832"	"doi:10.1101/2021.04.02.21254832"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change."	""	""	""	"Teyssou"	"2021"	"https://doi.org/10.1101/2021.03.21.21253498"	"doi:10.1101/2021.03.21.21253498"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 (""UK variant"").  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H."	""	""	""	"Ratcliff"	"2021"	"https://doi.org/10.1101/2021.02.24.21251989"	"doi:10.1101/2021.02.24.21251989"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 ""wild type"" SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples."	""	""	""	"Couzens"	"2021"	"https://doi.org/10.1101/2021.04.02.21254832"	"doi:10.1101/2021.04.02.21254832"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change."	""	""	""	"Teyssou"	"2021"	"https://doi.org/10.1101/2021.03.21.21253498"	"doi:10.1101/2021.03.21.21253498"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively."	""	""	""	"Roquebert"	"2021"	"https://doi.org/10.1101/2021.03.19.21253971"	"doi:10.1101/2021.03.19.21253971"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity."	""	""	""	"Nyayanit"	"2021"	"https://doi.org/10.1101/2021.04.30.442222"	"doi:10.1101/2021.04.30.442222"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 ""wild type"" SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples."	""	""	""	"Couzens"	"2021"	"https://doi.org/10.1101/2021.04.02.21254832"	"doi:10.1101/2021.04.02.21254832"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change."	""	""	""	"Teyssou"	"2021"	"https://doi.org/10.1101/2021.03.21.21253498"	"doi:10.1101/2021.03.21.21253498"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The median Ct value of RT-qPCR tests of the N-gene target in the Daxing B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P=0.036)."	""	""	""	"Song"	"2021"	"https://doi.org/10.1101/2021.05.04.21256655"	"doi:10.1101/2021.05.04.21256655"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38])."	""	""	""	"Frampton"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1038/s41586-021-03426-1"	"doi:10.1038/s41586-021-03426-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older."	""	""	""	"Nyberg"	"2021"	"https://doi.org/10.48550/arXiv.2104.05560"	"doi:10.48550/arXiv.2104.05560"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases)."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age."	""	""	""	"Bager"	"2021"	"https://doi.org/10.2139/ssrn.3792894"	"doi:10.2139/ssrn.3792894"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x)."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38])."	""	""	""	"Frampton"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR=1.31, 95%CI 1.14-1.49)"	""	""	""	"Buchan"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models."	""	""	""	"Lamers"	"2021"	"https://doi.org/10.1101/2021.05.03.441080"	"doi:10.1101/2021.05.03.441080"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"VSV pseudotype B.1.1.7 showed no significant difference in cell entry relative to wild type in 6 cell lines. Cell fusion proficiency was unchanged."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR=1.31, 95%CI 1.14-1.49)"	""	""	""	"Buchan"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants."	""	""	""	"Lindstrøm"	"2021"	"https://doi.org/10.1101/2021.03.29.21254122"	"doi:10.1101/2021.03.29.21254122"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks."	""	""	""	"Munitz"	"2021"	"https://doi.org/10.1016/j.xcrm.2021.100264"	"doi:10.1016/j.xcrm.2021.100264"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Based on 36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020,  Rt of B.1.1.7 was 1.35x (95% CI 1.02-1.69) relative to pre-existing variants. However, Rt fell below 1 during regional and  national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant."	""	""	""	"Graham"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66)."	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks."	""	""	""	"Munitz"	"2021"	"https://doi.org/10.1016/j.xcrm.2021.100264"	"doi:10.1016/j.xcrm.2021.100264"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR=1.31, 95%CI 1.14-1.49)"	""	""	""	"Buchan"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66)."	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country."	""	""	""	"Davies"	"2021"	"https://doi.org/10.1126/science.abg3055"	"doi:10.1126/science.abg3055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants."	""	""	""	"Lindstrøm"	"2021"	"https://doi.org/10.1101/2021.03.29.21254122"	"doi:10.1101/2021.03.29.21254122"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR=1.31, 95%CI 1.14-1.49)"	""	""	""	"Buchan"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66)."	""	""	""	"Stefanelli"	"2021"	"https://doi.org/10.1101/2021.04.06.21254923"	"doi:10.1101/2021.04.06.21254923"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants."	""	""	""	"Lindstrøm"	"2021"	"https://doi.org/10.1101/2021.03.29.21254122"	"doi:10.1101/2021.03.29.21254122"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load."	""	""	""	"Lyngse"	"2021"	"https://doi.org/10.1101/2021.04.16.21255459"	"doi:10.1101/2021.04.16.21255459"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Slight neutralization improvement on average in 16 health workers' convalescent sera."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23604"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,P681H"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,22679,23521,23522,23524,23525,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,23060,23061,23062,23063,22879,22881,22882,22882,23071,23074,23075,22992,22995,22810,22811,22812,22813,22813,23018,22576,22577,22578,22783,22784,22785,22786,22786,23604,22686,23053,23054,23055,22992,23009,23010,23012,23013,21761,21762,21763,21764,21765,21766,21766,23399,23401,23402,23403,22915,22916,22917"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,S373P,H655Y,H655Y,H655Y,H655Y,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,N501Y,N501Y,N501Y,N501Y,N440K,N440K,N440K,N440K,Y505H,Y505H,Y505H,T478K,T478K,K417N,K417N,K417N,K417N,K417N,F486V,G339D,G339D,G339D,R408S,R408S,R408S,R408S,R408S,P681H,S375F,Q498R,Q498R,Q498R,S477N,E484A,E484A,E484A,E484A,V70del,V70del,V70del,V70del,V70del,V70del,V70del,D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1117T>C,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1456T>G,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.2042C>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Phe486Val,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,22679,23521,23522,23524,23525,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,23060,23061,23062,23063,22879,22881,22882,22882,23071,23074,23075,22992,22995,22810,22811,22812,22813,22813,23018,22576,22577,22578,22783,22784,22785,22786,22786,23604,22686,23053,23054,23055,22992,23009,23010,23012,23013,21761,21762,21763,21764,21765,21766,21766,23399,23401,23402,23403,22915,22916,22917"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,S373P,H655Y,H655Y,H655Y,H655Y,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,N501Y,N501Y,N501Y,N501Y,N440K,N440K,N440K,N440K,Y505H,Y505H,Y505H,T478K,T478K,K417N,K417N,K417N,K417N,K417N,F486V,G339D,G339D,G339D,R408S,R408S,R408S,R408S,R408S,P681H,S375F,Q498R,Q498R,Q498R,S477N,E484A,E484A,E484A,E484A,V70del,V70del,V70del,V70del,V70del,V70del,V70del,D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1117T>C,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1456T>G,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.2042C>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Phe486Val,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,22810,22811,22812,22813,22813,23009,23010,23012,23013"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,K417N,K417N,K417N,K417N,K417N,E484A,E484A,E484A,E484A"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR=0.46, 95%CI: 0.27, 0.77) among Omicron cases, after adjusting for vaccination statis and time since 2nd shot. The ratio for >60yo was 0.55 (95%CI: 0.28-1.06), and <60yo was 0.30 (95%CI: 0.16-0.57)."	""	""	""	"Ulloa"	"2021"	"https://doi.org/10.1101/2021.12.24.21268382"	"doi:10.1101/2021.12.24.21268382"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21761,21762,21763,21764,21765,21766,21766,23009,23010,23012,23013"	"H69del,H69del,H69del,H69del,H69del,H69del,H69del,E484A,E484A,E484A,E484A"	"NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron]"	""	""	""	"Pulliam"	"2021"	"https://doi.org/10.1101/2021.11.11.21266068"	"doi:10.1101/2021.11.11.21266068"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21800"	"D80N"	"NC_045512.2:g.238G>A"	"YP_009724390.1:p.Asp80Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21800"	"D80Y"	"NC_045512.2:g.238G>T"	"YP_009724390.1:p.Asp80Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This AA substitution outside the receptor binding domain in pseudotyped VSV promoted a 7.2% transduction rate in golden hamster cells, which was higher than that of human epithelial-like Huh-7 cells (6.6%)."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21800,22188,22206,22597,22599,23012,23521,23522,23524,23525,23604"	"D80Y,I210del,D215G,R346K,R346K,E484K,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.238G>T,NC_045512.2:g.629_631del,NC_045512.2:g.644A>G,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Asp80Tyr,YP_009724390.1:p.Ile210del,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against A.VOI.V2 (first identified in Angola) reduced 8.0x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801"	"D80A"	"NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801"	"D80A"	"NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2."	""	""	""	"Riou"	"2021"	"https://doi.org/10.1126/scitranslmed.abj6824"	"doi:10.1126/scitranslmed.abj6824"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801"	"D80A"	"NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801"	"D80A"	"NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern."	""	""	""	"Redd"	"2021"	"https://doi.org/10.1101/2021.02.11.21251585"	"doi:10.1101/2021.02.11.21251585"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801"	"D80A"	"NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+."	""	""	""	"Pegu"	"2021"	"https://doi.org/10.1101/2021.05.13.444010"	"doi:10.1101/2021.05.13.444010"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]"	""	""	""	"Abe"	"2021"	"https://doi.org/10.1101/2021.08.06.21261721"	"doi:10.1101/2021.08.06.21261721"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]"	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose."	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Beta (B.1.351) variant is 0.4x fold the wildtype."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined."	""	""	""	"Madhi"	"2021"	"https://doi.org/10.1101/2021.02.10.21251247"	"doi:10.1101/2021.02.10.21251247"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used)."	""	""	""	"Gallagher"	"2021"	"https://doi.org/10.1101/2021.05.03.442455"	"doi:10.1101/2021.05.03.442455"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used)."	""	""	""	"Gallagher"	"2021"	"https://doi.org/10.1101/2021.05.03.442455"	"doi:10.1101/2021.05.03.442455"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination."	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Unlike wild type or B.1.1.7, B.1.351 lineage virus was able to infect and replicate in common lab mouse strains, with high titer. PG: The virus used in these expriments has a non-typical deletion+sub in the 242 region."	""	""	""	"Montagutelli"	"2021"	"https://doi.org/10.1101/2021.03.18.436013"	"doi:10.1101/2021.03.18.436013"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Beta (B.1.351) has an IC50 fold change of 0.13x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Beta (B.1.351) has an IC50 fold change of 0.15x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001)."	""	""	""	"Zhou"	"2021"	"http://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001)."	""	""	""	"Zhou"	"2021"	"http://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~6x cleavage of S2 relative to WA1 (D614G) wildtype by Beta variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but A701V is downstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Beta Molnupiravir (MK-4482) had ~1.75x fold drop."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Beta (B.1.351) has an IC50 fold change of 0.13x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001)."	""	""	""	"Zhou"	"2021"	"http://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination."	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta.  Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher."	""	""	""	"Abu-Raddad"	"2021"	"https://doi.org/10.1101/2021.08.02.21261465"	"doi:10.1101/2021.08.02.21261465"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 34 convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7, neutralization titers  against B.1.351 were, on average, 13.3-fold reduced compared with an early Victoria sample (p < 0.0001). Significantly, 18  of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity. In 13 convalescent cases 4–9 weeks following infection with B.1.1.7, neutralization titers  against B.1.351 were, on average, 3.1-fold reduced compared with an early Victoria sample (p < 0.0001)."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Testing against B.1.351 the 20 most effective mAbs (19 anti-RBD, 1 anti-NTD) from a screen of 377 against wild type,  4 of 20 antibodies had >10-fold fall in neutralization titers, with most of these showing a complete knockout of  activity. This is in line with the key roles of K417, E484, and N501, in particular E484, in antibody recognition  of the ACE2 interaction surface of the RBD. Regeneron mAb cocktail: The neutralization of REGN10987 was unaffected by B.1.351, while REGN10933 was severely impaired (773-fold). AstraZeneca mAb cocktail: Neutralization by the AZ pair of antibodies was little affected on B.1.351 compared with Victoria."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible."	""	""	""	"Funk"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348"	"doi:10.2807/1560-7917.ES.2021.26.16.2100348"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The B.1.351 variant constellation causes an ∼20-fold increase in affinity for ACE2 compared with Wuhan RBD, which may influence transmissibility."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.037"	"doi:10.1016/j.cell.2021.02.037"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1056/NEJMc2102017"	"doi:10.1056/NEJMc2102017"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"humoral response durability"	""	""	"In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant."	""	""	""	"Betton"	"2020"	"https://doi.org/10.1093/cid/ciab308"	"doi:10.1093/cid/ciab308"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 47D10. Beta (B.1.351) has an IC50 fold change of 0.88x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664,23399,23401,23402,23403"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V,D614G,D614G,D614G,D614G"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."	""	""	""	"Stamatatos"	"2021"	"https://doi.org/10.1126/science.abg9175"	"doi:10.1126/science.abg9175"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23664,23060,23061,23062,23063,23012"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,A701V,N501Y,N501Y,N501Y,N501Y,E484K"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.2102C>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission."	""	""	""	"Yinda"	"2021"	"https://doi.org/10.1101/2021.05.05.442780"	"doi:10.1101/2021.05.05.442780"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23664,23060,23061,23062,23063,23012"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,A701V,N501Y,N501Y,N501Y,N501Y,E484K"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.2102C>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."	""	""	""	"Munster"	"2021"	"https://doi.org/10.1101/2021.05.07.443115"	"doi:10.1101/2021.05.07.443115"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23664,23060,23061,23062,23063,23012"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,A701V,N501Y,N501Y,N501Y,N501Y,E484K"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.2102C>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."	""	""	""	"Staub"	"2021"	"https://doi.org/10.2807/1560-7917.ES.2021.26.18.2100423"	"doi:10.2807/1560-7917.ES.2021.26.18.2100423"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22206,22810,22811,22812,22813,22813,23664,23060,23061,23062,23063,23012"	"D80A,D215G,K417N,K417N,K417N,K417N,K417N,A701V,N501Y,N501Y,N501Y,N501Y,E484K"	"NC_045512.2:g.239A>C,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.2102C>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Ala701Val,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission."	""	""	""	"Yinda"	"2021"	"https://doi.org/10.1101/2021.05.05.442780"	"doi:10.1101/2021.05.05.442780"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351."	""	""	""	""	"2021"	"https://www.fda.gov/media/146217/download"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The dominant circulating B.1.351 spike variant originating in RSA, which harbors E484K and additional substitutions in the  RBD, NTD, and S2 and deletions in the NTD (amino acids 242–244), was neutralized with a 5.02-fold reduced titer"	""	""	""	"Solfrosi"	"2021"	"https://doi.org/10.1084/jem.20202756"	"doi:10.1084/jem.20202756"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.351 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the B.1.351 variants used, using the most popular as a stad in]"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was significantly lower against B.1.351 in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In a Syrian hamster model, B.1.351 variant virus had >4x reduction in YRNT90 (measure of neutralization) using wild type convalescent sera. PG: Note that exact sequence for B.1.351 used was not disclosed."	""	""	""	"Cochin"	"2021"	"https://doi.org/10.1101/2021.04.19.440435"	"doi:10.1101/2021.04.19.440435"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"During an outbreak of SARS-CoV-2 501Y.V2 in a nursing home, all non-vaccinated residents (5/5) versus  half of those fully vaccinated 2-5 weeks prior with BNT162b2 (13/26) were infected. Two of 13 vaccinated versus 4 of 5  non-vaccinated residents presented severe disease. BNT162b2 did not prevent the outbreak, but reduced  transmission and disease severity. Among the 13 fully vaccinated residents who were infected, 2 (15.4%) presented with an asymptomatic disease, 9 (69.2%) developed mild to moderate symptoms, and 2 (15.4%) progressed to severe disease with fatal evolution secondary to acute respiratory distress syndrome (ARDS). There was no relationship between anti-S antibody levels at diagnosis and disease severity. Overall, the proportion of residents with severe disease in the non-vaccinated group (4/5)  was higher than that in the vaccinated group (2/13). Only 1 vaccinated staff, but 10 unvaccinated were infected in the outbreak (no severe disease)."	""	""	""	"Bailly"	"2021"	"https://doi.org/10.1093/cid/ciab446"	"doi:10.1093/cid/ciab446"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The dominant circulating B.1.351 spike variant originating in RSA, which harbors E484K and additional substitutions in the  RBD, NTD, and S2 and deletions in the NTD (amino acids 242–244), was neutralized with a 5.02-fold reduced titer"	""	""	""	"Solfrosi"	"2021"	"https://doi.org/10.1084/jem.20202756"	"doi:10.1084/jem.20202756"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped B.1.351 v3 virus has reduced neutralization activity vs wild type: 42.4x (30 sera Pfizer median 9 days post 2nd dose)  and 19.2x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p=0.04). Both vaccines largely  preserved their neutralizing titres."	""	""	""	"Huang"	"2021"	"https://doi.org/10.1101/2021.02.01.429069"	"doi:10.1101/2021.02.01.429069"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1)."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351."	""	""	""	""	"2021"	"https://www.fda.gov/media/146217/download"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1056/NEJMc2103022"	"doi:10.1056/NEJMc2103022"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351."	""	""	""	""	"2021"	"https://www.fda.gov/media/146217/download"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens."	""	""	""	"Röltgen"	"2021"	"https://doi.org/10.1101/2021.04.05.21254952"	"doi:10.1101/2021.04.05.21254952"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"B.1.1.351 in 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"B.1.1.351 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P=0.0020 for moderate resistance."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"B.1.1.351 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. B.1.1.351 variant constellation ablates Class 3 N-terminal domain targeting antibodies COV2-2489 and COV2-2676 (the only two tested)."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"We analyzed 34 convalescent samples including the WHONIBSC 20/130 reference serum, and, although  a few sera showed near identical FRNT 50 values, the FRNT50 dilutions for the B.1.1.7 strain  were 2.9-fold lower (geometric mean) than those for the Victoria strain (p < 0.0001). Sera from 13 subjects post-B.1.1.7 infection showed no significant change in neutralization against Victoria (~wild type), suggesting that B.1.1.7 infection also protects against ancestral virus. [Note that D1119H was included in the original paper, assuming typographical error and correcting to D1118H]"	""	""	""	"Supasa"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.033"	"doi:10.1016/j.cell.2021.02.033"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.351 pseudotyped lentivirus showed 3.4 and 3.8x reduction in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Vaccine elicited antibodies neutralized virus with the B.1.351 spike protein had an average 3-fold reduction in titer (1:500),  a titer that was still higher than the average titer with which convalescent sera neutralized D614G (1:139). Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater  than convalescent sera."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"VSV pseudotype B.1.351 entry mediated by the S proteins of the B.1.351 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.351 lineage effectiveness was observed as 16.9% (95% CI [10.4,23.0]) against infection, and 0% against severe/critical/fatal disease  (95% CI [0-19.0]). Two weeks or more after 2nd dose, effectiveness climbed to 75.0% [70.5,78.9] against infection, and 100% against  severe/critical/fatal disease (95% CI [73.7,100])."	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  6.5-fold against B.1.351 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  6.5-fold against B.1.351 (contrast with 3.4 fold against original SARS-CoV-2)."	""	""	""	"Leier"	"2021"	"https://doi.org/10.1101/2021.04.25.21256049"	"doi:10.1101/2021.04.25.21256049"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.351 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.351 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"VSV pseudotype B.1.351 showed 7.86-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections)."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 15 Pzifer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~11x."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"VSV pseudotype B.1.351 showed slight decrease in cell entry relative to wild type in 263T-ACE2 (kidney) cell line, and slight increase in Calu-3 (lung). Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"B.1.351 pseudotyped lentivirus showed 3.4 and 3.8x reduction in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 15 Pzifer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~11x."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Abrogates Bamlanivimab, Etesevimab, or their combined use neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 15 Pzifer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~11x."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Approximately 6-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.036"	"doi:10.1016/j.cell.2021.03.036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	""	""	""	""	""	""	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"In one of eight cell lines tested (293T lung cells), a modest increase in cell entry was observed."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21801,22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23664"	"D80A,K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,A701V"	"NC_045512.2:g.239A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"We analyzed 34 convalescent samples including the WHONIBSC 20/130 reference serum, and, although  a few sera showed near identical FRNT 50 values, the FRNT50 dilutions for the B.1.1.7 strain  were 2.9-fold lower (geometric mean) than those for the Victoria strain (p < 0.0001). Sera from 13 subjects post-B.1.1.7 infection showed no significant change in neutralization against Victoria (~wild type), suggesting that B.1.1.7 infection also protects against ancestral virus. [Note that D1119H was included in the original paper, assuming typographical error and correcting to D1118H]"	""	""	""	"Supasa"	"2021"	"https://doi.org/10.1016/j.cell.2021.02.033"	"doi:10.1016/j.cell.2021.02.033"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846"	"T95I"	"NC_045512.2:g.284C>T"	"YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"65yo female with no severe Covid-19 risk factors tested positive 36 days after second dose of BNT162b2 (Pfizer) vaccine.  Presented with fatigue, sinus congestion, and a headache developed; her symptoms plateaued and began to resolve six days later. [Mising genome coverage in regions of Spike covering clinically relevant mutations K417T, L452R, E484K, A701V, D796H, N501Y]"	""	""	""	"Hacisuleyman"	"2021"	"https://doi.org/10.1056/NEJMoa2105000"	"doi:10.1056/NEJMoa2105000"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"T95I,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.284C>T,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22317,22319,22320,23399,23401,23402,23403"	"T95I,D253G,D253G,D253G,D614G,D614G,D614G,D614G"	"NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds,  82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed]"	""	""	""	"Yang"	"2021"	"https://doi.org/10.1101/2021.08.04.21261596"	"doi:10.1101/2021.08.04.21261596"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against B.1.621."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Sera from vaccinees [ChAdOx1 and BNT162b2 primarily used in UK] shows decreased ability to neutralize B.1.621 compared to first wave virus and Alpha, with a magnitude of change similar to Beta."	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 69 test-positive were Mu. Two dose vaccine efficacy against Mu was 90.4% (73.9-96.5%), one dose VE was 45.8% (0.0-88.9%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Sera from individuals who have been infected with Delta does not have strong neutralising activity against B.1.621"	""	""	""	""	"2021"	"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera."	""	""	""	"Luftig"	"2021"	"https://doi.org/10.1056/NEJMc2104036"	"doi:10.1056/NEJMc2104036"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604,24410"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H,D950N"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 12.4x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset. [This is a greater reduction than Beta @ 8.2x]"	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604,24410"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H,D950N"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using live B.1.621 virus and a cytopathic effect-based assay, sera from 37 Pfizer/BioNTech BNT162b2 vaccinees collected 10-20 days post-booster showed significantly lower (95) but still ""robust"" neutralization than against ancestral B.1 virus (107)."	""	""	""	"Messali"	"2021"	"https://doi.org/10.1002/jmv.27247"	"doi:10.1002/jmv.27247"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22597,22599,23012,23060,23061,23062,23063,23399,23401,23402,23403,23604,24410"	"T95I,R346K,R346K,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H,D950N"	"NC_045512.2:g.284C>T,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2848G>A"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asp950Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 7.6x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster. [This is a greater reduction than Beta @ 6.3x]"	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22679,23039,23040,23521,23522,23524,23525,24130,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,23060,23061,23062,23063,22879,22881,22882,22882,21618,23071,23074,23075,22992,22995,23048,22810,22811,22812,22813,22813,22576,22577,22578,23604,22686,23053,23054,23055,22992,23009,23010,23012,23013,23399,23401,23402,23403"	"T95I,S373P,Q493R,Q493R,H655Y,H655Y,H655Y,H655Y,N856K,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,N501Y,N501Y,N501Y,N501Y,N440K,N440K,N440K,N440K,T19R,Y505H,Y505H,Y505H,T478K,T478K,G496S,K417N,K417N,K417N,K417N,K417N,G339D,G339D,G339D,P681H,S375F,Q498R,Q498R,Q498R,S477N,E484A,E484A,E484A,E484A,D614G,D614G,D614G,D614G"	"NC_045512.2:g.284C>T,NC_045512.2:g.1117T>C,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2568C>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.56C>G,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1486G>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,22679,23039,23040,23521,23522,23524,23525,24130,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,23060,23061,23062,23063,22879,22881,22882,22882,21618,23071,23074,23075,22992,22995,23048,22810,22811,22812,22813,22813,22576,22577,22578,23604,22686,23053,23054,23055,22992,23009,23010,23012,23013,23399,23401,23402,23403"	"T95I,S373P,Q493R,Q493R,H655Y,H655Y,H655Y,H655Y,N856K,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,N501Y,N501Y,N501Y,N501Y,N440K,N440K,N440K,N440K,T19R,Y505H,Y505H,Y505H,T478K,T478K,G496S,K417N,K417N,K417N,K417N,K417N,G339D,G339D,G339D,P681H,S375F,Q498R,Q498R,Q498R,S477N,E484A,E484A,E484A,E484A,D614G,D614G,D614G,D614G"	"NC_045512.2:g.284C>T,NC_045512.2:g.1117T>C,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2568C>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.56C>G,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1486G>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1124C>T,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Thr19Arg,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,23012,23271,23399,23401,23402,23403,23604,23948"	"T95I,E484K,A570D,D614G,D614G,D614G,D614G,P681H,D796H"	"NC_045512.2:g.284C>T,NC_045512.2:g.1450G>A,NC_045512.2:g.1709C>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A,NC_045512.2:g.2386G>C"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Asp796His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"51yo female with no severe COVID-19 risk factors tested positive 19 days after second dose of mRNA-1273 (Moderna) vaccine. Presented with sore throat, congestion, and headache developed; the next day she lost her sense of smell. Symptoms resolved over a one week period. Serum obtained 4 days after symptom onset was tested for neutralization against wild-type  virus, the E484K mutant, and the B.1.526 variant. It was equally effective against each.  These data suggest that the antibody response recognized these variants but was nonetheless insufficient to prevent a  breakthrough infection. The virus detected matched neither B.1.1.7 nor B.1.526 VOC strains in wide circulation in New York at the time of infection, though shared some mutations."	""	""	""	"Hacisuleyman"	"2021"	"https://doi.org/10.1056/NEJMoa2105000"	"doi:10.1056/NEJMoa2105000"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21846,23399,23401,23402,23403"	"T95I,D614G,D614G,D614G,D614G"	"NC_045512.2:g.284C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21855"	"S98F"	"NC_045512.2:g.293C>T"	"YP_009724390.1:p.Ser98Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain significantly enhanced the transduction rate in raccoon dog (Nyctereutes procyonoides) kidney (62.4%) and Rickett’s big-footed  bat (Myotis pilosus) kidney (45.0%) cell cultures compared to epithelial-like human Huh-7 cells (38.9%)."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21929"	"A123S"	"NC_045512.2:g.367G>T"	"YP_009724390.1:p.Ala123Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Selected in passage with mAb COV2-2489 during alanine mutagenesis antibody mapping experiment."	""	""	""	"Suryadevara"	"2021"	"https://doi.org/10.1101/2021.01.19.427324"	"doi:10.1101/2021.01.19.427324"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21969"	"C136Y"	"NC_045512.2:g.407G>A"	"YP_009724390.1:p.Cys136Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massively decreases N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21969"	"C136Y"	"NC_045512.2:g.407G>A"	"YP_009724390.1:p.Cys136Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Selected twice in passage with mAb COV2-2489."	""	""	""	"Suryadevara"	"2021"	"https://doi.org/10.1101/2021.01.19.427324"	"doi:10.1101/2021.01.19.427324"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"branch specific selection pressure"	""	""	"Using the Contrast-FEL method, this mutation is differentially selected along the B.1.1.529 (WHO VOC Omicron) branch. [PG: This mutation is adjacent to a well known deletion, which may confound the significance of this variant]"	""	""	""	"Lucaci"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"These variants dominate in mink infections in North America, sometime supplemented with F486L.   The Y453F variant found in other jurisdictions in mink infections is notably absent in North America."	""	""	""	""	"2021"	"https://doi.org/10.1101/2021.03.18.21253734v3"	"doi:10.1101/2021.03.18.21253734v3"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]"	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages."	""	""	""	"Yadav"	"2021"	"https://doi.org/10.1101/2021.04.23.441101"	"doi:10.1101/2021.04.23.441101"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a cluster of B.1.617[.1] infections related to travel from India to USA, one patient with mild symptoms had received their second dose of Pfizer vaccine more than two weeks before the infection [i.e. vaccine breakthrough]."	""	""	""	"Verghese"	"2021"	"https://doi.org/10.1128/JCM.00741-21"	"doi:10.1128/JCM.00741-21"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing lineage B.1.617.1) showed a 2x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing lineage B.1.617.1) showed a 1.79x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.64x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site)."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273)."	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775,21846"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H,T95I"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Kappa (B.1.617.1) has an IC50 fold change of 2.3x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775,21846"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H,T95I"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Kappa (B.1.617.1) has an IC50 fold change of 0.13x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775,21846"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H,T95I"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 47D10. Kappa (B.1.617.1) has an IC50 fold change of 80.2x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22022,22915,22916,22917,23012,23399,23401,23402,23403,23604,24775,21846"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R,Q1071H,T95I"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G,NC_045512.2:g.3213A>T,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Gln1071His,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Kappa (B.1.617.1) has an IC50 fold change of 0.68x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently."	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype."	""	""	""	"Kumar"	"2022"	"https://doi.org/10.1101/2022.05.13.491770"	"doi:10.1101/2022.05.13.491770"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22992,22992,22995,23009,23010,23012,23013,23053,23054,23055,23060,23061,23062,23063,23071,23074,23075,23399,23401,23402,23403,23521,23522,23524,23525,23604"	"G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,S477N,T478K,T478K,E484A,E484A,E484A,E484A,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H,D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y,P681H"	"NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G"	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21974"	"D138Y"	"NC_045512.2:g.412G>T"	"YP_009724390.1:p.Asp138Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21977"	"P139S"	"NC_045512.2:g.415C>T"	"YP_009724390.1:p.Pro139Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21981"	"F140S"	"NC_045512.2:g.419T>C"	"YP_009724390.1:p.Phe140Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2L28, S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21981"	"F140S"	"NC_045512.2:g.419T>C"	"YP_009724390.1:p.Phe140Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Selected once in passage with mAb COV2-2676."	""	""	""	"Suryadevara"	"2021"	"https://doi.org/10.1101/2021.01.19.427324"	"doi:10.1101/2021.01.19.427324"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21981"	"F140S"	"NC_045512.2:g.419T>C"	"YP_009724390.1:p.Phe140Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2L28, S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21981"	"F140S"	"NC_045512.2:g.419T>C"	"YP_009724390.1:p.Phe140Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21987,21990"	"Y145del,Y145del"	"NC_045512.2:g.432_434del,NC_045512.2:g.432_434del"	"YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21987,21990"	"Y145del,Y145del"	"NC_045512.2:g.432_434del,NC_045512.2:g.432_434del"	"YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient."	""	""	""	"McCarthy"	"2021"	"https://doi.org/10.1126/science.abf6950"	"doi:10.1126/science.abf6950"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21987,21990,21993,21995,23012,23399,23401,23402,23403"	"Y145del,Y145del,H146del,H146del,E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.436_438del,NC_045512.2:g.436_438del,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.His146del,YP_009724390.1:p.His146del,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Normalized for particle number, on ACE2.293T cells showed that the B.1.618 spike protein was about as infective as D614G wild type."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21993,21995"	"H146del,H146del"	"NC_045512.2:g.436_438del,NC_045512.2:g.436_438del"	"YP_009724390.1:p.His146del,YP_009724390.1:p.His146del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient."	""	""	""	"McCarthy"	"2021"	"https://doi.org/10.1126/science.abf6950"	"doi:10.1126/science.abf6950"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21997,21998,21999,22000,22001"	"K147E,K147E,K147E,K147E,K147E"	"NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G"	"YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21997,21998,21999,22000,22001"	"K147E,K147E,K147E,K147E,K147E"	"NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G,NC_045512.2:g.439A>G"	"YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu,YP_009724390.1:p.Lys147Glu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2X28, S2X333"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"21998"	"H146Y"	"NC_045512.2:g.436C>T"	"YP_009724390.1:p.His146Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition), but much milder effect on mAbs within antigenic supersite ""i"""	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22001"	"K147Q"	"NC_045512.2:g.439A>C"	"YP_009724390.1:p.Lys147Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22002"	"K147T"	"NC_045512.2:g.440A>C"	"YP_009724390.1:p.Lys147Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X333"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22002"	"K147T"	"NC_045512.2:g.440A>C"	"YP_009724390.1:p.Lys147Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massively decreases N terminal domain antigen recognition by supersite i mAbs S2M28, S2X28, S2X333, 4A8 (but not S2L28)."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22003"	"K147N"	"NC_045512.2:g.441A>T"	"YP_009724390.1:p.Lys147Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22005"	"N148S"	"NC_045512.2:g.443A>G"	"YP_009724390.1:p.Asn148Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong positive selection (up to 72% of supernatant sequences) under six rounds of COV47 convalescent plasma passage"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22010"	"K150E"	"NC_045512.2:g.448A>G"	"YP_009724390.1:p.Lys150Glu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong positive selection (up to 40% of supernatant sequences) under three rounds of COV47 convalescent plasma passage"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22010"	"K150E"	"NC_045512.2:g.448A>G"	"YP_009724390.1:p.Lys150Glu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22011"	"K150T"	"NC_045512.2:g.449A>C"	"YP_009724390.1:p.Lys150Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Positive selection (up to 22% of supernatant sequences) after COV47 convalescent plasma assay"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22011"	"K150R"	"NC_045512.2:g.449A>G"	"YP_009724390.1:p.Lys150Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Positive selection (up to 18% of supernatant sequences) under two rounds of COV47 convalescent plasma passage"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22016,22016"	"W152R,W152R"	"NC_045512.2:g.454T>A,NC_045512.2:g.454T>C"	"YP_009724390.1:p.Trp152Arg,YP_009724390.1:p.Trp152Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"For NTD-binding neutralizing antibody ADI-56479 this mutation causes a 1000x drop in neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22016,22016"	"W152R,W152R"	"NC_045512.2:g.454T>A,NC_045512.2:g.454T>C"	"YP_009724390.1:p.Trp152Arg,YP_009724390.1:p.Trp152Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22018"	"W152C"	"NC_045512.2:g.456G>T"	"YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to  D614G alone in 293T cells and human airway organoids."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22018"	"W152C"	"NC_045512.2:g.456G>T"	"YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"The W152C mutation reduced recognition of six NTD neutralizing mAbs, including a complete loss of binding for two of them, with a complementary pattern to that observed for S13I (also found in lineage B.1.427/B.1.429) out of 11 neutralizing mAbs evaluated."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22022"	"E154K"	"NC_045512.2:g.460G>A"	"YP_009724390.1:p.Glu154Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22022,22915,22916,22917,23012,23399,23401,23402,23403,23604"	"E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Approximately 2-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded  luciferase activity in cell lysates at 16-18 h post transduction. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]"	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22022,22915,22916,22917,23012,23399,23401,23402,23403,23604"	"E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Abrogates Bamlanivimab neutralization as quantified by measuring virus-encoded luciferase activity in cell lysates at 16-18 h post transduction. Significant decrease in combined Etesevimab+Bamlanivimab neutralization except at the highest concentration measured. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]"	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22022,22915,22916,22917,23012,23399,23401,23402,23403,23604"	"E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"In two of eight cell lines tested (Caco-2 intenstinal and Calu-3 lung), a modest increase in cell entry was observed. This increase was not observed in a Calu-3 cell line with overexpressed ACE2. [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]"	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22022,22915,22916,22917,23012,23399,23401,23402,23403,23604"	"E154K,L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G,P681R"	"NC_045512.2:g.460G>A,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Glu154Lys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 15 Pfizer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~3x (compared to ~11x for B.1.351). [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]"	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1101/2021.05.04.442663"	"doi:10.1101/2021.05.04.442663"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22028,22034"	"R158G,R158G"	"NC_045512.2:g.467_472del,NC_045512.2:g.472A>G"	"YP_009724390.1:p.Glu156_Arg158delinsGly,YP_009724390.1:p.Arg158Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22033,23012,23604"	"F157L,E484K,P681R"	"NC_045512.2:g.471C>A,NC_045512.2:g.1450G>A,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Phe157Leu,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against A.23.1-v2 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22033,23604"	"F157L,P681R"	"NC_045512.2:g.471C>A,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Phe157Leu,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	""	""	""	"Choi"	"2021"	"https://doi.org/10.1101/2021.06.28.449914"	"doi:10.1101/2021.06.28.449914"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22036"	"R158S"	"NC_045512.2:g.474A>T"	"YP_009724390.1:p.Arg158Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Selected three times in passage with mAb COV2-2489."	""	""	""	"Suryadevara"	"2021"	"https://doi.org/10.1101/2021.01.19.427324"	"doi:10.1101/2021.01.19.427324"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*05:03."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type C*07:02."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DPB1*04:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*05:02."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*02:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*02:02."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*16:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22093,22093,22093"	"M177I,M177I,M177I"	"NC_045512.2:g.531G>A,NC_045512.2:g.531G>T,NC_045512.2:g.531G>C"	"YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile,YP_009724390.1:p.Met177Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*07:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22107,22111"	"Q183H,Q183H"	"NC_045512.2:g.549G>T,NC_045512.2:g.549G>T"	"YP_009724390.1:p.Gln183His,YP_009724390.1:p.Gln183His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome"	""	""	""	"Choi"	"2020"	"https://doi.org/10.1056/NEJMc2031364"	"doi:10.1056/NEJMc2031364"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22132"	"R190S"	"NC_045512.2:g.570G>T"	"YP_009724390.1:p.Arg190Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22132,22600,22600,22907,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"R190S,R346S,R346S,Y449N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.570G>T,NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C,NC_045512.2:g.1345T>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Tyr449Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in B.1.640.2 variant was ~1000x folds more significant in 8 individuals."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22132,22600,22600,22907,23060,23061,23062,23063,23399,23401,23402,23403,23604"	"R190S,R346S,R346S,Y449N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.570G>T,NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C,NC_045512.2:g.1345T>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Tyr449Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1.640.2 variant was ~5.6x folds more significant in 9  individuals."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22188,23399,23401,23402,23403"	"I210del,D614G,D614G,D614G,D614G"	"NC_045512.2:g.629_631del,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ile210del,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"A 42yo Iranian male was reinfected with B.1.36 lineage virus 128 days after infection with genetically distinct B.1.36 virus, with negative PCR tests in between. In the first instance patient presented with cough, headache, severe diarrhea. In the second instance symptoms were more severe: body pain, shortness of breath, headache and anosmia. Anti-SARS-CoV-2 IgG and IgM tests were negative after both episodes. [Non-seroconversion may be associated with elevated risk of re-infection] [I210del is a homoplasy that has appeared in several disparate parts of the global phylogenetic tree, including A and B lineages, primarily in LMICs]"	""	""	""	"Salehi-Vaziri"	"2021"	"https://doi.org/10.1016/j.virusres.2021.198421"	"doi:10.1016/j.virusres.2021.198421"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*03:01."	""	""	""	"Riou"	"2021"	"https://doi.org/10.1126/scitranslmed.abj6824"	"doi:10.1126/scitranslmed.abj6824"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*13:02."	""	""	""	"Riou"	"2021"	"https://doi.org/10.1126/scitranslmed.abj6824"	"doi:10.1126/scitranslmed.abj6824"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*03:02."	""	""	""	"Riou"	"2021"	"https://doi.org/10.1126/scitranslmed.abj6824"	"doi:10.1126/scitranslmed.abj6824"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22206"	"D215G"	"NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22224,22227"	"A222V,A222V"	"NC_045512.2:g.665C>T,NC_045512.2:g.665C>T"	"YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Ala222Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22224,22227,23399,23401,23402,23403"	"A222V,A222V,D614G,D614G,D614G,D614G"	"NC_045512.2:g.665C>T,NC_045512.2:g.665C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"humoral response durability"	""	""	"27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two lineages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V"	""	""	""	"Brehm"	"2021"	"https://doi.org/10.3390/v13040661"	"doi:10.3390/v13040661"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22224,22227,23399,23401,23402,23403"	"A222V,A222V,D614G,D614G,D614G,D614G"	"NC_045512.2:g.665C>T,NC_045512.2:g.665C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Ala222Val,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V"	""	""	""	"Brehm"	"2021"	"https://doi.org/10.3390/v13040661"	"doi:10.3390/v13040661"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22293"	"L244S"	"NC_045512.2:g.731T>C"	"YP_009724390.1:p.Leu244Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22301"	"S247R"	"NC_045512.2:g.739A>C"	"YP_009724390.1:p.Ser247Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22304"	"Y248H"	"NC_045512.2:g.742T>C"	"YP_009724390.1:p.Tyr248His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22314"	"P251L"	"NC_045512.2:g.752C>T"	"YP_009724390.1:p.Pro251Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22317"	"G252D"	"NC_045512.2:g.755G>A"	"YP_009724390.1:p.Gly252Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22317,22319,22320"	"D253G,D253G,D253G"	"NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G"	"YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22317,22319,22320"	"D253G,D253G,D253G"	"NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G"	"YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22319"	"D253Y"	"NC_045512.2:g.757G>T"	"YP_009724390.1:p.Asp253Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22323"	"S254Y"	"NC_045512.2:g.761C>A"	"YP_009724390.1:p.Ser254Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22323"	"S254F"	"NC_045512.2:g.761C>T"	"YP_009724390.1:p.Ser254Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22326"	"S255F"	"NC_045512.2:g.764C>T"	"YP_009724390.1:p.Ser255Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22328,22329,22331"	"G257S,G257S,G257S"	"NC_045512.2:g.769G>A,NC_045512.2:g.769G>A,NC_045512.2:g.769G>A"	"YP_009724390.1:p.Gly257Ser,YP_009724390.1:p.Gly257Ser,YP_009724390.1:p.Gly257Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22334"	"W258R"	"NC_045512.2:g.772T>C"	"YP_009724390.1:p.Trp258Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22334"	"W258R"	"NC_045512.2:g.772T>C"	"YP_009724390.1:p.Trp258Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28"	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.01.14.426475"	"doi:10.1101/2021.01.14.426475"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22334,22879,22881,22882,22882,22904,22910,23012"	"W258R,N440K,N440K,N440K,N440K,N450D,N450D,E484K"	"NC_045512.2:g.772T>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Trp258Arg,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments shows ablated neutralization efficacy (NT50 ~ 0) in two of 21 convalescents plasma collected mean 1.3 months post infection. Greater than 4-fold reduction was observed in most of the other plasma. 14 vaccinee plasma showed a slightly lower reduction in efficacy, albeit from a higher average starting point titre than convalescents."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22340"	"A260T"	"NC_045512.2:g.778G>A"	"YP_009724390.1:p.Ala260Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22344"	"G261D"	"NC_045512.2:g.782G>A"	"YP_009724390.1:p.Gly261Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Multiple mink but no humans on one farm in Denmark, potential adaptation."	""	""	""	"Oude Munnink"	"2020"	"https://doi.org/10.1126/science.abe5901"	"doi:10.1126/science.abe5901"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22377"	"P272L"	"NC_045512.2:g.815C>T"	"YP_009724390.1:p.Pro272Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*02:01."	""	""	""	"Dolton"	"2021"	"https://doi.org/10.1101/2021.06.21.21259010v2.full.pdf"	"doi:10.1101/2021.06.21.21259010v2.full.pdf"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22377"	"P272L"	"NC_045512.2:g.815C>T"	"YP_009724390.1:p.Pro272Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*08:01."	""	""	""	"Dolton"	"2021"	"https://doi.org/10.1101/2021.06.21.21259010v2.full.pdf"	"doi:10.1101/2021.06.21.21259010v2.full.pdf"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22576,22577,22578"	"G339D,G339D,G339D"	"NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A"	"YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation found in the epitope from Sotrovimab causes a 1.2x reduction in neutralization efficacy using a VSV model on Vero E6 cells."	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22576,22577,22578"	"G339D,G339D,G339D"	"NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A"	"YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.3 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22576,22577,22578"	"G339D,G339D,G339D"	"NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A"	"YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22583"	"V341I"	"NC_045512.2:g.1021G>A"	"YP_009724390.1:p.Val341Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.21 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22595,22596,22597,22599"	"R346T,R346T,R346T,R346T"	"NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C"	"YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22595,22596,22597,22599"	"R346T,R346T,R346T,R346T"	"NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C"	"YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.15 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22595,22596,22597,22599,22679,22686,22783,22784,22785,22786,22786,22810,22811,22812,22813,22813,22879,22881,22882,22882,22939,22942,22942,22992,23009,23010,23012,23013,23027,23029,23030,23031,23053,23054,23055,22992,22995,23060,23061,23062,23063,23071,23074,23075"	"R346T,R346T,R346T,R346T,S373P,S375F,R408S,R408S,R408S,R408S,R408S,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N460K,N460K,N460K,S477N,E484A,E484A,E484A,E484A,F490S,F490S,F490S,F490S,Q498R,Q498R,Q498R,T478K,T478K,N501Y,N501Y,N501Y,N501Y,Y505H,Y505H,Y505H"	"NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1037G>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A,NC_045512.2:g.1430G>A,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Arg346Thr,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays."	""	""	""	"Yue"	"2023"	"https://doi.org/10.1101/2023.01.03.522427"	"doi:10.1101/2023.01.03.522427"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22597,22599"	"R346K,R346K"	"NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A"	"YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.12 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22597,22599"	"R346I,R346I"	"NC_045512.2:g.1037G>T,NC_045512.2:g.1037G>T"	"YP_009724390.1:p.Arg346Ile,YP_009724390.1:p.Arg346Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Provides ~80% escape from mAb COV2-2130, even though its appearance in culture is formed without selective mAb pressure."	""	""	""	"Dong"	"2021"	"https://doi.org/10.1101/2021.01.27.428529"	"doi:10.1101/2021.01.27.428529"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22597,22599"	"R346K,R346K"	"NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A"	"YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation, which has emerged in some Omicron sequences, has a 0.7x reduction in  neutralization activity with Sotrovimab in a VSV model on Vero E6 cells.  [Omicron sequences with R346K may very well have a non-additive neutralization rather than 2.7x+0.7x = 3.4x]"	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22597,22599"	"R346K,R346K"	"NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A"	"YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22600,22600"	"R346S,R346S"	"NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C"	"YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22600,22600"	"R346S,R346S"	"NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C"	"YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to class 2/3 antibody C603."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22600,22600"	"R346S,R346S"	"NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C"	"YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to class 2/3 antibody C603."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22600,22600"	"R346S,R346S"	"NC_045512.2:g.1038A>T,NC_045512.2:g.1038A>C"	"YP_009724390.1:p.Arg346Ser,YP_009724390.1:p.Arg346Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Positive selection (up to 30% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22622"	"N354D"	"NC_045512.2:g.1060A>G"	"YP_009724390.1:p.Asn354Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.13 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22624"	"N354K"	"NC_045512.2:g.1062C>A"	"YP_009724390.1:p.Asn354Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.21 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22627,22629"	"K356T,K356T"	"NC_045512.2:g.1067A>C,NC_045512.2:g.1067A>C"	"YP_009724390.1:p.Lys356Thr,YP_009724390.1:p.Lys356Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.14 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22629"	"K356R"	"NC_045512.2:g.1067A>G"	"YP_009724390.1:p.Lys356Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.21 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22632"	"R357K"	"NC_045512.2:g.1070G>A"	"YP_009724390.1:p.Arg357Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.18 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22634"	"I358F"	"NC_045512.2:g.1072A>T"	"YP_009724390.1:p.Ile358Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected variants in an in vitro evolution experiment for ACE2 binding, described as ""stabilizing"" since it nicely fitsinside the hydrophobic pocket formed in the RBD domain."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22634"	"I358F"	"NC_045512.2:g.1072A>T"	"YP_009724390.1:p.Ile358Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.72 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22634"	"I358F"	"NC_045512.2:g.1072A>T"	"YP_009724390.1:p.Ile358Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected variants in an in vitro evolution experiment for ACE2 binding, described as ""stabilizing"" since it nicely fitsinside the hydrophobic pocket formed in the RBD domain."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22634"	"I358F"	"NC_045512.2:g.1072A>T"	"YP_009724390.1:p.Ile358Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.1 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22661"	"V367I"	"NC_045512.2:g.1099G>A"	"YP_009724390.1:p.Val367Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.12 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22679"	"S373P"	"NC_045512.2:g.1117T>C"	"YP_009724390.1:p.Ser373Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)"	""	""	""	"Long"	"2020"	"https://doi.org/10.1128/mBio.02707-20"	"doi:10.1128/mBio.02707-20"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22679,23009,23010,23012,23013"	"S373P,E484A,E484A,E484A,E484A"	"NC_045512.2:g.1117T>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here]"	""	""	""	""	"2021"	"https://doi.org/10.47326/ocsat.dashboard.2021.1.0"	"doi:10.47326/ocsat.dashboard.2021.1.0"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22686"	"S375F"	"NC_045512.2:g.1124C>T"	"YP_009724390.1:p.Ser375Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"branch specific selection pressure"	""	""	"Using the Contrast-FEL method, this mutation is differentially selected along the B.1.1.529 (WHO VOC Omicron) branch."	""	""	""	"Lucaci"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22696"	"K378N"	"NC_045512.2:g.1134G>T"	"YP_009724390.1:p.Lys378Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22713,23399,23401,23402,23403"	"P384L,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1151C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Pro384Leu,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22713,23399,23401,23402,23403"	"P384L,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1151C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Pro384Leu,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22713,23399,23401,23402,23403"	"P384L,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1151C>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Pro384Leu,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22745"	"V395I"	"NC_045512.2:g.1183G>A"	"YP_009724390.1:p.Val395Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22766"	"I402V"	"NC_045512.2:g.1204A>G"	"YP_009724390.1:p.Ile402Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.1 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22783,22784,22785,22786,22786"	"R408S,R408S,R408S,R408S,R408S"	"NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C"	"YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.21 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22783,22784,22785,22786,22786,23009,23010,23012,23013,23060,23061,23062,23063"	"R408S,R408S,R408S,R408S,R408S,E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%."	""	""	""	"Zhou"	"2022"	"https://doi.org/10.1101/2022.05.09.491254"	"doi:10.1101/2022.05.09.491254"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.1 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"1.1 fold drop in IC50 of P2C-1F11."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes no detectable change in KD value for antibody binding of P22A-1D1."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	">20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P22A-1D1."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes no detectable change in KD value for antibody binding of P5A-1D2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P5A-1D2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 1.5 fold decrease in KD value of antibody binding of ACE2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P5A-3C8."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistance P=0.0361."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813"	"K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres"	""	""	""	"Wibmer"	"2021"	"https://doi.org/10.1101/2021.01.18.427166"	"doi:10.1101/2021.01.18.427166"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 19 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	""	""	""	"Wibmer"	"2021"	"https://doi.org/10.1101/2021.01.18.427166"	"doi:10.1101/2021.01.18.427166"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	""	""	""	"Wibmer"	"2021"	"https://doi.org/10.1101/2021.01.18.427166"	"doi:10.1101/2021.01.18.427166"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM)."	""	""	""	"Ramanathan"	"2021"	"https://doi.org/10.1101/2021.02.22.432359"	"doi:10.1101/2021.02.22.432359"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."	""	""	""	"Laffeber"	"2021"	"https://doi.org/10.1101/2021.02.22.432357"	"doi:10.1101/2021.02.22.432357"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."	""	""	""	"Vogel"	"2021"	"https://doi.org/10.1101/2021.03.04.433887"	"doi:10.1101/2021.03.04.433887"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."	""	""	""	"Laffeber"	"2021"	"https://doi.org/10.1101/2021.02.22.432357"	"doi:10.1101/2021.02.22.432357"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."	""	""	""	"Vogel"	"2021"	"https://doi.org/10.1101/2021.03.04.433887"	"doi:10.1101/2021.03.04.433887"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."	""	""	""	"Vogel"	"2021"	"https://doi.org/10.1101/2021.03.04.433887"	"doi:10.1101/2021.03.04.433887"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."	""	""	""	"Vogel"	"2021"	"https://doi.org/10.1101/2021.03.04.433887"	"doi:10.1101/2021.03.04.433887"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM)."	""	""	""	"Ramanathan"	"2021"	"https://doi.org/10.1101/2021.02.22.432359"	"doi:10.1101/2021.02.22.432359"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."	""	""	""	"Laffeber"	"2021"	"https://doi.org/10.1101/2021.02.22.432357"	"doi:10.1101/2021.02.22.432357"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26)."	""	""	""	"Teyssou"	"2021"	"https://doi.org/10.1101/2021.03.21.21253498"	"doi:10.1101/2021.03.21.21253498"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26)."	""	""	""	"Teyssou"	"2021"	"https://doi.org/10.1101/2021.03.21.21253498"	"doi:10.1101/2021.03.21.21253498"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.16.431305"	"doi:10.1101/2021.02.16.431305"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively."	""	""	""	"Roquebert"	"2021"	"https://doi.org/10.1101/2021.03.19.21253971"	"doi:10.1101/2021.03.19.21253971"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30"	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300."	""	""	""	"Wu"	"2021"	"https://doi.org/10.1101/2021.01.25.427948"	"doi:10.1101/2021.01.25.427948"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions."	""	""	""	"Roquebert"	"2021"	"https://doi.org/10.1101/2021.05.12.21257130"	"doi:10.1101/2021.05.12.21257130"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure."	""	""	""	"Pearson"	"2021"	"https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9–11 days post-second dose;  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure."	""	""	""	"Pearson"	"2021"	"https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."	""	""	""	"Madhi"	"2021"	"https://doi.org/10.1056/NEJMoa2102214"	"doi:10.1056/NEJMoa2102214"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046."	""	""	""	"Hu"	"2021"	"https://doi.org/10.1101/2021.01.22.427749"	"doi:10.1101/2021.01.22.427749"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23012,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9–11 days post-second dose;  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23041,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,Q493H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1479A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Gln493His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trachea viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~750x fold drop in the R3P1-E4 antibody in comparison to  the IgG control."	""	""	""	"Li"	"2022"	"https://doi.org/10.1186/s13578-022-00794-7"	"doi:10.1186/s13578-022-00794-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23041,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,Q493H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1479A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Gln493His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Lung viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~2266x fold drop in the R3P1-E4 antibody in comparison to  the IgG control."	""	""	""	"Li"	"2022"	"https://doi.org/10.1186/s13578-022-00794-7"	"doi:10.1186/s13578-022-00794-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23041,23060,23061,23062,23063"	"K417N,K417N,K417N,K417N,K417N,Q493H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1479A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Gln493His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"100% of the 5 8‑month‑old male R3P1-E4 antibody treated mice suvived 14 days after infection while only 60% the control group mice survived 5 days post infection."	""	""	""	"Li"	"2022"	"https://doi.org/10.1186/s13578-022-00794-7"	"doi:10.1186/s13578-022-00794-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]"	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9–11 days post-second dose;  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23060,23061,23062,23063,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22810,22811,22812,22813,22813,23399,23401,23402,23403"	"K417N,K417N,K417N,K417N,K417N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 57.1 fold decrease in KD value for antibody binding of P5A-3C8."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes no detectable change in KD value for antibody binding of P5A-1D2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P22A-1D1."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes no detectable change in KD value for antibody binding of P22A-1D1."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P5A-3C8."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 1.1 fold decrease in KD value of antibody binding of ACE2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.25 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In vitro selection against class 1 antibody C682"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"No detectable fold drop in IC50 of P5A-1D2."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~16x binding against this isolated mutation. Estesevimab lost ~16x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Causes 2.9 fold decrease in KD value for antibody binding of P2C-1F11."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812"	"K417T"	"NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"2.6 fold increase in IC50 of P2C-1F11."	""	""	""	"Zhang"	"2021"	"https://doi.org/10.1038/s41467-021-24514-w"	"doi:10.1038/s41467-021-24514-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812,23012,23060,23061,23062,23063"	"K417T,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812,23012,23060,23061,23062,23063"	"K417T,E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22812,23012,23060,23061,23062,23063,23399,23401,23402,23403"	"K417T,E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type."	""	""	""	"Dejnirattisai"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.055"	"doi:10.1016/j.cell.2021.03.055"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22820"	"D420N"	"NC_045512.2:g.1258G>A"	"YP_009724390.1:p.Asp420Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22851"	"T430I"	"NC_045512.2:g.1289C>T"	"YP_009724390.1:p.Thr430Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22865"	"A435S"	"NC_045512.2:g.1303G>T"	"YP_009724390.1:p.Ala435Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to neutralizing mAb H014 (on D614G background)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample."	""	""	""	"Tandel"	"2021"	"https://doi.org/10.1101/2021.04.30.441434"	"doi:10.1101/2021.04.30.441434"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells."	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23"	""	""	""	"Cheng"	"2021"	"https://doi.org/10.1186/s12985-021-01554-8"	"doi:10.1186/s12985-021-01554-8"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882"	"N440K,N440K,N440K,N440K"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22879,22881,22882,22882,23399,23401,23402,23403"	"N440K,N440K,N440K,N440K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*"	""	""	""	"Rani"	"2021"	"https://doi.org/10.1002/jmv.26997"	"doi:10.1002/jmv.26997"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22893"	"K444T"	"NC_045512.2:g.1331A>C"	"YP_009724390.1:p.Lys444Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22893"	"K444R"	"NC_045512.2:g.1331A>G"	"YP_009724390.1:p.Lys444Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Identified in 6/20 replicates of recombinant VSV growth in the presence of mAb COV2-2130."	""	""	""	"Dong"	"2021"	"https://doi.org/10.1101/2021.01.27.428529"	"doi:10.1101/2021.01.27.428529"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22893"	"K444T"	"NC_045512.2:g.1331A>C"	"YP_009724390.1:p.Lys444Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Results in 3.7-fold drop in neutralization potency for COVA2-29, which is a cluster I RBD141 specific antibody."	""	""	""	"Rees-Spear"	"2021"	"https://doi.org/10.1101/2021.01.15.426849"	"doi:10.1101/2021.01.15.426849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22893"	"K444R"	"NC_045512.2:g.1331A>G"	"YP_009724390.1:p.Lys444Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Positive selection (up to 20% of supernatant sequences) under two rounds of COV-NY convalescent plasma passage, eliminated in rounds three and four"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22893"	"K444T"	"NC_045512.2:g.1331A>C"	"YP_009724390.1:p.Lys444Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Abolishes binding efficiency vs wild type for mAb REGN10933."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Positive selection (up to 14% of supernatant sequences) after COV-NY convalescent plasma assay"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Improvement in neutralization capability of all 4 convalescent sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22894,22894"	"K444N,K444N"	"NC_045512.2:g.1332G>C,NC_045512.2:g.1332G>T"	"YP_009724390.1:p.Lys444Asn,YP_009724390.1:p.Lys444Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAb SARS2-01 and moderately resistant to 2H04 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22896"	"V445A"	"NC_045512.2:g.1334T>C"	"YP_009724390.1:p.Val445Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 41% appearance in 2 passages against Regeneron monoclonal antibody RGN10987 @ 10ug/mL"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 1 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-02, SARS2-32 and SARS2-35 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22899"	"G446D"	"NC_045512.2:g.1337G>A"	"YP_009724390.1:p.Gly446Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Decrease in neutralization capability of all 4 convalescent sera tested (1 ablated)."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations), triple replicates. Against a broader panel of 16 convalescent plasma (no replicates), reductions in neutralization are considerably less dramatic  in pattern, and sometime neutralization increases."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 95% appearance in 2 passages against Regeneron monoclonal antibody RGN10934 @ 50ug/mL"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Significant decrease in neutralization across 4 of 16 sera tested 7-17 days post symptoms onset."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01 and SARS2-32 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Most effective mutant against this position in the RBD for highly neutralizing COV2-2096"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450Y,N450Y"	"NC_045512.2:g.1348A>T,NC_045512.2:g.1348A>T"	"YP_009724390.1:p.Asn450Tyr,YP_009724390.1:p.Asn450Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 2 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 2 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations)."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910"	"N450D,N450D"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAb SARS2-07 nd moderately resistant to SARS2-16 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22904,22910,23012,23039,23040,23373,25046"	"N450D,N450D,E484K,Q493R,Q493R,T604I,P1162S"	"NC_045512.2:g.1348A>G,NC_045512.2:g.1348A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1811C>T,NC_045512.2:g.3484C>T"	"YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Asn450Asp,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Thr604Ile,YP_009724390.1:p.Pro1162Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments shows ablated neutralization efficacy (NT50 ~ 0) in two of 21 convalescents plasma collected mean 1.3 months post infection. Greater than 4-fold reduction was observed in most of the other plasma. 14 vaccinee plasma showed a slightly lower reduction in efficacy, albeit from a higher average starting point titre than convalescents."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22905"	"N448S"	"NC_045512.2:g.1343A>G"	"YP_009724390.1:p.Asn448Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22907"	"Y449H"	"NC_045512.2:g.1345T>C"	"YP_009724390.1:p.Tyr449His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.12 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22907"	"Y449N"	"NC_045512.2:g.1345T>A"	"YP_009724390.1:p.Tyr449Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912"	"N450K"	"NC_045512.2:g.1350T>G"	"YP_009724390.1:p.Asn450Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01 and SARS2-32 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912,22916"	"L452M,L452M"	"NC_045512.2:g.1354C>A,NC_045512.2:g.1354C>A"	"YP_009724390.1:p.Leu452Met,YP_009724390.1:p.Leu452Met"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.16 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22912,22916"	"L452M,L452M"	"NC_045512.2:g.1354C>A,NC_045512.2:g.1354C>A"	"YP_009724390.1:p.Leu452Met,YP_009724390.1:p.Leu452Met"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Observed ~2x decrease on average in neutralization efficacy in convalescent sera of 16 health workers."	""	""	""	"Alenquer"	"2021"	"https://doi.org/10.1101/2021.04.22.441007"	"doi:10.1101/2021.04.22.441007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 3 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape."	""	""	""	"Jacobson"	"2021"	"https://doi.org/10.1101/2021.04.14.21255431"	"doi:10.1101/2021.04.14.21255431"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"~1.7-fold increase in binding affinity vs wild type."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456)."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids."	""	""	""	"Deng"	"2021"	"https://doi.org/10.1101/2021.03.07.21252647"	"doi:10.1101/2021.03.07.21252647"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.32 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1016/j.chom.2021.06.006"	"doi:10.1016/j.chom.2021.06.006"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4]"	""	""	""	"Ferriera"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size."	""	""	""	"Ferreira"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency."	""	""	""	"McCallum"	"2021"	"https://doi.org/10.1101/2021.03.31.437925"	"doi:10.1101/2021.03.31.437925"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Increased stability of RBD expression in yeast, suggesting increased Spike protein stability."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917"	"L452R,L452R,L452R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012"	"L452R,L452R,L452R,E484K"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone."	""	""	""	"Ferriera"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012"	"L452R,L452R,L452R,E484Q"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x), suggesting no evidence for an additive effect [perhaps even E484Q effect dilution]."	""	""	""	"Ferreira"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2.5x."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x drop in neutralization (NT50)  [working with the delins, less than just L452R but more than just E484Q]."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x infectivity advantage to the spike particles  [less than L452R or E484Q alone working with the delins]."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]"	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23604"	"L452R,L452R,L452R,E484Q,P681R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently."	""	""	""	"Yadav"	"2021"	"https://doi.org/10.1101/2021.05.05.442760"	"doi:10.1101/2021.05.05.442760"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23604"	"L452R,L452R,L452R,E484Q,P681R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected."	""	""	""	"Yadav"	"2021"	"https://doi.org/10.1101/2021.05.05.442760"	"doi:10.1101/2021.05.05.442760"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23604"	"L452R,L452R,L452R,E484K,P681R"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>A,NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants."	""	""	""	"Ferriera"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23012,23604,23399,23401,23402,23403"	"L452R,L452R,L452R,E484Q,P681R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1450G>C,NC_045512.2:g.2042C>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23060,23061,23062,23063"	"L452R,L452R,L452R,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape."	""	""	""	"Jacobson"	"2021"	"https://doi.org/10.1101/2021.04.14.21255431"	"doi:10.1101/2021.04.14.21255431"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"The L452R mutation increased the infectivity more than two-fold in these conditions."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2x."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a  7.42x drop in neutralization (NT50) [mostly from 3 of the sera]."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50)."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~2x infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22915,22916,22917,23399,23401,23402,23403"	"L452R,L452R,L452R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%)."	""	""	""	"Bruxvoort"	"2021"	"https://doi.org/10.1101/2021.09.29.21264199"	"doi:10.1101/2021.09.29.21264199"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917"	"L452Q"	"NC_045512.2:g.1355T>A"	"YP_009724390.1:p.Leu452Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917"	"L452Q"	"NC_045512.2:g.1355T>A"	"YP_009724390.1:p.Leu452Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.27 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917,23027,23029,23030,23031,23399,23401,23402,23403"	"L452Q,F490S,F490S,F490S,F490S,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>A,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mean 3.4x reduction of NT50 value for C.37 (Lambda) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917,23027,23029,23030,23031,23399,23401,23402,23403"	"L452Q,F490S,F490S,F490S,F490S,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>A,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR16m had a 0.038x fold change in IC50 in C.37 Lambda"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917,23027,23029,23030,23031,23399,23401,23402,23403"	"L452Q,F490S,F490S,F490S,F490S,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>A,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Mean 1.7x reduction of NT50 value for C.37 (Lambda) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster."	""	""	""	"Uriu"	"2021"	"https://doi.org/10.1101/2021.09.06.459005"	"doi:10.1101/2021.09.06.459005"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22917,23027,23029,23030,23031,23399,23401,23402,23403"	"L452Q,F490S,F490S,F490S,F490S,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1355T>A,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR22 had a 0.048x fold change in IC50 in C.37 Lambda"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"VSV pseudotyped with Y453F reduced inhibition by most of the 13 potent convalescent serum/plasma samples tested, albeit with variable efficiency  (median increase of serum/plasma titer required for 50% neutralization [NT50] = 1.62x, range = 1.02x to 3.43x), indicating that this  RBD mutation may compromise SARS-CoV-2 control by preexisting neutralizing antibody responses."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.celrep.2021.109017"	"doi:10.1016/j.celrep.2021.109017"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.25 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"10-fold reduction in binding efficiency vs wild type for MAb REGN10933."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~12x binding against this double mutation. Casirivimab lost ~64x binding against this double mutation. Cligavimab lost ~6x binding against this double mutation. Estesevimab lost ~10x binding against this double mutation. Imdevimab lost ~5x binding against this double mutation. Regdanvimab lost ~8x binding against this double mutation. Sotrovimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"~4-fold increase in binding affinity vs wild type."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Observed in 4 separate mink farms in Denmark, and Y453F is circulating relatively widely in humans."	""	""	""	"Oude Munnink"	"2020"	"https://doi.org/10.1126/science.abe5901"	"doi:10.1126/science.abe5901"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing modest decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1016/j.chom.2021.06.006"	"doi:10.1016/j.chom.2021.06.006"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"The induction level of IFN-gamma expression by the Y453F derivative in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456) was significantly lower."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	""	""	""	""	"Oude Munnink"	"2020"	"https://doi.org/10.1126/science.abe5901"	"doi:10.1126/science.abe5901"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Casirivimab lost >50x binding against this mutation."	""	""	""	"Hoffman"	"2021"	"https://doi.org/10.1016/j.celrep.2021.109017"	"doi:10.1016/j.celrep.2021.109017"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing modest decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920"	"Y453F"	"NC_045512.2:g.1358A>T"	"YP_009724390.1:p.Tyr453Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22920,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"Y453F,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.1358A>T,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.Tyr453Phe,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"The so-called ""delta F"" variant combination previously observed in mink spillover events also emerged in a lymphoma  patient (non-Hodgkin diffuse B-cell lymphoma IV stage B) with a long-term COVID-19 infection (4 months) where 18 de novo mutation occureed overall. Patient was taking rituximab, the B-cell-depleting agent, and had no detectable neutralizing antibody response."	""	""	""	"Bazykin"	"2021"	"https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22924,22925,22926"	"L455S,L455S,L455S"	"NC_045512.2:g.1364T>C,NC_045512.2:g.1364T>C,NC_045512.2:g.1364T>C"	"YP_009724390.1:p.Leu455Ser,YP_009724390.1:p.Leu455Ser,YP_009724390.1:p.Leu455Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.45 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22926,22927,22927,22928,22930,22930"	"F456L,F456L,F456L,F456L,F456L,F456L"	"NC_045512.2:g.1366T>C,NC_045512.2:g.1366T>C,NC_045512.2:g.1368T>A,NC_045512.2:g.1366T>C,NC_045512.2:g.1368T>G,NC_045512.2:g.1368T>A"	"YP_009724390.1:p.Phe456Leu,YP_009724390.1:p.Phe456Leu,YP_009724390.1:p.Phe456Leu,YP_009724390.1:p.Phe456Leu,YP_009724390.1:p.Phe456Leu,YP_009724390.1:p.Phe456Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value."	""	""	""	"Rees-Spear"	"2021"	"https://doi.org/10.1101/2021.01.15.426849"	"doi:10.1101/2021.01.15.426849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22928"	"F456V"	"NC_045512.2:g.1366T>G"	"YP_009724390.1:p.Phe456Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22928"	"F456V"	"NC_045512.2:g.1366T>G"	"YP_009724390.1:p.Phe456Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Moderate in vitro selection against class 1 (Spike 'up' conformation) antibodies C683 and C664. Unclassified antibody C666  selected for the emergence of the F456V mutation in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22928"	"F456V"	"NC_045512.2:g.1366T>G"	"YP_009724390.1:p.Phe456Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22936"	"K458N"	"NC_045512.2:g.1374G>T"	"YP_009724390.1:p.Lys458Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.16 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.09 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22939,22942,22942"	"N460K,N460K,N460K"	"NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>G,NC_045512.2:g.1380T>A"	"YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys,YP_009724390.1:p.Asn460Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22940"	"N460Y"	"NC_045512.2:g.1378A>T"	"YP_009724390.1:p.Asn460Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22940"	"N460H"	"NC_045512.2:g.1378A>C"	"YP_009724390.1:p.Asn460His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Mild escape mutant emergent for class 1 antibody C613 in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22940"	"N460H"	"NC_045512.2:g.1378A>C"	"YP_009724390.1:p.Asn460His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22940"	"N460H"	"NC_045512.2:g.1378A>C"	"YP_009724390.1:p.Asn460His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22941"	"N460I"	"NC_045512.2:g.1379A>T"	"YP_009724390.1:p.Asn460Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22941"	"N460S"	"NC_045512.2:g.1379A>G"	"YP_009724390.1:p.Asn460Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22964"	"I468V"	"NC_045512.2:g.1402A>G"	"YP_009724390.1:p.Ile468Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22964"	"I468V"	"NC_045512.2:g.1402A>G"	"YP_009724390.1:p.Ile468Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22976"	"I472V"	"NC_045512.2:g.1414A>G"	"YP_009724390.1:p.Ile472Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22976"	"I472V"	"NC_045512.2:g.1414A>G"	"YP_009724390.1:p.Ile472Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to neutralizing mAb X593 (on D614G background)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with C102, C105 and C144 monoclonal antibodies vs. wild type Spike protein RBD domain AAs."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~50x binding against this isolated mutation. Estesevimab lost ~8x binding against this isolated mutation. Sotrovimab lost ~30x binding against this isolated mutation. Tixagevimab lost ~15x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to some class 1 (Spike 'up' conformation) antibodies tested."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22986"	"A475V"	"NC_045512.2:g.1424C>T"	"YP_009724390.1:p.Ala475Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations)."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 host variant dependency"	""	""	"This mutation's measured interaction affinity with ACE2:p.S19P (0.03% minor allele frequency,  found almost exclusively in African/African-Americans in the GnomAD database) was significantly lower than the predicted value,  indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19  is adjacent to RBD residue S477 in the contact interface."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation found in the epitope from Sotrovimab causes a 2.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells."	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"While S477N itself is highly resistent to a broad range of monoclonal antibodies, combined with S514F high neutralization is restricted to only three antibodies in a broad screen."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Significant decrease in neutralization across 11 of 16 sera tested 7-17 days post symptoms onset."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 0.22 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01, SARS2-07, SARS2-16 and SARS2-19 of 10 antibodies tested, and moderately high resistance to the remaining."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility."	""	""	""	"Singh"	"2021"	"https://assets.researchsquare.com/files/rs-106969/v2_stamped.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility."	""	""	""	"Singh"	"2021"	"https://assets.researchsquare.com/files/rs-106969/v2_stamped.pdf"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding, with increasing proportion in subsequent rounds."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 2 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992"	"S477N"	"NC_045512.2:g.1430G>A"	"YP_009724390.1:p.Ser477Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-07 and SARS2-16 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,22995,23042"	"T478K,T478K,S494P"	"NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab."	""	""	""	"Choi"	"2020"	"https://doi.org/10.1056/NEJMc2031364"	"doi:10.1056/NEJMc2031364"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,23012"	"S477N,E484K"	"NC_045512.2:g.1430G>A,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,23399,23401,23402,23403"	"S477N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,23399,23401,23402,23403"	"S477N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,23399,23401,23402,23403"	"S477N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"symptom prevalence"	""	""	"Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I;A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant."	""	""	""	"Fournier"	"2021"	"https://doi.org/10.1016/j.ijid.2021.03.068"	"doi:10.1016/j.ijid.2021.03.068"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"22992,23399,23401,23402,23403"	"S477N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1430G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I;A376T"	""	""	""	"Fournier"	"2021"	"https://doi.org/10.1016/j.ijid.2021.03.068"	"doi:10.1016/j.ijid.2021.03.068"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23003"	"N481Y"	"NC_045512.2:g.1441A>T"	"YP_009724390.1:p.Asn481Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Minor variant in initial round of in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009"	"V483L"	"NC_045512.2:g.1447G>C"	"YP_009724390.1:p.Val483Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"""	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"""	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"""	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in all 4 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013"	"E484A,E484A,E484A,E484A"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23018,23027,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,F486I,Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1456T>A,NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Phe486Ile,YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotype for Day 152 virus from a chronically infected patient: although mAb C1A-B12 had no activity against this pseudotype,  all three affinity optimized versions were active; the antibody containing the most mutations,  C1A-B12.3, was the most potent (IC50 <0.5 μg/mL)."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23018,23027,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,F486I,Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1456T>A,NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Phe486Ile,YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotype for Day 152 virus from a chronically infected patient, neutralizing activity of purified IgG  from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 152 S pseudotype was resistant to neutralization."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23018,23027,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,F486I,Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1456T>A,NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Phe486Ile,YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This Spike pseudotype for Day 152 virus from a chronically infected patient was completely resistent to REGN10933."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2)."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous."	""	""	""	"Braeye"	"2022"	"https://doi.org/10.1101/2022.05.09.22274623"	"doi:10.1101/2022.05.09.22274623"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2)."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2)."	""	""	""	"Yuan"	"2022"	"https://doi.org/10.1101/2022.05.11.491588"	"doi:10.1101/2022.05.11.491588"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"3rd exposure to antigen by Delta (B.1.617.2) (n=24) breakthrough increases the number of memory B cells that produce antibodies with comparable potency and breadth to a 3rd mRNA vaccine dose in individuals aged 21 –63 years, median age=30 years. Data collected 5.5 months after 2nd vaccination."	""	""	""	"Wang"	"2022"	"https://doi.org/10.1101/2022.08.11.503601"	"doi:10.1101/2022.08.11.503601"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous."	""	""	""	"Braeye"	"2022"	"https://doi.org/10.1101/2022.05.09.22274623"	"doi:10.1101/2022.05.09.22274623"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers."	""	""	""	"Sheward"	"2021"	"https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23009,23010,23012,23013,23071,23074,23075,22992,23060,23061,23062,23063"	"E484A,E484A,E484A,E484A,Y505H,Y505H,Y505H,S477N,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1430G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using molecular dynamics simulation, ACE2-RBD (Omicron) complex is destabilized by the E484A and Y505H mutations and stabilized by S477N and N501Y mutations."	""	""	""	"Zhang"	"2022"	"https://doi.org/10.1101/2022.06.05.493249"	"doi:10.1101/2022.06.05.493249"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	""	""	""	"Zhou"	"2021"	"https://doi.org/10.1101/2021.03.24.436620"	"doi:10.1101/2021.03.24.436620"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test)."	""	""	""	"Solfrosi"	"2021"	"https://doi.org/10.1084/jem.20202756"	"doi:10.1084/jem.20202756"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-01, SARS2-02, 1B07, SARS2-16, SARS2-32, SARS2-35 and 2B04 of 10 antibodies tested, and moderately high resistance to the remaining."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Multiple individuals in two related households were infected with a newly acquired E484K mutation within the B.1.311 lineage.  The timing and patterns of subsequent spread were consistent  with de novo emergence of this E484K variant in the initially affected individual who had been treated with bamlanivimab monotherapy.  The subsequent transmission to close contacts occurred several days after the resolution of symptoms and the end of this patient's quarantine period."	""	""	""	"Sabin"	"2021"	"https://doi.org/10.1101/2021.10.02.21264415"	"doi:10.1101/2021.10.02.21264415"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K."	""	""	""	"Li"	"2021"	"https://doi.org/10.1101/2021.04.19.440481"	"doi:10.1101/2021.04.19.440481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain."	""	""	""	"Jangra"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484Q"	"NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~20x binding against this isolated mutation. Casirivimab lost ~4x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera."	""	""	""	"Ferreira"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484Q"	"NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at  later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b. Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104. Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113. Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32,  and no E484K immune escape at day 104. Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102. Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26,  and no E484K immune escape at day 102."	""	""	""	"Greaney"	"2021"	"https://doi.org/10.1016/j.chom.2021.02.003"	"doi:10.1016/j.chom.2021.02.003"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected variants in an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected variants in an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in all 4 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Individual variants appearing at <=30% frequency at day 21 in immunocompromised host on tacrolimus, steroids and convalescent  plasma therapy, then appearing all at >95% frequency at day 27."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1101/2021.04.08.21254791"	"doi:10.1101/2021.04.08.21254791"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy."	""	""	""	"Ikegame"	"2021"	"https://doi.org/10.21203/rs.3.rs-400230/v1"	"doi:10.21203/rs.3.rs-400230/v1"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484Q"	"NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	">20% (ELISA significance threshold) drop in antibody binding by this variant against monoclonal antibody VH-Fc ab8."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484Q"	"NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This variant alone shows a 10x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G."	""	""	""	"Ferriera"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8"	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.03.19.436183"	"doi:10.1101/2021.03.19.436183"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity"	""	""	""	"Andreano"	"2020"	"https://doi.org/10.1101/2020.12.28.424451"	"doi:10.1101/2020.12.28.424451"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in binding efficiency vs wild type for mAb LY-CoV555."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape due to E484K [given Dec 2020-Apr 2021 time frame of the study, this is assumed to entail both  Beta and Gamma lineages]."	""	""	""	"Chung"	"2021"	"https://doi.org/10.1136/bmj.n1943"	"doi:10.1136/bmj.n1943"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484K"	"NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G."	""	""	""	"Ferriera"	"2021"	"https://doi.org/10.1101/2021.05.08.443253"	"doi:10.1101/2021.05.08.443253"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012"	"E484Q"	"NC_045512.2:g.1450G>C"	"YP_009724390.1:p.Glu484Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,22597,22599"	"E484K,R346K,R346K"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1037G>A,NC_045512.2:g.1037G>A"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Arg346Lys,YP_009724390.1:p.Arg346Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In serial experiment of mAb 2B04 resistent mutation isolate E484K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,22810,22811,22812,22813,22813"	"E484K,K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,22810,22811,22812,22813,22813,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,K417N,K417N,K417N,K417N,K417N,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,22810,22811,22812,22813,22813,23399,23401,23402,23403"	"E484K,K417N,K417N,K417N,K417N,K417N,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23053,23054,23055,23060,23061,23062,23063"	"E484K,Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2, forming a strong network of new interactions supporting the impact of these residues on affinity.  Q498R alone appears to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative to WT."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron BA.4 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently."	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Omicron BA.5 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently."	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron BA.4 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G"	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~17.5x folds more significant in 9 individuals."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Values taken 28 days after booster dose was given for BBIBP-CorVvaccine to 390 participants with 130 participants in the 0-14d-10m, 0-21d-10m and 0-28d-10m group. The geometric mean titers (GMT) of neutralizing antibody in 0-28d-10m and 0-21d-10m group were significantly higher than 0-14d-10m group at month 3, month 6 and month 10 after the second dose. A sharply decrease by 4.85-fold (GMT: 94.4-20.3), 4.67-fold (GMT: 134.4-28.8) and 4.49-fold (GMT: 145.5-32.4) was observed from day 28 to month 10 after the second dose in 0-14d-10m, 0-21d-10m and 0-28d-10m group, respectively, and they had similar decline kinetics."	""	""	""	"Yao T"	"2022"	"https://doi.org/10.1101/2022.06.22.22276690"	"doi:10.1101/2022.06.22.22276690"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Omicron neutralizing antibodies is 0.686x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of 55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~100x folds more significant in 3 individuals."	""	""	""	"Arora"	"2022"	"https://doi.org/10.1038/s41423-022-00870-5"	"doi:10.1038/s41423-022-00870-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Viral load from oral swabs from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR  targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Viral load from lung tissue from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR  targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)]"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)]"	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"Protection against symptomatic infection caused by Beta/Gamma (assumed by combined presence of N501Y and E484K) was also higher with partial  vaccination for mRNA-1273 (77%) than BNT162b2 (60%) and ChAdOx1 (48%), and full vaccination increased effectiveness for BNT162b2 (84%)."	""	""	""	"Nasreen"	"2021"	"https://doi.org/10.1101/2021.06.28.21259420"	"doi:10.1101/2021.06.28.21259420"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Log10ID50 of Omicron neutralizing antibodies is 0.722x the WT pre-third dose of pfizer-BioNTech BNT162b2 in  13 Kidney transplant recipients (KTR) with median age  of 55.5."	""	""	""	"McEvoy C"	"2022"	"https://doi.org/10.1101/2022.06.24.22276144"	"doi:10.1101/2022.06.24.22276144"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines."	""	""	""	"Xie"	"2021"	"https://doi.org/10.1038/s41591-021-01270-4"	"doi:10.1038/s41591-021-01270-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR22 had a 0.0015x fold change in IC50 in B.1.1.529 Omicron"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Trimeric proteins FSR16m had a 0.025x fold change in IC50 in B.1.1.529 Omicron"	""	""	""	"Chonira"	"2022"	"https://doi.org/10.1101/2022.05.30.493765"	"doi:10.1101/2022.05.30.493765"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Omicron Molnupiravir (MK-4482) had no statistically  significant change."	""	""	""	"Rosenke"	"2022"	"https://doi.org/10.1172/jci.insight.160108"	"doi:10.1172/jci.insight.160108"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063"	"E484K,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Omicron BA.5 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G"	""	""	""	"Neerukonda"	"2022"	"https://doi.org/10.1101/2022.06.01.494385"	"doi:10.1101/2022.06.01.494385"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9–11 days post-second dose;  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]"	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23060,23061,23062,23063,23399,23401,23402,23403"	"E484K,N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 did not affect syncytium formation."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, RBD-specific mutation E484Q did not significantly confer infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a  1.34x drop in neutralization (NT50) [mostly from a single serum]."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484Q,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>C,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Gln,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~4x infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403"	"E484K,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The estimated vaccine effectiveness against R.1 strain SARS-CoV-2 infection among residents in a Kentucky skilled nursing facility was  66.2% (95% CI = 40.5%–80.8%) and among health care workers was 75.9% (95% CI = 32.5%–91.4%) in the cohort of only those  14d+ post-vaccination Pfizer booster dose. VE against symptomatic COVID-19 was 86.5% (95% CI = 65.6%–94.7%) among residents  and 87.1% (95% CI = 46.4%–96.9%) among HCP. VE against hospitalization was 94.4% (95% CI = 73.9%–98.8%) among residents;  no HCP were hospitalized. Three residents died, two of whom were unvaccinated (VE = 94.4%; 95% CI = 44.6%–99.4%)."	""	""	""	"Cavanaugh"	"2021"	"https://doi.org/10.15585/mmwr.mm7017e2"	"doi:10.15585/mmwr.mm7017e2"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403,25088"	"E484K,D614G,D614G,D614G,D614G,V1176F"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The study demonstrated 1.92 and 1.09 fold reductions (ELISA) in the neutralizing titer against B.1.1.28.2 (P2) variant (n=2 authentic virus) in comparison with prototype D614G variant with 42 sera of BBV152 (a.k.a. Covaxin) vaccine recipients  2mo post-booster and 19 natural infections respectively. [exact P.2 sequences were not given, using the common defining SNPs]"	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1101/2021.04.30.441559"	"doi:10.1101/2021.04.30.441559"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403,25088"	"E484K,D614G,D614G,D614G,D614G,V1176F"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The study demonstrated 1.92 and 1.09 fold reductions (ELISA) in the neutralizing titer against B.1.1.28.2 (P2) variant (n=2 authentic virus) in comparison with prototype D614G variant with 42 sera of BBV152 (a.k.a. Covaxin) vaccine recipients  2mo post-booster and 19 natural infections respectively. [exact P.2 sequences were not given, using the common defining SNPs]"	""	""	""	"Sapkal"	"2021"	"https://doi.org/10.1101/2021.04.30.441559"	"doi:10.1101/2021.04.30.441559"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403,25088"	"E484K,D614G,D614G,D614G,D614G,V1176F"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the P.1 & P.2 lineages of SARS-CoV-2 in Brazil. The Brazilian arm of the Phase 3 double blind study showed severe/critical disease VE of 81.9%  (95% CI: 17.0-98.1), and moderate to severe/critical disease VE of 66.2% (95% CI: 51.0-77.1). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 69.3% of mostly severe infections sequenced as of this report, 69.4% were of P.2 lineage [defining lineage SNPs reported here]."	""	""	""	""	"2021"	"https://www.fda.gov/media/146217/download"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23012,23399,23401,23402,23403,25088"	"E484K,D614G,D614G,D614G,D614G,V1176F"	"NC_045512.2:g.1450G>A,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3526G>T"	"YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Val1176Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23013"	"E484V"	"NC_045512.2:g.1451A>T"	"YP_009724390.1:p.Glu484Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23013"	"E484V"	"NC_045512.2:g.1451A>T"	"YP_009724390.1:p.Glu484Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23013"	"E484V"	"NC_045512.2:g.1451A>T"	"YP_009724390.1:p.Glu484Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 88% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486I"	"NC_045512.2:g.1456T>A"	"YP_009724390.1:p.Phe486Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 88% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.07 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486I"	"NC_045512.2:g.1456T>A"	"YP_009724390.1:p.Phe486Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486I"	"NC_045512.2:g.1456T>A"	"YP_009724390.1:p.Phe486Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486L"	"NC_045512.2:g.1456T>C"	"YP_009724390.1:p.Phe486Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486L"	"NC_045512.2:g.1456T>C"	"YP_009724390.1:p.Phe486Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Observed in 4 separate mink farms in Denmark, but not humans, potential adaptation (diff set of farms than N501T)."	""	""	""	"Oude Munnink"	"2020"	"https://doi.org/10.1126/science.abe5901"	"doi:10.1126/science.abe5901"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486L"	"NC_045512.2:g.1456T>C"	"YP_009724390.1:p.Phe486Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutation causes a greater than 100x fold change in IC50 of Ensovibep."	""	""	""	"Rothenberger"	"2021"	"https://doi.org/10.1101/2021.02.03.429164v4"	"doi:10.1101/2021.02.03.429164v4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This mutation causes a greater than 100x fold change in IC50 of Ensovibep."	""	""	""	"Rothenberger"	"2021"	"https://doi.org/10.1101/2021.02.03.429164v4"	"doi:10.1101/2021.02.03.429164v4"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018"	"F486V"	"NC_045512.2:g.1456T>G"	"YP_009724390.1:p.Phe486Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"IC50 relative to wildtype drops ~8x in neutralization efficiency between 7-17 days post symptoms onset."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 1 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	">60% drop in antibody binding (ELISA) by this variant against monoclonal antibody VH-Fc ab8."	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 5 antibodies."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.13 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAbs SARS2-07, SARS2-19, 1B07, SARS2-16 and 2B04 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed striking resistance with only 38% neutralization at the highest concentration tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Modest decrease in in neutralization capability of all 4 convalescent sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23018,23019"	"F486S,F486S"	"NC_045512.2:g.1457T>C,NC_045512.2:g.1457T>C"	"YP_009724390.1:p.Phe486Ser,YP_009724390.1:p.Phe486Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23023"	"N487K"	"NC_045512.2:g.1461T>G"	"YP_009724390.1:p.Asn487Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027"	"Y489H"	"NC_045512.2:g.1465T>C"	"YP_009724390.1:p.Tyr489His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027"	"Y489H"	"NC_045512.2:g.1465T>C"	"YP_009724390.1:p.Tyr489His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Based on structural modelling, this change detected on day 128 sequencing in a chronically infected patient  would alter an extensive network of polar interactions with antibody residue R94VH,  a germline antibody residue that is conserved in all of the potent VH3-53/3-66-derived antibodies isolated from a convalescent donor 5 weeks after infection."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027"	"Y489H"	"NC_045512.2:g.1465T>C"	"YP_009724390.1:p.Tyr489His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1101/2020.11.30.405472"	"doi:10.1101/2020.11.30.405472"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027"	"Y489H"	"NC_045512.2:g.1465T>C"	"YP_009724390.1:p.Tyr489His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027"	"Y489H"	"NC_045512.2:g.1465T>C"	"YP_009724390.1:p.Tyr489His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.11 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAb SARS2-32 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"No effective neutralization in 3 out of the 4 sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Complete loss of binding in ELISA by the variant against monoclonal antibody ab8"	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected."	""	""	""	"Witte"	"2022"	"https://doi.org/10.1101/2022.08.17.504313"	"doi:10.1101/2022.08.17.504313"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23029,23030,23031"	"F490S,F490S,F490S,F490S"	"NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C,NC_045512.2:g.1469T>C"	"YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser,YP_009724390.1:p.Phe490Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations)."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23060,23061,23062,23063"	"Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This Spike pseudotype for Day 146 virus from a chronically infected patient was completely resistent to REGN10933. The variant had a 4-fold decrease in REGN10987 neutralization sensitivity (2nd component of the Regeneron mAb cocktail)."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23060,23061,23062,23063"	"Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotype for Day 146 virus from a chronically infected patient: resistant to neutralization by mAb C1A-B12, and  was still resistant to the affinity enhanced antibodies derived from it (i.e. no affinity maturation effect on neutralization)."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23027,23060,23061,23062,23063"	"Y489H,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1465T>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Tyr489His,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Pseudotype for Day 146 virus from a chronically infected patient, neutralizing activity of purified IgG  from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 146 S pseudotype was resistant to neutralization."	""	""	""	"Clark"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.027"	"doi:10.1016/j.cell.2021.03.027"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490V"	"NC_045512.2:g.1468T>G"	"YP_009724390.1:p.Phe490Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody"	""	""	""	"Greaney"	"2020"	"https://doi.org/10.1016/j.chom.2020.11.007"	"doi:10.1016/j.chom.2020.11.007"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490L"	"NC_045512.2:g.1468T>C"	"YP_009724390.1:p.Phe490Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency."	""	""	""	"Haslwanter"	"2021"	"https://doi.org/10.1101/2021.06.10.447999"	"doi:10.1101/2021.06.10.447999"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490L"	"NC_045512.2:g.1468T>C"	"YP_009724390.1:p.Phe490Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape) resistant to 3 individual sera at >4x"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490L"	"NC_045512.2:g.1468T>C"	"YP_009724390.1:p.Phe490Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to some neutralizing antibodies: mAbs X593, 261-262, H4, and P2B-2F6"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490L"	"NC_045512.2:g.1468T>C"	"YP_009724390.1:p.Phe490Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Complete loss of binding in ELISA by the variant against monoclonal antibody ab8"	""	""	""	"Sun"	"2021"	"https://doi.org/10.1101/2021.03.22.436481"	"doi:10.1101/2021.03.22.436481"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23030"	"F490L"	"NC_045512.2:g.1468T>C"	"YP_009724390.1:p.Phe490Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Positive selection (up to 23% of supernatant sequences) after C121 monoclonal antibody assay"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23031"	"F490Y"	"NC_045512.2:g.1469T>A"	"YP_009724390.1:p.Phe490Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.1 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23031"	"F490Y"	"NC_045512.2:g.1469T>A"	"YP_009724390.1:p.Phe490Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23031"	"F490Y"	"NC_045512.2:g.1469T>A"	"YP_009724390.1:p.Phe490Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23031"	"F490Y"	"NC_045512.2:g.1469T>A"	"YP_009724390.1:p.Phe490Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Massive reduction in binding efficiency vs wild type for mAbs CB6/LY-CoV16 and LY-CoV555."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Somewhat resistent to some class 1 (Spike 'up') antibodies tested. Mix of non- to strongly resistent in class 2 antibodies tested."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Somewhat resistent to some class 1 (Spike 'up') antibodies tested. Mix of non- to strongly resistent in class 2 antibodies tested."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Class 2 mAb C627 modestly selected for the emergence of this mutation in vitro."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant."	""	""	""	"Gaebler"	"2021"	"https://doi.org/10.1101/2020.11.03.367391"	"doi:10.1101/2020.11.03.367391"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Dominant (70%) in day 21 of prolonged infection in immunocompromised host on tacrolimus, steroids and convalescent  plasma therapy, then nearly disappearing (<5%) by day 27."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1101/2021.04.08.21254791"	"doi:10.1101/2021.04.08.21254791"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs."	""	""	""	"Barnes"	"2020"	"https://doi.org/10.1038/s41586-020-2852-1"	"doi:10.1038/s41586-020-2852-1"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23039,23040"	"Q493R,Q493R"	"NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G"	"YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R"	""	""	""	"Weisblum"	"2020"	"https://doi.org/10.1101/2020.07.21.214759"	"doi:10.1101/2020.07.21.214759"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"	""	""	""	"Starr"	"2021"	"https://doi.org/10.1101/2021.02.17.431683"	"doi:10.1101/2021.02.17.431683"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555."	""	""	""	"Rappazzo"	"2021"	"https://doi.org/10.1126/science.abf4830"	"doi:10.1126/science.abf4830"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2020.11.06.372037"	"doi:10.1101/2020.11.06.372037"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  S484P shows a slightly resistant profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution)"	""	""	""	"Greaney"	"2021"	"https://doi.org/10.1016/j.chom.2021.02.003"	"doi:10.1016/j.chom.2021.02.003"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Highly resistant to mAb SARS2-01 of 10 antibodies tested."	""	""	""	"Liu"	"2020"	"https://doi.org/10.1016/j.chom.2021.01.014"	"doi:10.1016/j.chom.2021.01.014"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Minor variant selected in late rounds of an in vitro evolution experiment for ACE2 binding. Shown to increase the thermostability but decrease the association rate constant of the RBD to ACE2"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using molecular dynamic simulation, the mildly (~1kcal/mol) enhanced binding energy of this variant is primarily  contributed by Tyr505 (−4.98 kcal/mol) which is now involved in a strong hydrogen bonding network with Arg393.  Another important energetic contribution comes from the altered orientation of Tyr41 which is now involved with  two hydrogen-bonding interactions with Asp355 and Thr500."	""	""	""	""	"2021"	"https://doi.org/10.1016/j.bbrc.2021.01.035"	"doi:10.1016/j.bbrc.2021.01.035"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23042"	"S494P"	"NC_045512.2:g.1480T>C"	"YP_009724390.1:p.Ser494Pro"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation. Regdanvimab lost ~32x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23048"	"G496S"	"NC_045512.2:g.1486G>A"	"YP_009724390.1:p.Gly496Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.12 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23053,23054,23055,23060,23061,23062,23063"	"Q498R,Q498R,Q498R,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution."	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome"	""	""	""	"Choi"	"2020"	"https://doi.org/10.1056/NEJMc2031364"	"doi:10.1056/NEJMc2031364"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"homoplasy"	""	""	"Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin)."	""	""	""	"Flores-Alanis"	"2021"	"https://doi.org/10.3390/pathogens10020184"	"doi:10.3390/pathogens10020184"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses."	""	""	""	"Feng"	"2022"	"https://doi.org/10.1002/smtd.202200387"	"doi:10.1002/smtd.202200387"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years; day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay."	""	""	""	"Edara"	"2021"	"https://doi.org/10.1101/2021.02.02.21250799"	"doi:10.1101/2021.02.02.21250799"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine efficacy"	""	""	"In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative]."	""	""	""	"Chung"	"2021"	"https://doi.org/10.1136/bmj.n1943"	"doi:10.1136/bmj.n1943"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance."	""	""	""	"Barton"	"2021"	"https://doi.org/10.1101/2021.05.18.444646"	"doi:10.1101/2021.05.18.444646"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus."	""	""	""	"Bates"	"2021"	"https://doi.org/10.1101/2021.04.04.21254881"	"doi:10.1101/2021.04.04.21254881"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape."	""	""	""	"Jacobson"	"2021"	"https://doi.org/10.1101/2021.04.14.21255431"	"doi:10.1101/2021.04.14.21255431"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma."	""	""	""	"Tang"	"2021"	"https://doi.org/10.1101/2021.03.19.436183"	"doi:10.1101/2021.03.19.436183"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.02.428884"	"doi:10.1101/2021.02.02.428884"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)"	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.03.08.434499"	"doi:10.1101/2021.03.08.434499"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.02.428884"	"doi:10.1101/2021.02.02.428884"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.02.428884"	"doi:10.1101/2021.02.02.428884"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17."	""	""	""	"Rees-Spear"	"2021"	"https://doi.org/10.1101/2021.01.15.426849"	"doi:10.1101/2021.01.15.426849"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).  Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"~4-fold increase in binding affinity vs wild type."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"~4-fold increase in binding affinity vs wild type."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased."	""	""	""	""	"2021"	"https://doi.org/10.1101/2020.12.29.424708"	"doi:10.1101/2020.12.29.424708"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19."	""	""	""	"Collier"	"2021"	"https://doi.org/10.1038/s41586-021-03412-7"	"doi:10.1038/s41586-021-03412-7"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)"	""	""	""	"Shen"	"2021"	"https://doi.org/10.1101/2021.01.27.428516"	"doi:10.1101/2021.01.27.428516"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3"	""	""	""	"Wang"	"2021"	"https://doi.org/10.1101/2021.01.15.426911"	"doi:10.1101/2021.01.15.426911"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations."	""	""	""	"Klegerman"	"2021"	"https://doi.org/10.1101/2021.04.26.441517"	"doi:10.1101/2021.04.26.441517"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity."	""	""	""	"Zhu"	"2021"	"https://doi.org/10.1101/2021.01.11.426269"	"doi:10.1101/2021.01.11.426269"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.02.428884"	"doi:10.1101/2021.02.02.428884"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity."	""	""	""	"Zhu"	"2021"	"https://doi.org/10.1101/2021.01.11.426269"	"doi:10.1101/2021.01.11.426269"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.02.02.428884"	"doi:10.1101/2021.02.02.428884"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"	""	""	""	"Zahradnik"	"2021"	"https://doi.org/10.1101/2021.01.06.425392"	"doi:10.1101/2021.01.06.425392"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM)."	""	""	""	"Ramanathan"	"2021"	"https://doi.org/10.1101/2021.02.22.432359"	"doi:10.1101/2021.02.22.432359"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability."	""	""	""	"Motozono"	"2021"	"https://doi.org/10.1101/2021.04.02.438288"	"doi:10.1101/2021.04.02.438288"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM)."	""	""	""	"Tian"	"2021"	"https://doi.org/10.1101/2021.02.14.431117"	"doi:10.1101/2021.02.14.431117"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Experimentally, ACE2 binding affinity increased 0.24 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM)."	""	""	""	"Ramanathan"	"2021"	"https://doi.org/10.1101/2021.02.22.432359"	"doi:10.1101/2021.02.22.432359"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353."	""	""	""	"Gamez"	"2021"	"https://doi.org/10.1101/2021.04.09.439154"	"doi:10.1101/2021.04.09.439154"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063"	"N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity."	""	""	""	"Zhu"	"2021"	"https://doi.org/10.1101/2021.01.11.426269"	"doi:10.1101/2021.01.11.426269"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,22810,22811,22812,22813,22813"	"N501Y,N501Y,N501Y,N501Y,K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,22810,22811,22812,22813,22813,23012"	"N501Y,N501Y,N501Y,N501Y,K417N,K417N,K417N,K417N,K417N,E484K"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In post-vaccination sera from individuals who received one (3 weeks post-first dose; n = 5) or two doses (9–11 days post-second dose;  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,22810,22811,22812,22813,22813,23012"	"N501Y,N501Y,N501Y,N501Y,K417N,K417N,K417N,K417N,K417N,E484K"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23012"	"N501Y,N501Y,N501Y,N501Y,E484K"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23271"	"N501Y,N501Y,N501Y,N501Y,A570D"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"reinfection"	""	""	"Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection."	""	""	""	"Novazzi"	"2021"	"https://doi.org/10.1002/jmv.27066"	"doi:10.1002/jmv.27066"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403,23593,23593"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403,23593,23593"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23399,23401,23402,23403,23593,23593"	"N501Y,N501Y,N501Y,N501Y,D614G,D614G,D614G,D614G,Q677H,Q677H"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2031G>T,NC_045512.2:g.2031G>C"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Gln677His,YP_009724390.1:p.Gln677His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity)."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23060,23061,23062,23063,23521,23522,23524,23525"	"N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23071,23074,23075"	"Y505H,Y505H,Y505H"	"NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Observed first in a single tiger (cohort of 5), potential adaptation."	""	""	""	"McAloose"	"2020"	"https://doi.org/10.1128/mBio.02220-20"	"doi:10.1128/mBio.02220-20"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23071,23074,23075"	"Y505H,Y505H,Y505H"	"NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.16 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23102"	"S514T"	"NC_045512.2:g.1540T>A"	"YP_009724390.1:p.Ser514Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.12 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23108"	"E516Q"	"NC_045512.2:g.1546G>C"	"YP_009724390.1:p.Glu516Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.21 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23115"	"L518Q"	"NC_045512.2:g.1553T>A"	"YP_009724390.1:p.Leu518Gln"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.06 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23120"	"A520S"	"NC_045512.2:g.1558G>T"	"YP_009724390.1:p.Ala520Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"CR3022 (SARS-targeting mAb) cross-reactivity lost ~4x binding against this isolated mutation."	""	""	""	"Engelhart"	"2021"	"https://doi.org/10.1101/2021.04.27.440939"	"doi:10.1101/2021.04.27.440939"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23148"	"K529T"	"NC_045512.2:g.1586A>C"	"YP_009724390.1:p.Lys529Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"gene expression increase"	""	""	"Experimentally, Spike gene expression increased 0.15 fold"	""	""	""	"Starr"	"2020"	"https://doi.org/10.1016/j.cell.2020.08.012"	"doi:10.1016/j.cell.2020.08.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23271"	"A570D"	"NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing statistically significant increased infection rate amongst the cells."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23271"	"A570D"	"NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated that there is very little free energy change (ddG. -0.02 kcal/mol) for this variant (i.e. approx. same stability as wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23271"	"A570D"	"NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant raises PIWAS epitope score from 3.6% to 6.2% (improved immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23271"	"A570D"	"NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23373"	"T604I"	"NC_045512.2:g.1811C>T"	"YP_009724390.1:p.Thr604Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection, but also in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal immunity escape variant."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset."	""	""	""	"Kuzmina"	"2021"	"https://doi.org/10.1016/j.chom.2021.03.008"	"doi:10.1016/j.chom.2021.03.008"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to wild type, D614G showed increased infectivity (ie. cold stability) after storage at -20°C for up to 30 days."	""	""	""	"Huang"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."	""	""	""	"Garcia-Beltran"	"2021"	"https://doi.org/10.1016/j.cell.2021.03.013"	"doi:10.1016/j.cell.2021.03.013"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells."	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."	""	""	""	"Zhang"	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	""	""	""	"Yurkovetskiy"	"2020"	"https://doi.org/10.1016/j.cell.2020.09.032"	"doi:10.1016/j.cell.2020.09.032"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."	""	""	""	"Zhang"	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."	""	""	""	"Zhang"	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."	""	""	""	"Zhang"	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	""	""	""	"Weissman"	"2020"	"https://doi.org/10.1101/2020.07.22.20159905"	"doi:10.1101/2020.07.22.20159905"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"transmissibility"	""	""	"Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 conferred a nearly two-fold infectivity advantage to the spike particles."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD mutation conferred a 4.85x drop in neutralization (NT50)."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	""	""	""	"Yurkovetskiy"	"2020"	"https://doi.org/10.1016/j.cell.2020.09.032"	"doi:10.1016/j.cell.2020.09.032"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	""	""	""	"Weissman"	"2020"	"https://doi.org/10.1101/2020.07.22.20159905"	"doi:10.1101/2020.07.22.20159905"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	""	""	""	"Yurkovetskiy"	"2020"	"https://doi.org/10.1016/j.cell.2020.09.032"	"doi:10.1016/j.cell.2020.09.032"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"viral load"	""	""	"Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission."	""	""	""	"Plante"	"2020"	"https://doi.org/10.1038/s41586-020-2895-3"	"doi:10.1038/s41586-020-2895-3"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion."	""	""	""	""	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"tissue specific neutralization"	""	""	"The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract."	""	""	""	"Planas"	"2021"	"https://doi.org/10.1038/s41591-021-01318-5"	"doi:10.1038/s41591-021-01318-5"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus."	""	""	""	"Kim"	"2021"	"https://doi.org/10.3390/v13040633"	"doi:10.3390/v13040633"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses."	""	""	""	"Ozono"	"2020"	"https://doi.org/10.1038/s41467-021-21118-2"	"doi:10.1038/s41467-021-21118-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion."	""	""	""	""	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses."	""	""	""	"Ozono"	"2020"	"https://doi.org/10.1038/s41467-021-21118-2"	"doi:10.1038/s41467-021-21118-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike."	""	""	""	"Landis"	"2021"	"https://doi.org/10.1101/2021.05.08.21256775"	"doi:10.1101/2021.05.08.21256775"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction."	""	""	""	"Daniloski"	"2021"	"https://doi.org/10.7554/eLife.65365"	"doi:10.7554/eLife.65365"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"syncytium formation"	""	""	"Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 did not affect syncytium formation."	""	""	""	"Mishra"	"2021"	"https://doi.org/10.1101/2021.10.04.463028"	"doi:10.1101/2021.10.04.463028"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403"	"D614G,D614G,D614G,D614G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion."	""	""	""	""	"2020"	"https://doi.org/10.1038/s41467-020-19808-4"	"doi:10.1038/s41467-020-19808-4"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575"	"D614G,D614G,D614G,D614G,L5F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575"	"D614G,D614G,D614G,D614G,L5F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575"	"D614G,D614G,D614G,D614G,L5F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575,21846,22317,22319,22320,23012,23664"	"D614G,D614G,D614G,D614G,L5F,T95I,D253G,D253G,D253G,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575,21846,22317,22319,22320,23012,23664"	"D614G,D614G,D614G,D614G,L5F,T95I,D253G,D253G,D253G,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21575,21846,22317,22319,22320,23012,23664"	"D614G,D614G,D614G,D614G,L5F,T95I,D253G,D253G,D253G,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.13C>T,NC_045512.2:g.284C>T,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu5Phe,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600"	"D614G,D614G,D614G,D614G,S13I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600"	"D614G,D614G,D614G,D614G,S13I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600"	"D614G,D614G,D614G,D614G,S13I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600,22018,22915,22916,22917"	"D614G,D614G,D614G,D614G,S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600,22018,22915,22916,22917"	"D614G,D614G,D614G,D614G,S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21600,22018,22915,22916,22917"	"D614G,D614G,D614G,D614G,S13I,W152C,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.38G>T,NC_045512.2:g.456G>T,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser13Ile,YP_009724390.1:p.Trp152Cys,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614"	"D614G,D614G,D614G,D614G,L18F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614"	"D614G,D614G,D614G,D614G,L18F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614"	"D614G,D614G,D614G,D614G,L18F"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"D614G,D614G,D614G,D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"D614G,D614G,D614G,D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21621,21638,21974,22132,22812,23012,23060,23061,23062,23063,23521,23522,23524,23525,24642"	"D614G,D614G,D614G,D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,N501Y,N501Y,N501Y,H655Y,H655Y,H655Y,H655Y,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.59C>A,NC_045512.2:g.76C>T,NC_045512.2:g.412G>T,NC_045512.2:g.570G>T,NC_045512.2:g.1250A>C,NC_045512.2:g.1450G>A,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Thr20Asn,YP_009724390.1:p.Pro26Ser,YP_009724390.1:p.Asp138Tyr,YP_009724390.1:p.Arg190Ser,YP_009724390.1:p.Lys417Thr,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21801,23060,23061,23062,23063,22206,22810,22811,22812,22813,22813,23012,23664"	"D614G,D614G,D614G,D614G,L18F,D80A,N501Y,N501Y,N501Y,N501Y,D215G,K417N,K417N,K417N,K417N,K417N,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing B.1.351 aka Beta)  showed a 1.04x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, in contrast to the largely positive binding values for each individual mutation that comprises the set."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21801,23060,23061,23062,23063,22206,22810,22811,22812,22813,22813,23012,23664"	"D614G,D614G,D614G,D614G,L18F,D80A,N501Y,N501Y,N501Y,N501Y,D215G,K417N,K417N,K417N,K417N,K417N,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing B.1.351 aka Beta)  showed a 1.28x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. It shows a 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21614,21801,23060,23061,23062,23063,22206,22810,22811,22812,22813,22813,23012,23664"	"D614G,D614G,D614G,D614G,L18F,D80A,N501Y,N501Y,N501Y,N501Y,D215G,K417N,K417N,K417N,K417N,K417N,E484K,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.52C>T,NC_045512.2:g.239A>C,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.644A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1450G>A,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu18Phe,YP_009724390.1:p.Asp80Ala,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asp215Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Glu484Lys,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.351 aka Beta)  showed a 3.56x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21621"	"D614G,D614G,D614G,D614G,T20N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.59C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr20Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21621"	"D614G,D614G,D614G,D614G,T20N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.59C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr20Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21621"	"D614G,D614G,D614G,D614G,T20N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.59C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr20Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21638"	"D614G,D614G,D614G,D614G,P26S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.76C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro26Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21638"	"D614G,D614G,D614G,D614G,P26S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.76C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro26Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21638"	"D614G,D614G,D614G,D614G,P26S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.76C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro26Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of  Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"This variant combination (representing B.1.1.7 aka Alpha) showed a 1.15x increase in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21761,21762,21763,21764,21765,21766,21766,21761,21762,21763,21764,21765,21766,21766,23060,23061,23062,23063,23271,23604,23709,24506,24914"	"D614G,D614G,D614G,D614G,H69del,H69del,H69del,H69del,H69del,H69del,H69del,V70del,V70del,V70del,V70del,V70del,V70del,V70del,N501Y,N501Y,N501Y,N501Y,A570D,P681H,T716I,S982A,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1709C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.2147C>T,NC_045512.2:g.2944T>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Ala570Asp,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Thr716Ile,YP_009724390.1:p.Ser982Ala,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.1.7 aka Alpha) had 5.43x increased binding relative to D614G alone."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21801"	"D614G,D614G,D614G,D614G,D80A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21801"	"D614G,D614G,D614G,D614G,D80A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21801"	"D614G,D614G,D614G,D614G,D80A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.239A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp80Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21846"	"D614G,D614G,D614G,D614G,T95I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21846"	"D614G,D614G,D614G,D614G,T95I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21846"	"D614G,D614G,D614G,D614G,T95I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.284C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr95Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21974"	"D614G,D614G,D614G,D614G,D138Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.412G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp138Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21974"	"D614G,D614G,D614G,D614G,D138Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.412G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp138Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,21974"	"D614G,D614G,D614G,D614G,D138Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.412G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp138Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22018"	"D614G,D614G,D614G,D614G,W152C"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.456G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22018"	"D614G,D614G,D614G,D614G,W152C"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.456G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22018"	"D614G,D614G,D614G,D614G,W152C"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.456G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Trp152Cys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22132"	"D614G,D614G,D614G,D614G,R190S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.570G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Arg190Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22132"	"D614G,D614G,D614G,D614G,R190S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.570G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Arg190Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22132"	"D614G,D614G,D614G,D614G,R190S"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.570G>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Arg190Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22206"	"D614G,D614G,D614G,D614G,D215G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22206"	"D614G,D614G,D614G,D614G,D215G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22206"	"D614G,D614G,D614G,D614G,D215G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.644A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp215Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22317,22319,22320"	"D614G,D614G,D614G,D614G,D253G,D253G,D253G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22317,22319,22320"	"D614G,D614G,D614G,D614G,D253G,D253G,D253G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22317,22319,22320"	"D614G,D614G,D614G,D614G,D253G,D253G,D253G"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G,NC_045512.2:g.758A>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly,YP_009724390.1:p.Asp253Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22810,22811,22812,22813,22813"	"D614G,D614G,D614G,D614G,K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22810,22811,22812,22813,22813"	"D614G,D614G,D614G,D614G,K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22810,22811,22812,22813,22813"	"D614G,D614G,D614G,D614G,K417N,K417N,K417N,K417N,K417N"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22812"	"D614G,D614G,D614G,D614G,K417T"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22812"	"D614G,D614G,D614G,D614G,K417T"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22812"	"D614G,D614G,D614G,D614G,K417T"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1250A>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Lys417Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22915,22916,22917"	"D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]"	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22915,22916,22917"	"D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273)."	""	""	""	"Wilhelm"	"2021"	"https://doi.org/10.1101/2021.08.09.21261704"	"doi:10.1101/2021.08.09.21261704"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22915,22916,22917"	"D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22915,22916,22917"	"D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,22915,22916,22917"	"D614G,D614G,D614G,D614G,L452R,L452R,L452R"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G,NC_045512.2:g.1355T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg,YP_009724390.1:p.Leu452Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23048,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,24130,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,G496S,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,N856K,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1486G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2568C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen."	""	""	""	"Hao"	"2022"	"https://doi.org/10.1101/2022.08.12.22278720"	"doi:10.1101/2022.08.12.22278720"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23048,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,24130,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,G496S,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,N856K,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1486G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2568C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23048,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,24130,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,G496S,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,N856K,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1486G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2568C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n=29) infection increased variant specific plasma antibody and memory B cell responses as well as overall increased strain specific memory in individuals aged 22 –79 years, median age=33.5 years. Data collected 2.4 months after 3rd vaccination."	""	""	""	"Wang"	"2022"	"https://doi.org/10.1101/2022.08.11.503601"	"doi:10.1101/2022.08.11.503601"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23048,21761,21762,21763,21764,21765,21766,21766,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,24130,23604,23039,23040,23053,23054,23055,22679,22686,22992,21846,22992,22995,21761,21762,21763,21764,21765,21766,21766,21987,21990,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,G496S,H69del,H69del,H69del,H69del,H69del,H69del,H69del,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,N856K,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,S373P,S375F,S477N,T95I,T478K,T478K,V70del,V70del,V70del,V70del,V70del,V70del,V70del,Y145del,Y145del,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1486G>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2568C>A,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.284C>T,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.204_209del,NC_045512.2:g.205_210del,NC_045512.2:g.204_209del,NC_045512.2:g.432_434del,NC_045512.2:g.432_434del,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly496Ser,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn856Lys,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr95Ile,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.His69_Val70del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr145del,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22783,22784,22785,22786,22786,22679,22686,22992,22992,22995,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,R408S,R408S,R408S,R408S,R408S,S373P,S375F,S477N,T478K,T478K,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22783,22784,22785,22786,22786,22679,22686,22992,22992,22995,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,R408S,R408S,R408S,R408S,R408S,S373P,S375F,S477N,T478K,T478K,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold."	""	""	""	"Uhal B"	"2022"	"https://doi.org/10.1101/2022.06.23.497326"	"doi:10.1101/2022.06.23.497326"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23521,23522,23524,23525,22810,22811,22812,22813,22813,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22783,22784,22785,22786,22786,22679,22686,22992,22992,22995,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,R408S,R408S,R408S,R408S,R408S,S373P,S375F,S477N,T478K,T478K,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23521,23522,23524,23525,22810,22811,22812,22813,22813,22917,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22783,22784,22785,22786,22786,22679,22686,22992,22992,22995,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,L452Q,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,R408S,R408S,R408S,R408S,R408S,S373P,S375F,S477N,T478K,T478K,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1355T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23009,23010,23012,23013,21971,21972,21974,21976,21979,21981,21982,21984,21985,21986,21987,22576,22577,22578,23521,23522,23524,23525,22810,22811,22812,22813,22813,22917,22879,22881,22882,22882,23060,23061,23062,23063,23604,23039,23040,23053,23054,23055,22783,22784,22785,22786,22786,22679,22686,22992,22992,22995,23071,23074,23075"	"D614G,D614G,D614G,D614G,E484A,E484A,E484A,E484A,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G142D,G339D,G339D,G339D,H655Y,H655Y,H655Y,H655Y,K417N,K417N,K417N,K417N,K417N,L452Q,N440K,N440K,N440K,N440K,N501Y,N501Y,N501Y,N501Y,P681H,Q493R,Q493R,Q498R,Q498R,Q498R,R408S,R408S,R408S,R408S,R408S,S373P,S375F,S477N,T478K,T478K,Y505H,Y505H,Y505H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.1451A>C,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.425G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1016G>A,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>T,NC_045512.2:g.1251G>C,NC_045512.2:g.1355T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>G,NC_045512.2:g.1320T>A,NC_045512.2:g.1320T>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.2042C>A,NC_045512.2:g.1478A>G,NC_045512.2:g.1478A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1493A>G,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>C,NC_045512.2:g.1224A>T,NC_045512.2:g.1224A>C,NC_045512.2:g.1117T>C,NC_045512.2:g.1124C>T,NC_045512.2:g.1430G>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1433C>A,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C,NC_045512.2:g.1513T>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Glu484Ala,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly142Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.Gly339Asp,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Lys417Asn,YP_009724390.1:p.Leu452Gln,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn440Lys,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Pro681His,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln493Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Gln498Arg,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Arg408Ser,YP_009724390.1:p.Ser373Pro,YP_009724390.1:p.Ser375Phe,YP_009724390.1:p.Ser477Asn,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Thr478Lys,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His,YP_009724390.1:p.Tyr505His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020."	""	""	""	"Kurhade"	"2022"	"https://doi.org/10.1101/2022.06.05.494889"	"doi:10.1101/2022.06.05.494889"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23012"	"D614G,D614G,D614G,D614G,E484K"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23012"	"D614G,D614G,D614G,D614G,E484K"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23012"	"D614G,D614G,D614G,D614G,E484K"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1450G>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Glu484Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23060,23061,23062,23063"	"D614G,D614G,D614G,D614G,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23060,23061,23062,23063"	"D614G,D614G,D614G,D614G,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23060,23061,23062,23063"	"D614G,D614G,D614G,D614G,N501Y,N501Y,N501Y,N501Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T,NC_045512.2:g.1501A>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr,YP_009724390.1:p.Asn501Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23271"	"D614G,D614G,D614G,D614G,A570D"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23271"	"D614G,D614G,D614G,D614G,A570D"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23271"	"D614G,D614G,D614G,D614G,A570D"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1709C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala570Asp"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23521,23522,23524,23525"	"D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23521,23522,23524,23525"	"D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23521,23522,23524,23525"	"D614G,D614G,D614G,D614G,H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23604"	"D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccine neutralization efficacy"	""	""	"No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]"	""	""	""	"Zuckerman"	"2021"	"https://doi.org/10.1101/2021.03.25.21253908"	"doi:10.1101/2021.03.25.21253908"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23604"	"D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23604"	"D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23604"	"D614G,D614G,D614G,D614G,P681H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23664"	"D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23664"	"D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23664"	"D614G,D614G,D614G,D614G,A701V"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23709"	"D614G,D614G,D614G,D614G,T716I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.12x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23709"	"D614G,D614G,D614G,D614G,T716I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,23709"	"D614G,D614G,D614G,D614G,T716I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.58x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24506"	"D614G,D614G,D614G,D614G,S982A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24506"	"D614G,D614G,D614G,D614G,S982A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.3x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24506"	"D614G,D614G,D614G,D614G,S982A"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24642"	"D614G,D614G,D614G,D614G,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24642"	"D614G,D614G,D614G,D614G,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24642"	"D614G,D614G,D614G,D614G,T1027I"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24914"	"D614G,D614G,D614G,D614G,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"vaccinee plasma binding"	""	""	"1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24914"	"D614G,D614G,D614G,D614G,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23399,23401,23402,23403,24914"	"D614G,D614G,D614G,D614G,D1118H"	"NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma binding"	""	""	"1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset."	""	""	""	"Gong"	"2021"	"https://doi.org/10.1101/2021.08.04.455140"	"doi:10.1101/2021.08.04.455140"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23429"	"A623T"	"NC_045512.2:g.1867G>A"	"YP_009724390.1:p.Ala623Thr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23521,23522,23524,23525"	"H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23521,23522,23524,23525"	"H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23521,23522,23524,23525"	"H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23521,23522,23524,23525"	"H655Y,H655Y,H655Y,H655Y"	"NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T,NC_045512.2:g.1963C>T"	"YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr,YP_009724390.1:p.His655Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection."	""	""	""	"Esclera"	"2021"	"https://doi.org/10.1101/2021.08.05.455290"	"doi:10.1101/2021.08.05.455290"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23587,23587"	"Q675H,Q675H"	"NC_045512.2:g.2025G>C,NC_045512.2:g.2025G>T"	"YP_009724390.1:p.Gln675His,YP_009724390.1:p.Gln675His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain significantly enhanced the ability of the pseudotyped VSV to infect fat-tailed gerbil (Pachyuromys duprasi) kidney cell cultures, with a  transduction rate of 13.4%, close to the 15.7% in epithelial-like human Huh-7 cells while starting from a significantly lower wildtype (Wuhan-Hu-1 Spike VSVdeltaG psuedotype) rate."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681R"	"NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H]"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic."	""	""	""	"Johnson"	"2020"	"https://doi.org/10.1101/2020.08.26.268854"	"doi:10.1101/2020.08.26.268854"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"In the absence of N501Y, this Alpha lineage change in the furin clevage site did NOT show significant increase in infectivity relative to wild type,  as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters."	""	""	""	"Liu"	"2021"	"https://doi.org/10.1101/2021.03.08.434499"	"doi:10.1101/2021.03.08.434499"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry)."	""	""	""	""	"2021"	"https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry)."	""	""	""	""	"2021"	"https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"pharmaceutical effectiveness"	""	""	"This individual mutation found in the epitope from Sotrovimab causes a 0.9x reduction in neutralization efficacy using a VSV model on Vero E6 cells."	""	""	""	"Cathcart"	"2021"	"https://doi.org/10.1101/2021.03.09.434607v9"	"doi:10.1101/2021.03.09.434607v9"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic."	""	""	""	"Johnson"	"2020"	"https://doi.org/10.1101/2020.08.26.268854"	"doi:10.1101/2020.08.26.268854"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."	""	""	""	"Chen"	"2021"	"https://doi.org/10.1038/s41591-021-01294-w"	"doi:10.1038/s41591-021-01294-w"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681R"	"NC_045512.2:g.2042C>G"	"YP_009724390.1:p.Pro681Arg"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work]"	""	""	""	""	"2021"	"https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication"	""	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604"	"P681H"	"NC_045512.2:g.2042C>A"	"YP_009724390.1:p.Pro681His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC)."	""	""	""	"Lubinski"	"2021"	"https://doi.org/10.1101/2021.04.06.438731"	"doi:10.1101/2021.04.06.438731"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23604,23399,23401,23402,23403"	"P681R,D614G,D614G,D614G,D614G"	"NC_045512.2:g.2042C>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G,NC_045512.2:g.1841A>G"	"YP_009724390.1:p.Pro681Arg,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly,YP_009724390.1:p.Asp614Gly"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.05.14.444076"	"doi:10.1101/2021.05.14.444076"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23664"	"A701V"	"NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23664"	"A701V"	"NC_045512.2:g.2102C>T"	"YP_009724390.1:p.Ala701Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23709"	"T716I"	"NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Not in a major wildtype epitope, mutant increases PIWAS epitope score from 0.69% to 2.3% Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23709"	"T716I"	"NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain showed a decreased capacity to transduce PK-15 (pig kidney, Sus scrofa) and PaKi (black flying fox kidney, Pteropus alecto) cell line cultures using a pseudotyped VSV assay."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23709"	"T716I"	"NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Observed first in a single tiger (cohort of 5), potential adaptation."	""	""	""	"McAloose"	"2020"	"https://doi.org/10.1128/mBio.02220-20"	"doi:10.1128/mBio.02220-20"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23709"	"T716I"	"NC_045512.2:g.2147C>T"	"YP_009724390.1:p.Thr716Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness. T716I was expressed at significantly lower level, accounting for the decreased infectivity of this spike protein. This property may be specific to spike protein biosynthesis in 293T cells and is not likely to reflect the situation in vivo given the reported increase in infectivity of the B.1.1.7 virus."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23897"	"Q779K"	"NC_045512.2:g.2335C>A"	"YP_009724390.1:p.Gln779Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"monoclonal antibody serial passage escape"	""	""	"Escape variant 20% appearance in 2 passages against Regeneron monoclonal antibody RGN10989 @ 50ug/mL"	""	""	""	"Baum"	"2020"	"https://doi.org/10.1126/science.abd0831"	"doi:10.1126/science.abd0831"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"23948"	"D796H"	"NC_045512.2:g.2386G>C"	"YP_009724390.1:p.Asp796His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma"	""	""	""	"Kemp"	"2020"	"https://doi.org/10.1101/2020.12.05.20241927"	"doi:10.1101/2020.12.05.20241927"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24000"	"S813I"	"NC_045512.2:g.2438G>T"	"YP_009724390.1:p.Ser813Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24054"	"A831V"	"NC_045512.2:g.2492C>T"	"YP_009724390.1:p.Ala831Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Resistent to neutralizing mAb B38"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24054"	"A831V"	"NC_045512.2:g.2492C>T"	"YP_009724390.1:p.Ala831Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24054"	"A831V"	"NC_045512.2:g.2492C>T"	"YP_009724390.1:p.Ala831Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"	""	""	""	"Li"	"2020"	"https://doi.org/10.1016/j.cell.2020.07.012"	"doi:10.1016/j.cell.2020.07.012"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24077"	"D839N"	"NC_045512.2:g.2515G>A"	"YP_009724390.1:p.Asp839Asn"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant near the internal fusion peptide shown in vitro to reduce Spike subunit fusion required for cell entry."	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24077"	"D839Y"	"NC_045512.2:g.2515G>T"	"YP_009724390.1:p.Asp839Tyr"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant near the internal fusion peptide shown in vitro to reduce Spike subunit fusion required for cell entry."	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24130"	"N856K"	"NC_045512.2:g.2568C>A"	"YP_009724390.1:p.Asn856Lys"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"branch specific selection pressure"	""	""	"Using the Contrast-FEL method, this mutation is differentially selected along the B.1.1.529 (WHO VOC Omicron) branch."	""	""	""	"Lucaci"	"2021"	""	""	""	""	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24170"	"I870V"	"NC_045512.2:g.2608A>G"	"YP_009724390.1:p.Ile870Val"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome Appeared at same time as T478K,S494P but listed separately due to distance and different domains affected in the Spike (i.e. putatively an independent mutation from a functional standpoint since the former are from S1, the latter from S2)."	""	""	""	"Choi"	"2020"	"https://doi.org/10.1056/NEJMc2031364"	"doi:10.1056/NEJMc2031364"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24377,24378"	"S939F,S939F"	"NC_045512.2:g.2816C>T,NC_045512.2:g.2816C>T"	"YP_009724390.1:p.Ser939Phe,YP_009724390.1:p.Ser939Phe"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"This mutation outside the receptor binding domain significantly reduced the tropism of SARS-CoV-2 to MfuKi (eastern bent-wing bat kidney cell, Miniopterus fuliginosus) cell cultures using a pseudotyped VSV assay."	""	""	""	"Li"	"2023"	"https://doi.org/10.1038/s41396-023-01368-2"	"doi:10.1038/s41396-023-01368-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24506"	"S982A"	"NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model, showing similar patterns to the pseudotyped virus model of B.1.1.7."	""	""	""	"Wang"	"2021"	"https://doi.org/10.1038/s41586-021-03398-2"	"doi:10.1038/s41586-021-03398-2"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24506"	"S982A"	"NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"environmental condition stability"	""	""	"Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour"	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24506"	"S982A"	"NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"ACE2 receptor binding affinity"	""	""	"This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24506"	"S982A"	"NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major (70%) increase in infection rate amongst the cells, hence this individual variant  is likely to significantly contribute to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24506"	"S982A"	"NC_045512.2:g.2944T>G"	"YP_009724390.1:p.Ser982Ala"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24642"	"T1027I"	"NC_045512.2:g.3080C>T"	"YP_009724390.1:p.Thr1027Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"virion structure"	""	""	"Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type)"	""	""	""	"Spratt"	"2021"	"https://doi.org/10.1101/2021.03.24.436850"	"doi:10.1101/2021.03.24.436850"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24914"	"D1118H"	"NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24914"	"D1118H"	"NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Mutation is predicted to lose the T cell epitope for people carrying DRB1*0301 and DRB1*0401,  but not for example in those who are DRB1*0701 or DRB1*1501 who would be predicted to show an enhanced response. This is also observed in a study of 26 each post-infection and post first dose HCWs."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24914"	"D1118H"	"NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2."	""	""	""	"Reynolds"	"2021"	"https://doi.org/10.1126/science.abh1282"	"doi:10.1126/science.abh1282"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"24914"	"D1118H"	"NC_045512.2:g.3352G>C"	"YP_009724390.1:p.Asp1118His"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"antibody epitope effects"	""	""	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"25046"	"P1162S"	"NC_045512.2:g.3484C>T"	"YP_009724390.1:p.Pro1162Ser"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"convalescent plasma escape"	""	""	"Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection."	""	""	""	"Schmidt"	"2021"	"https://doi.org/10.1101/2021.08.06.455491"	"doi:10.1101/2021.08.06.455491"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"25249,25249,25249"	"M1229I,M1229I,M1229I"	"NC_045512.2:g.3687G>C,NC_045512.2:g.3687G>A,NC_045512.2:g.3687G>T"	"YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile,YP_009724390.1:p.Met1229Ile"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness."	""	""	""	"Tada"	"2021"	"https://doi.org/10.1101/2021.02.05.430003"	"doi:10.1101/2021.02.05.430003"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"25350"	"P1263L"	"NC_045512.2:g.3788C>T"	"YP_009724390.1:p.Pro1263Leu"	""	"surface glycoprotein gene (SARS-CoV-2)"	"s gene (SARS-CoV-2)"	"surface glycoprotein (SARS-CoV-2)"	"S protein (SARS-CoV-2)"	"trafficking"	""	""	"Circulating variant in the cytoplasmic tail, shown in vitro to increase Spike subunit fusion required for cell entry"	""	""	""	"Barrett"	"2021"	"https://doi.org/10.1101/2021.01.24.428007"	"doi:10.1101/2021.01.24.428007"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"25855"	"D155Y"	"NC_045512.2:g.463G>T"	"YP_009724391.1:p.Asp155Tyr"	""	"open reading frame 3a gene (SARS-CoV-2)"	"orf3a gene (SARS-CoV-2)"	"open reading frame 3a protein (SARS-CoV-2)"	"Orf3a protein (SARS-CoV-2)"	"caveolin binding"	""	""	"In silico, this mutation is the only one weakening ORF3a's binding affinity for caveolin-1 (essential for entry and endomembrane trafficking of SARS-CoV-2). This mutation is a widespread homoplasy in 20A and 20B lineages."	""	""	""	"Gupta"	"2021"	"https://doi.org/10.1101/2021.03.26.437194"	"doi:10.1101/2021.03.26.437194"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26029"	"Q213K"	"NC_045512.2:g.637C>A"	"YP_009724391.1:p.Gln213Lys"	""	"open reading frame 3a gene (SARS-CoV-2)"	"orf3a gene (SARS-CoV-2)"	"open reading frame 3a protein (SARS-CoV-2)"	"Orf3a protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*01:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26029"	"Q213K"	"NC_045512.2:g.637C>A"	"YP_009724391.1:p.Gln213Lys"	""	"open reading frame 3a gene (SARS-CoV-2)"	"orf3a gene (SARS-CoV-2)"	"open reading frame 3a protein (SARS-CoV-2)"	"Orf3a protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes complete loss of T cell line responsiveness to A*01:01-restricted CD8+ ORF3a epitope, which is otherwise ""consistently dominant and of high magnitude""."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26256"	"F4F"	"NC_045512.2:g.12C>T"	"YP_009724392.1:p.Phe4Phe"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (17x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26268,26269,26270"	"T9I,T9I,T9I"	"NC_045512.2:g.26C>T,NC_045512.2:g.26C>T,NC_045512.2:g.26C>T"	"YP_009724392.1:p.Thr9Ile,YP_009724392.1:p.Thr9Ile,YP_009724392.1:p.Thr9Ile"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26268,26269,26270"	"T9I,T9I,T9I"	"NC_045512.2:g.26C>T,NC_045512.2:g.26C>T,NC_045512.2:g.26C>T"	"YP_009724392.1:p.Thr9Ile,YP_009724392.1:p.Thr9Ile,YP_009724392.1:p.Thr9Ile"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26296"	"L18I"	"NC_045512.2:g.52C>A"	"YP_009724392.1:p.Leu18Ile"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (47x overrepresentation vs expected count of ~39 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26299"	"L19F"	"NC_045512.2:g.55C>T"	"YP_009724392.1:p.Leu19Phe"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26312"	"F23C"	"NC_045512.2:g.68T>G"	"YP_009724392.1:p.Phe23Cys"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (14x overrepresentation vs expected count of ~8.8 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26314"	"V24M"	"NC_045512.2:g.70G>A"	"YP_009724392.1:p.Val24Met"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26319"	"V25V"	"NC_045512.2:g.75A>G"	"YP_009724392.1:p.Val25Val"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (45x overrepresentation vs expected count of ~102 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26333"	"T30I"	"NC_045512.2:g.89C>T"	"YP_009724392.1:p.Thr30Ile"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26353"	"L37F"	"NC_045512.2:g.109C>T"	"YP_009724392.1:p.Leu37Phe"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26395"	"L51I"	"NC_045512.2:g.151C>A"	"YP_009724392.1:p.Leu51Ile"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (47x overrepresentation vs expected count of ~24 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26416"	"V58L"	"NC_045512.2:g.172G>C"	"YP_009724392.1:p.Val58Leu"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (133x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26428"	"V62F"	"NC_045512.2:g.184G>T"	"YP_009724392.1:p.Val62Phe"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (18x overrepresentation vs expected count of ~333 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26442"	"N66K"	"NC_045512.2:g.198T>G"	"YP_009724392.1:p.Asn66Lys"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (14x overrepresentation vs expected count of ~23 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26447"	"S68F"	"NC_045512.2:g.203C>T"	"YP_009724392.1:p.Ser68Phe"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26447"	"S68C"	"NC_045512.2:g.203C>G"	"YP_009724392.1:p.Ser68Cys"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (58x overrepresentation vs expected count of ~12 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26456"	"P71R"	"NC_045512.2:g.212C>G"	"YP_009724392.1:p.Pro71Arg"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (20x overrepresentation vs expected count of ~12 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26467"	"V75L"	"NC_045512.2:g.223G>C"	"YP_009724392.1:p.Val75Leu"	""	"envelope gene (SARS-CoV-2)"	"e gene (SARS-CoV-2)"	"envelope protein (SARS-CoV-2)"	"E protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (3762.7x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26526"	"A2S"	"NC_045512.2:g.4G>T"	"YP_009724393.1:p.Ala2Ser"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Emergent as 16% variant by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.  Variant became 100% in day 70 culture. Variant disappeared after convalescent plasma treatment (day 71) in subsequent patient sample sequencing."	""	""	""	"Avanzato"	"2020"	"https://doi.org/10.1016/j.cell.2020.10.049"	"doi:10.1016/j.cell.2020.10.049"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26526"	"A2S"	"NC_045512.2:g.4G>T"	"YP_009724393.1:p.Ala2Ser"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (38x overrepresentation vs expected count of ~334 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26526,26527,26529"	"D3H,D3H,D3H"	"NC_045512.2:g.7G>C,NC_045512.2:g.7G>C,NC_045512.2:g.7G>C"	"YP_009724393.1:p.Asp3His,YP_009724393.1:p.Asp3His,YP_009724393.1:p.Asp3His"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (227x overrepresentation vs expected count of ~14 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26528,26528,26528"	"A2A,A2A,A2A"	"NC_045512.2:g.6A>T,NC_045512.2:g.6A>G,NC_045512.2:g.6A>C"	"YP_009724393.1:p.Ala2Ala,YP_009724393.1:p.Ala2Ala,YP_009724393.1:p.Ala2Ala"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (25x overrepresentation vs expected count of ~102 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26530"	"D3G"	"NC_045512.2:g.8A>G"	"YP_009724393.1:p.Asp3Gly"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (31x overrepresentation vs expected count of ~53 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26542"	"T7I"	"NC_045512.2:g.20C>T"	"YP_009724393.1:p.Thr7Ile"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26546"	"I8I"	"NC_045512.2:g.24T>C"	"YP_009724393.1:p.Ile8Ile"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~80 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26573,26576,26577"	"Q19E,Q19E,Q19E"	"NC_045512.2:g.55C>G,NC_045512.2:g.55C>G,NC_045512.2:g.55C>G"	"YP_009724393.1:p.Gln19Glu,YP_009724393.1:p.Gln19Glu,YP_009724393.1:p.Gln19Glu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26620"	"C33S"	"NC_045512.2:g.98G>C"	"YP_009724393.1:p.Cys33Ser"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (16x overrepresentation vs expected count of ~32 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26645"	"N41N"	"NC_045512.2:g.123C>T"	"YP_009724393.1:p.Asn41Asn"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (19x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26681"	"F53F"	"NC_045512.2:g.159C>T"	"YP_009724393.1:p.Phe53Phe"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (163x overrepresentation vs expected count of ~567 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26730"	"V70L"	"NC_045512.2:g.208G>C"	"YP_009724393.1:p.Val70Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (16x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26748"	"I76V"	"NC_045512.2:g.226A>G"	"YP_009724393.1:p.Ile76Val"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~73 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26748"	"I76L"	"NC_045512.2:g.226A>C"	"YP_009724393.1:p.Ile76Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (20x overrepresentation vs expected count of ~9 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26749"	"I76T"	"NC_045512.2:g.227T>C"	"YP_009724393.1:p.Ile76Thr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (19x overrepresentation vs expected count of ~66 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26767"	"I82T"	"NC_045512.2:g.245T>C"	"YP_009724393.1:p.Ile82Thr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"homoplasy"	""	""	"This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds."	""	""	""	"Shen"	"2021"	"https://doi.org/10.1080/22221751.2021.1922097"	"doi:10.1080/22221751.2021.1922097"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26767"	"I82T"	"NC_045512.2:g.245T>C"	"YP_009724393.1:p.Ile82Thr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (67x overrepresentation vs expected count of ~42 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26801,26801,26801"	"L93L,L93L,L93L"	"NC_045512.2:g.279C>G,NC_045512.2:g.279C>A,NC_045512.2:g.279C>T"	"YP_009724393.1:p.Leu93Leu,YP_009724393.1:p.Leu93Leu,YP_009724393.1:p.Leu93Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (29x overrepresentation vs expected count of ~628 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26855,26858"	"F112F,F112F"	"NC_045512.2:g.336C>T,NC_045512.2:g.336C>T"	"YP_009724393.1:p.Phe112Phe,YP_009724393.1:p.Phe112Phe"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (11x overrepresentation vs expected count of ~463 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26861"	"N113N"	"NC_045512.2:g.339T>C"	"YP_009724393.1:p.Asn113Asn"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (57x overrepresentation vs expected count of ~66 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26873"	"N117N"	"NC_045512.2:g.351C>T"	"YP_009724393.1:p.Asn117Asn"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (29x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26882,26882"	"L120L,L120L"	"NC_045512.2:g.360C>A,NC_045512.2:g.360C>T"	"YP_009724393.1:p.Leu120Leu,YP_009724393.1:p.Leu120Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~622 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26894,26894"	"L124L,L124L"	"NC_045512.2:g.372C>T,NC_045512.2:g.372C>G"	"YP_009724393.1:p.Leu124Leu,YP_009724393.1:p.Leu124Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (11x overrepresentation vs expected count of ~622 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26895"	"H125Y"	"NC_045512.2:g.373C>T"	"YP_009724393.1:p.His125Tyr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (22x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26895"	"H125Y"	"NC_045512.2:g.373C>T"	"YP_009724393.1:p.His125Tyr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARA_CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26907,26909,26909"	"L129L,L129L,L129L"	"NC_045512.2:g.385C>T,NC_045512.2:g.387G>A,NC_045512.2:g.387G>T"	"YP_009724393.1:p.Leu129Leu,YP_009724393.1:p.Leu129Leu,YP_009724393.1:p.Leu129Leu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (15x overrepresentation vs expected count of ~12 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26927"	"E135E"	"NC_045512.2:g.405A>G"	"YP_009724393.1:p.Glu135Glu"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (232x overrepresentation vs expected count of ~73 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26951,26951,26951"	"V143V,V143V,V143V"	"NC_045512.2:g.429G>C,NC_045512.2:g.429G>A,NC_045512.2:g.429G>T"	"YP_009724393.1:p.Val143Val,YP_009724393.1:p.Val143Val,YP_009724393.1:p.Val143Val"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (15x overrepresentation vs expected count of ~508 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26966"	"H148H"	"NC_045512.2:g.444T>C"	"YP_009724393.1:p.His148His"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (17x overrepresentation vs expected count of ~66 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26972"	"R150R"	"NC_045512.2:g.450T>C"	"YP_009724393.1:p.Arg150Arg"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (10x overrepresentation vs expected count of ~89 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26985"	"H155N"	"NC_045512.2:g.463C>A"	"YP_009724393.1:p.His155Asn"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (20x overrepresentation vs expected count of ~39 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"26987"	"H155H"	"NC_045512.2:g.465T>C"	"YP_009724393.1:p.His155His"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (10x overrepresentation vs expected count of ~66 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27021"	"E167Q"	"NC_045512.2:g.499G>C"	"YP_009724393.1:p.Glu167Gln"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (133x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27035,27038"	"T172T,T172T"	"NC_045512.2:g.516A>G,NC_045512.2:g.516A>G"	"YP_009724393.1:p.Thr172Thr,YP_009724393.1:p.Thr172Thr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (15x overrepresentation vs expected count of ~102 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27059"	"Y179Y"	"NC_045512.2:g.537C>T"	"YP_009724393.1:p.Tyr179Tyr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (10x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27112"	"S197T"	"NC_045512.2:g.590G>C"	"YP_009724393.1:p.Ser197Thr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (18x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27134"	"Y204Y"	"NC_045512.2:g.612T>C"	"YP_009724393.1:p.Tyr204Tyr"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (29x overrepresentation vs expected count of ~66 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27143"	"N207N"	"NC_045512.2:g.621C>T"	"YP_009724393.1:p.Asn207Asn"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (10x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27147"	"D209H"	"NC_045512.2:g.625G>C"	"YP_009724393.1:p.Asp209His"	""	"membrane glycoprotein gene (SARS-CoV-2)"	"m gene (SARS-CoV-2)"	"membrane glycoprotein (SARS-CoV-2)"	"M protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (81x overrepresentation vs expected count of ~18 in public genome datasets), analysis as of 2023-05-11"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"27367"	"Q56X"	"NC_045512.2:g.166C>T"	"YP_009724394.1:p.Gln56Xaa"	""	"open reading frame 6 gene (SARS-CoV-2)"	"orf6 gene (SARS-CoV-2)"	"open reading frame 6 protein (SARS-CoV-2)"	"Orf6 protein (SARS-CoV-2)"	"IFN activity"	""	""	"The residues listed are determinants of the potent IFN-antagonistic activity of SARS-CoV-2 ORF6 (via blocking mRNA nuclear export)"	""	""	""	"Kimura"	"2020"	"https://doi.org/10.2139/ssrn.3690468"	"doi:10.2139/ssrn.3690468"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28144"	"L84S"	"NC_045512.2:g.251T>C"	"YP_009724396.1:p.Leu84Ser"	""	"open reading frame 8 gene (SARS-CoV-2)"	"orf8 gene (SARS-CoV-2)"	"open reading frame 8 protein (SARS-CoV-2)"	"Orf8 protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28307,28309,28310,28311"	"P13L,P13L,P13L,P13L"	"NC_045512.2:g.38C>T,NC_045512.2:g.38C>T,NC_045512.2:g.38C>T,NC_045512.2:g.38C>T"	"YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28307,28309,28310,28311"	"P13L,P13L,P13L,P13L"	"NC_045512.2:g.38C>T,NC_045512.2:g.38C>T,NC_045512.2:g.38C>T,NC_045512.2:g.38C>T"	"YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu,YP_009724397.2:p.Pro13Leu"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13)."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28310"	"P13S"	"NC_045512.2:g.37C>T"	"YP_009724397.2:p.Pro13Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13)."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28310"	"P13S"	"NC_045512.2:g.37C>T"	"YP_009724397.2:p.Pro13Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*27:05."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28769"	"T166A"	"NC_045512.2:g.496A>G"	"YP_009724397.2:p.Thr166Ala"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"variant linear antibody epitope effects"	""	""	"Confers a significant PIWAS value decrease (reduced antigenicity)"	""	""	""	"Haynes"	"2020"	"https://doi.org/10.1101/2020.11.23.20235002"	"doi:10.1101/2020.11.23.20235002"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28853"	"S194T"	"NC_045512.2:g.580T>A"	"YP_009724397.2:p.Ser194Thr"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"anthropozoonotic events"	""	""	"Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains."	""	""	""	"Rathnasinghe"	"2021"	"https://doi.org/10.1101/2021.01.19.21249592"	"doi:10.1101/2021.01.19.21249592"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28854"	"S194L"	"NC_045512.2:g.581C>T"	"YP_009724397.2:p.Ser194Leu"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"homoplasy"	""	""	"Mutation with a population frequency of 30% in a Mexican dataset, primarily of lineage 20B, but also present in a substantial number of 20A lineage sequences, suggesting convergent evolution."	""	""	""	"Barona-Gomez"	"2021"	"https://doi.org/10.1101/2021.05.18.21256128"	"doi:10.1101/2021.05.18.21256128"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28854"	"S194L"	"NC_045512.2:g.581C>T"	"YP_009724397.2:p.Ser194Leu"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"outcome hazard ratio"	""	""	"In March 2021 this variant had an allele frequency of 47.62 and 7.25% in deceased patients, compared to 35.16 and 3.20% of the same variant in recovered patients, from the Gujarat and global datasets."	""	""	""	"Joshi"	"2021"	"https://doi.org/10.3389/fgene.2021.586569"	"doi:10.3389/fgene.2021.586569"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28869"	"P199L"	"NC_045512.2:g.596C>T"	"YP_009724397.2:p.Pro199Leu"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"RNA binding"	""	""	"Northern blot analysis of novel mutant virus-like-particles (VLPs) shows increase in RNA content with this mutation, suggesting that it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP)."	""	""	""	"Syed"	"2021"	"https://doi.org/10.1101/2021.08.05.455082"	"doi:10.1101/2021.08.05.455082"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28879"	"S202R"	"NC_045512.2:g.606T>G"	"YP_009724397.2:p.Ser202Arg"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"RNA binding"	""	""	"Northern blot analysis of novel mutant virus-like-particles (VLPs) shows major increase in RNA content with this mutation, suggesting that  it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP)."	""	""	""	"Syed"	"2021"	"https://doi.org/10.1101/2021.08.05.455082"	"doi:10.1101/2021.08.05.455082"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28881"	"R203M"	"NC_045512.2:g.608G>T"	"YP_009724397.2:p.Arg203Met"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"RNA binding"	""	""	"Northern blot analysis of novel mutant virus-like-particles (VLPs) shows most increase in RNA content of any N mutation tested, suggesting that this mutation improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP)."	""	""	""	"Syed"	"2021"	"https://doi.org/10.1101/2021.08.05.455082"	"doi:10.1101/2021.08.05.455082"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"28977"	"S235F"	"NC_045512.2:g.704C>T"	"YP_009724397.2:p.Ser235Phe"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"variant linear antibody epitope effects"	""	""	"Substantially increases epitope and antigen scores in 2 of 579 individuals (should increase immune response). In the B1.1.7 lineage this is largely counteracted by the D3L mutation, which decreases PIWAS signal significantly in 1.5% of COVID patients, for a net neutral effect at the population level."	""	""	""	"Haynes"	"2021"	"https://doi.org/10.1101/2021.01.06.20248960"	"doi:10.1101/2021.01.06.20248960"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29239,29239"	"M322I,M322I"	"NC_045512.2:g.966G>A,NC_045512.2:g.966G>T"	"YP_009724397.2:p.Met322Ile,YP_009724397.2:p.Met322Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*40:01."	""	""	""	"Agerer"	"2021"	"https://doi.org/10.1126/sciimmunol.abg6461"	"doi:10.1126/sciimmunol.abg6461"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29247"	"T325I"	"NC_045512.2:g.974C>T"	"YP_009724397.2:p.Thr325Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes partial loss of T cell line responsiveness and CTL killing ability by B*40:01-restricted CD8+ N epitope MEVTPSGTWL 322-331."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29247"	"T325I"	"NC_045512.2:g.974C>T"	"YP_009724397.2:p.Thr325Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*40:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29266,29266"	"L331F,L331F"	"NC_045512.2:g.993G>T,NC_045512.2:g.993G>C"	"YP_009724397.2:p.Leu331Phe,YP_009724397.2:p.Leu331Phe"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*40:01."	""	""	""	"Agerer"	"2021"	"https://doi.org/10.1126/sciimmunol.abg6461"	"doi:10.1126/sciimmunol.abg6461"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29358"	"T362I"	"NC_045512.2:g.1085C>T"	"YP_009724397.2:p.Thr362Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*11:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29358"	"T362I"	"NC_045512.2:g.1085C>T"	"YP_009724397.2:p.Thr362Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*03:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29358"	"T362I"	"NC_045512.2:g.1085C>T"	"YP_009724397.2:p.Thr362Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes complete loss of T cell line responsiveness to A*03:01/A*11:01-restricted CD8+ N epitope  KTFPPTEPK 361-369(2,8,10,20), which otherwise is ""consistently dominant and of high magnitude""."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29358"	"T362I"	"NC_045512.2:g.1085C>T"	"YP_009724397.2:p.Thr362Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*68:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29366"	"P365S"	"NC_045512.2:g.1093C>T"	"YP_009724397.2:p.Pro365Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"Variant causes complete loss of T cell line responsiveness to A*03:01/A*11:01-restricted CD8+ N epitope  KTFPPTEPK 361-369(2,8,10,20), which otherwise is ""consistently dominant and of high magnitude""."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29366"	"P365S"	"NC_045512.2:g.1093C>T"	"YP_009724397.2:p.Pro365Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*11:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29366"	"P365S"	"NC_045512.2:g.1093C>T"	"YP_009724397.2:p.Pro365Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*03:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29366"	"P365S"	"NC_045512.2:g.1093C>T"	"YP_009724397.2:p.Pro365Ser"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"T cell evasion"	""	""	"This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*68:01."	""	""	""	"de Silva"	"2021"	"https://doi.org/10.1101/2021.04.08.438904"	"doi:10.1101/2021.04.08.438904"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"29409"	"T379I"	"NC_045512.2:g.1136C>T"	"YP_009724397.2:p.Thr379Ile"	""	"nucleocapsid phosphoprotein gene (SARS-CoV-2)"	"n gene (SARS-CoV-2)"	"nucleocapsid phosphoprotein (SARS-CoV-2)"	"N protein (SARS-CoV-2)"	"homoplasy"	""	""	"In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent."	""	""	""	"Borges"	"2021"	"https://doi.org/10.1101/2021.05.19.444774"	"doi:10.1101/2021.05.19.444774"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"335"	"R24C"	"NC_045512.2:g.70C>T"	"YP_009724389.1:p.Arg24Cys"	"YP_009724389.1:Arg24Cys"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (25x overrepresentation vs expected count of 514 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"347"	"V28I"	"NC_045512.2:g.82G>A"	"YP_009724389.1:p.Val28Ile"	"YP_009724389.1:Val28Ile"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (30x overrepresentation vs expected count of 143 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"383"	"S40P"	"NC_045512.2:g.118T>C"	"YP_009724389.1:p.Ser40Pro"	"YP_009724389.1:Ser40Pro"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (16x overrepresentation vs expected count of ~58 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"396"	"Q44L"	"NC_045512.2:g.131A>T"	"YP_009724389.1:p.Gln44Leu"	"YP_009724389.1:Gln44Leu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (11x overrepresentation vs expected count of ~19 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"443"	"V60I"	"NC_045512.2:g.178G>A"	"YP_009724389.1:p.Val60Ile"	"YP_009724389.1:Val60Ile"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~143 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"489"	"D75G"	"NC_045512.2:g.224A>G"	"YP_009724389.1:p.Asp75Gly"	"YP_009724389.1:Asp75Gly"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (13x overrepresentation vs expected count of ~65 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"490,490"	"D75E,D75E"	"NC_045512.2:g.225T>G,NC_045512.2:g.225T>A"	"YP_009724389.1:p.Asp75Glu,YP_009724389.1:p.Asp75Glu"	"YP_009724389.1:Asp75Glu,YP_009724389.1:Asp75Glu"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (15x overrepresentation vs expected count of ~20 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"507,507,508,508,509,509,510,510,513,514,514,515,515,517,517,518"	"M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del"	"NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del"	"YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del"	"YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"immunosuppression variant emergence"	""	""	"Emergent as 22% variant by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.  Variant became 100% in day 70 culture. Variant disappeared after convalescent plasma treatment (day 71) in subsequent patient sample sequencing."	""	""	""	"Avanzato"	"2020"	"https://doi.org/10.1016/j.cell.2020.10.049"	"doi:10.1016/j.cell.2020.10.049"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"507,507,508,508,509,509,510,510,513,514,514,515,515,517,517,518,508,510,514,517,518,520"	"M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,V86del,V86del,V86del,V86del,V86del,V86del"	"NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del"	"YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del"	"YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"IFN activity"	""	""	"Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 509-517) was tested in vitro for IFN response."	""	""	""	"Lin"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.015"	"doi:10.1016/j.chom.2021.01.015"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"507,507,508,508,509,509,510,510,513,514,514,515,515,517,517,518,508,510,514,517,518,520"	"M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,V86del,V86del,V86del,V86del,V86del,V86del"	"NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del"	"YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del"	"YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"IFN activity"	""	""	"Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 509-523) was tested in vitro for IFN response."	""	""	""	"Lin"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.015"	"doi:10.1016/j.chom.2021.01.015"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"507,507,508,508,509,509,510,510,513,514,514,515,515,517,517,518,508,510,514,517,518,520"	"M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,M85del,V86del,V86del,V86del,V86del,V86del,V86del"	"NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.252_254del,NC_045512.2:g.253_255del,NC_045512.2:g.253_255del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del,NC_045512.2:g.257_259del"	"YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Met85del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del,YP_009724389.1:p.Val86del"	"YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Met85del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del,YP_009724389.1:Val86del"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"IFN activity"	""	""	"Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 500-523) was tested in vitro for IFN response."	""	""	""	"Lin"	"2021"	"https://doi.org/10.1016/j.chom.2021.01.015"	"doi:10.1016/j.chom.2021.01.015"	""	"true"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"507,509,518"	"M85V,M85V,M85V"	"NC_045512.2:g.253A>G,NC_045512.2:g.253A>G,NC_045512.2:g.253A>G"	"YP_009724389.1:p.Met85Val,YP_009724389.1:p.Met85Val,YP_009724389.1:p.Met85Val"	"YP_009724389.1:Met85Val,YP_009724389.1:Met85Val,YP_009724389.1:Met85Val"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~65 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"508"	"H81Q"	"NC_045512.2:g.243T>A"	"YP_009724389.1:p.His81Gln"	"YP_009724389.1:His81Gln"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (30x overrepresentation vs expected count of ~20 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"510"	"M85K"	"NC_045512.2:g.254T>A"	"YP_009724389.1:p.Met85Lys"	"YP_009724389.1:Met85Lys"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (17x overrepresentation vs expected count of ~12 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"561"	"R99H"	"NC_045512.2:g.296G>A"	"YP_009724389.1:p.Arg99His"	"YP_009724389.1:Arg99His"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (17x overrepresentation vs expected count of ~143 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"563"	"S100C"	"NC_045512.2:g.298A>T"	"YP_009724389.1:p.Ser100Cys"	"YP_009724389.1:Ser100Cys"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (33x overrepresentation vs expected count of ~19 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"593"	"H110Y"	"NC_045512.2:g.328C>T"	"YP_009724389.1:p.His110Tyr"	"YP_009724389.1:His110Tyr"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (22x overrepresentation vs expected count of ~514 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"593"	"H110D"	"NC_045512.2:g.328C>G"	"YP_009724389.1:p.His110Asp"	"YP_009724389.1:His110Asp"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (12x overrepresentation vs expected count of ~11 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"606"	"I114T"	"NC_045512.2:g.341T>C"	"YP_009724389.1:p.Ile114Thr"	"YP_009724389.1:Ile114Thr"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (155x overrepresentation vs expected count of ~58 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"657"	"A131V"	"NC_045512.2:g.392C>T"	"YP_009724389.1:p.Ala131Val"	"YP_009724389.1:Ala131Val"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (14x overrepresentation vs expected count of ~514 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"677"	"A138T"	"NC_045512.2:g.412G>A"	"YP_009724389.1:p.Ala138Thr"	"YP_009724389.1:Ala138Thr"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (14x overrepresentation vs expected count of ~143 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"761"	"S166G"	"NC_045512.2:g.496A>G"	"YP_009724389.1:p.Ser166Gly"	"YP_009724389.1:Ser166Gly"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (132x overrepresentation vs expected count of ~65 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
"Severe acute respiratory syndrome coronavirus 2"	"NC_045512.2"	"RefSeq"	"798"	"N178S"	"NC_045512.2:g.533A>G"	"YP_009724389.1:p.Asn178Ser"	"YP_009724389.1:Asn178Ser"	"open reading frame 1ab gene (SARS-CoV-2)"	"orf1ab gene (SARS-CoV-2)"	"open reading frame 1a polyprotein (SARS-CoV-2)"	"Orf1a protein (SARS-CoV-2)"	"frequency based fitness"	""	""	"Calculated to have an increased fitness (13x overrepresentation vs expected count of ~65 in public genome datasets)"	""	""	""	""	"2023"	"https://doi.org/10.1101/2023.01.30.526314"	"doi:10.1101/2023.01.30.526314"	""	"false"	"Paul Gordon"	"Pokay"
